Clinical Trials Appendix

Q1 2026 Results Update

29 April 2026

Pipeline
at a glance

Across five focus therapy areas:

Oncology

BioPharmaceuticals
CVRM | R&I | Infectious Disease

Rare Disease

186

projects in our development pipeline

21

new molecular entities (NME) in our late-stage pipeline

118

new molecular entities (NME) or major lifecycle management (LCM) projects in Phase II or Phase III

14

regulatory approvals in major markets since FY 2025

As of 29 April 2026.
Appendix: Glossary.

Key upcoming pipeline catalysts: 2026 and 2027

Oncology BioPharmaceuticals Rare Disease

	H1 2026	H2 2026	2027
Regulatory decision[1,2]	***Enhertu*** | neoadjuvant HER2+ Stage II or III breast cancer | DESTINY-Breast11 (US) ***Datroway*** | met. TNBC not candidate for IO | TROPION-Breast02 ***Imfinzi*** | resectable early-stage gastric and GEJ cancers | MATTERHORN (JP) ***Imfinzi*** | high-risk non-muscle invasive bladder cancer | POTOMAC ***Truqap*** | PTEN-deficient mHSPC | CAPItello-281 **camizestrant** | *ESR1*m HR+ HER2- adv. breast cancer (1L switch) | SERENA-6 **baxdrostat** | uncontrolled hypertension | BaxHTN	***Calquence*** | CLL (1L fixed duration) | AMPLIFY (JP) ***Enhertu*** | 1L HER2+ mBC | DESTINY-Breast09 (EU, JP, CN) ***Enhertu*** | high-risk HER2+ eBC | DESTINY-Breast05 ***Enhertu*** | previously treated HER2+ solid tumours | DESTINY-PanTumor02 (EU) ***Breztri*** | uncontrolled asthma | KALOS/LOGOS (EU, JP) **anselamimab** | AL amyloidosis | CARES **gefurulimab** | generalised myasthenia gravis | PREVAIL	***Calquence*** | CLL (1L fixed duration) | AMPLIFY (CN) ***Calquence*** | 1L MCL | ECHO (CN) ***Breztri*** | uncontrolled asthma | KALOS/LOGOS (CN)
Key Phase III data readouts	***Imfinzi +/- Imjudo*** | muscle-invasive bladder cancer | VOLGA ***Ultomiris*** | HSCT-TMA | TMA-313	***Datroway + Imfinzi*** | NSQ/NSQ TROP2+ NSCLC (1L) | AVANZAR ***Datroway +/- Tagrisso*** | *EGFR*m NSCLC (2L) | TROPION-Lung15 ***Imfinzi* + oleclumab/monalizumab** | unresectable stage III NSCLC | PACIFIC-9 ***Tagrisso + Orpathys*** | *EGFR*m NSCLC (2L) | SAFFRON **camizestrant** | HR+ HER2- adv. breast cancer (1L) | SERENA-4 **sonesitatug vedotin (AZD0901)** | CLDN18.2+ gastric cancer (2L+) | CLARITY-Gastric01 ***Wainua*** | ATTR-CM | CARDIO-TTRansform ***Tezspire*** | eosinophilic esophagitis (EoE) | CROSSING **tozorakimab** | LRTD | TILIA	***Datroway*** | NSQ/NSQ TROP2+ NSCLC (1L) | TROPION-Lung07 ***Datroway + Imfinzi*** | TNBC with residual disease (post-neoadj) | TROPION-Breast03 ***Datroway + Imfinzi*** | PD-L1 CPS ≥10 TNBC (1L) | TROPION-Breast05 ***Tagrisso*** | stage IA2-IA3 EGFRm NSCLC | ADAURA2 ***Truqap*** | 1L early relapse/ET resistant advanced HR+ BC | CAPItello-292 **camizestrant** | adj. switch HR+ HER2- early breast cancer | CAMBRIA-1 **puxi-sam** | B7-H4+ endometrial cancer (2-3L) | Bluestar-Endometrial01 **saruparib** | HRRm and non-HRRm CSPC | evoPAR-Prostate01 **volrustomig** | high-risk locally advanced cervical cancer | eVOLVE-Cervical **volrustomig** | mNSCLC (1L) | eVOLVE-Lung02 ***Saphnelo*** | lupus nephritis | IRIS ***Saphnelo*** | systemic sclerosis | DAISY ***Saphnelo*** | myositis | JASMINE ***Saphnelo*** | CLE | LAVENDER **bacli/dapa** | HF with renal impairment | BalanceD-HF **zibo/dapa** | CKD and high proteinuria | ZENITH **laroprovstat** | dyslipidemia | AZURE-LDL/AZURE-HeFH

Key upcoming pipeline catalysts are defined by a threshold of non-risk adjusted global peak year revenue expectations as of 10 February 2026.

1. Regulatory decision includes programmes under review in a major market. 2. Inclusion dependent on status of regulatory submission and/or submission acceptance in regions in which submission acceptance is granted.

As of 29 April 2026.

Appendix: Glossary.

Clinical Trials Appendix: selected highlights

	Oncology	BioPharmaceuticals	Rare Disease
Approved medicines Key LCM	*Calquence*	*Farxiga*	*Ultomiris*
	Datroway	*Airsupra*	*Koselugo*
	Enhertu	*Breztri*	
	Imfinzi/Imjudo	*Fasenra*	
	Lynparza	*Tezspire*	
	Tagrisso	*Saphnelo*	
	Truqap	*Wainua*	
Next-wave pipeline Registrational studies ongoing	**camizestrant** | next generation oral SERD	**balcinrenone/dapagliflozin** | MR antagonist/modulator / SGLT2	**cliramitug** | ALXN2220, TTR depleter
	puxitatug samrotecan | B7H4 TOP1i ADC	**baxdrostat** | aldosterone synthase inhibitor	**efzimfotase alfa** | enzyme replacement therapy
	rilvegostomig | PD-1/TIGIT bispecific mAb	**baxdrostat/dapagliflozin** | ASI/SGLT2	**eneboparatide** | PTH 1 agonist
	saruparib | PARP1 inhibitor	**laroprovstat** | oral PSCK9	**gefurulimab** | C5 inhibitor
	sonesitatug vedotin | Claudin18.2 MMAE ADC	**zibotentan/dapagliflozin** | ETA receptor antagonist/SGLT2	
	surovatamig | CD19/CD3 TCE	**tozorakimab** | **IL-33 ligand mAb**	
	torvutatug samrotecan | FRα TOP1i ADC		
	volrustomig | PD-1/CTLA-4 bispecific mAb		
	AZD0120 | BCMA/CD19 CAR-T		

As of 29 April 2026.
Appendix: Glossary.

Project movements since Q4 2025 update

New to Phase I

NME

ALXN2230
healthy participants

AZD1043
mAb obesity

AZD4956
POLq inhibitor solid tumours

New to Phase II

NME

AZD4144
NLRP3 cardiorenal disease

New to pivotal trial

NME

AZD0120 DURGA-4
CD19/BCMA CAR-T relapsed/refractory multiple myeloma

Additional indication

sonesitatug vedotin + CTx +/- rilvegostomig CLARITY-Gastric02
CLDN18.2 MMAE ADC + CTx +/- PD-1/TIGIT bispecific mAb 1L CLDN18.2+ gastric cancer

New to registration

Life-cycle management

***Enhertu* DESTINY-Breast05[#]**
HER2 TOP1i ADC post-neoadjuvant high-risk HER2+ early breast cancer

***Enhertu* DESTINY-PanTumor03 (China)[#]**
HER2 TOP1i ADC HER2 expressing solid tumours

Removed from Phase I

NME

AZD1705
lipid lowering cardiovascular disease

AZD6912
siRNA rheumatoid arthritis

Additional indication

volrustomig eVOLVE-RCC02
PD-1/CTLA-4 bispecific mAb 1L advanced clear cell renal cell carcinoma

Removed from Phase II

NME

ALXN2420 ASTERIA
growth hormone receptor antagonist acromegaly

atuliflapon
FLAP inhibitor asthma

Removed from Phase III

Life-cycle management

***Breztri/Trixeo* ATHLOS**
LABA/LAMA/ICS COPD cardiopulmonary exercise test trial

***Orpathys* + *Imfinzi* SAMETA[#]**
METi + PD-L1 mAb 1L papillary renal cell carcinoma

***Ultomiris* ARTEMIS**
anti-complement C5 mAb cardiac surgery-associated acute kidney injury

Approved /removed from registration

Life-cycle management

***Breztri/Trixeo* KALOS LOGOS**
LABA/LAMA/ICS asthma

***Enhertu* followed by THP DESTINY-Breast11[#]**
HER2 TOP1i ADC neoadjuvant high-risk HER2+ early breast cancer

Phase progressions based on first subject in achievement
Partnered and/or in collaboration
As of 29 April 2026.
Appendix: Glossary.

Q1 2026 Oncology new molecular entity[1] pipeline

Phase I
23 New Molecular Entities

- surovatamig CD19/CD3 TCE r/r B-cell non-Hodgkin lymphoma
- volrustomig + lenvatinib PD-1/CTLA-4 bispecific mAb + VEGFi advanced RCC
- AZD0516 STEAP2 TOP1i ADC prostate cancer
- AZD2068 EGFR/cMET actinium radioconjugate solid tumours
- AZD2962 IRAK4 inhibitor haematological malignancies
- AZD4360 CLDN18.2 TOP1i ADC solid tumours
- AZD4956 POLq inhibitor POLq inhibitor
- AZD5863 CLDN18.2/CD3 bispecific antibody solid tumours
- AZD6750 CD8-guided IL2 solid tumours
- AZD8421 CDK2 inhibitor solid tumours
- AZD9793 GPC3 TCE solid tumours
- NT-175 TP53 R175H armoured TCR-T solid tumours
- surovatamig SOUNDTRACK-E CD19/CD3 TCE mature B-cell malignancies
- AZD0240 KRAS G12D armoured TCR-T solid tumours
- AZD0754 STEAP2 CAR-T prostate cancer
- AZD2284 STEAP2 actinium RC prostate cancer
- AZD3632 MENIN inhibitor haematological malignancies
- AZD4512 CD22 TOP1i ADC relapsed/refractory B-cell non-Hodgkin lymphoma
- AZD5492 CD20 TITAN T-cell engager haematology
- AZD6621 STEAP2 TCE prostate cancer
- AZD7003 GPC3 CAR-T hepatocellular carcinoma / squamous non-small cell lung cancer
- AZD9750 AR PROTAC prostate cancer
- NT-112 KRAS G12D armoured TCR-T solid tumours

Phase II
19 New Molecular Entities

- camizestrant ngSERD HR+ HER2- breast cancer
- IPH5201 + *Imfinzi*# CD39 mAb + PD-L1 mAb neoadjuvant/adjuvant NSCLC
- rilvegostomig ARTEMIDE-01# PD-1/TIGIT bispecific mAb solid tumours
- sonesitatug vedotin CLDN18.2 MMAE ADC solid tumours
- surovatamig SYRUS CD19/CD3 TCE B-cell acute lymphoblastic leukaemia
- torvutatug samrotecan (AZD5335) anti-FRα TOP1i ADC ovarian cancer, solid tumours
- volrustomig CANTOR PD-1/CTLA-4 bispecific mAb colorectal cancer (mCRC)
- volrustomig eVOLVE-02 PD-1/CTLA-4 bispecific mAb cervical cancer, head and neck squamous cell carcinoma, esophageal squamous cell carcinoma
- AZD0305 GPRC5D MMAE ADC relapsed/refractory multiple myeloma
- AZD9574 PARP1 inhibitor advanced solid malignancies
- FPI-2265# PSMA actinium RC prostate cancer
- puxitatug samrotecan B7-H4 TOP1i ADC solid tumours
- saruparib PARP1 inhibitor solid tumours
- surovatamig SOUNDTRACK-B CD19/CD3 TCE B-cell non-Hodgkin lymphoma
- tilatamig samrotecan EGFR/cMET TOP1i ADC solid tumours
- volrustomig PD-1/CTLA-4 bispecific mAb solid tumours
- volrustomig eVOLVE-01 PD-1/CTLA-4 bispecific mAb NSCLC
- AZD0120 CD19/BCMA CAR-T multiple myeloma
- AZD3470 PRMT5i classic Hodgkin lymphoma, solid tumours

Phase III
25 New Molecular Entities

- *Imfinzi* +/- oleclumab +/- monalizumab PACIFIC-9# PD-L1 mAb +/- CD73 mAb +/- NKG2A mAb unresectable stage III NSCLC
- camizestrant +/- abemaciclib CAMBRIA-2 ngSERD + CDK4/6i adjuvant HR+ HER2- early breast cancer
- puxitatug samrotecan Bluestar-Endometrial01 B7-H4 TOP1i ADC 2-3L B7-H4+ endometrial cancer
- rilvegostomig + bevacizumab +/- *Imjudo* ARTEMIDE-HCC01# PD-1/TIGIT bispecific mAb +VEGFi +/- CTLA-4 mAb 1L HCC
- rilvegostomig + CTx ARTEMIDE-Lung02# PD-1/TIGIT bispecific mAb + CTx 1L PD-L1 TC ≥1% SQ NSCLC
- rilvegostomig ARTEMIDE-Biliary02# PD-1/TIGIT bispecific mAb metastatic biliary tract cancer
- saruparib + ADT +/- abiraterone EvoPAR-Prostate02 PARP1i + ADT +/- NHA localised/locally advanced BRCAm prostate cancer
- saruparib + NHA EvoPAR-Prostate01 PARP1i + NHA HRRm/non-HRRm mCSPC
- sonesitatug vedotin + CTx +/- rilvegostomig CLARITY-Gastric02 CLDN18.2 MMAE ADC + CTx +/- PD-1/TIGIT bispecific mAb 1L CLDN18.2+ gastric cancer
- surovatamig SOUNDTRACK-D2 CD19/CD3 TCE 1L elderly DLBCL
- torvutatug samrotecan TREVI-OC-01 anti-FRα TOP1i ADC ovarian cancer
- volrustomig eVOLVE-HNSCC PD-1/CTLA-4 bispecific mAb unresected locally advanced HNSCC
- volrustomig eVOLVE-Meso PD-1/CTLA-4 bispecific mAb 1L unresectable malignant pleural mesothelioma
- camizestrant + palbociclib SERENA-4 ngSERD + CDK4/6i 1L HR+ HER2- advanced breast cancer
- camizestrant CAMBRIA-1 ngSERD adjuvant switch HR+ HER2- early breast cancer
- rilvegostomig ARTEMIDE-Lung03# PD-1/TIGIT bispecific mAb 1L PD-L1 TC ≥1% NSQ NSCLC
- rilvegostomig + CTx ARTEMIDE-Biliary01# PD-1/TIGIT bispecific mAb + CTx adjuvant biliary tract cancer
- rilvegostomig + *Enhertu* ARTEMIDE-Gastric01# PD-1/TIGIT bispecific mAb + HER2 TOP1i ADC 1L HER2+ gastric cancer
- rilvegostomig ARTEMIDE-Lung04# PD-1/TIGIT bispecific mAb 1L PD-L1≥50% NSCLC
- saruparib + camizestrant EvoPAR-Breast01 PARP1i + ngSERD BRCA/PALB2m HR+ HER2- metastatic breast cancer
- sonesitatug vedotin CLARITY-Gastric01 CLDN18.2 MMAE ADC 2L+ CLDN18.2+ gastric cancer
- surovatamig SOUNDTRACK-F1 CD19/CD3 TCE follicular lymphoma
- volrustomig eVOLVE-Cervical PD-1/CTLA-4 bispecific mAb high-risk locally advanced cervical cancer
- volrustomig eVOLVE-Lung02 PD-1/CTLA-4 bispecific mAb 1L metastatic NSCLC
- AZD0120 DURGA-4 CD19/BCMA CAR-T relapsed/refractory multiple myeloma

Under review
1 New Molecular Entity

- camizestrant + CDK4/6i SERENA-6 ngSERD + CDK4/6i 1L HR+ HER2- ESR1m advanced breast cancer

Phase progressions based on first subject in achievement
1. Includes additional indications for assets where the lead is not yet launched
Partnered and/or in collaboration
As of 29 April 2026.
Appendix: Glossary.

Q1 2026 Oncology lifecycle management[1] pipeline

Phase I
0 Projects

Phase II
4 Projects

- *Enhertu* (platform) DESTINY-Breast07#
  HER2 TOP1i ADC HER2+ breast cancer
- *Imfinzi* combinations BEGONIA
  PD-L1 mAb + paclitaxel/novel oncology therapies 1L TNBC
- *Imfinzi* combinations NeoCOAST-2#
  PD-L1 mAb + novel oncology therapies resectable NSCLC
- *Tagrisso* combinations ORCHARD#
  EGFR TKI + multiple novel ONC therapies 2L EGFRm osimertinib-resistant NSCLC

Phase III
28 Projects

- *Calquence* + R-CHOP ESCALADE
  BTKi + R-CHOP 1L DLBCL
- *Datroway* + *Imfinzi* TROPION-Breast05#
  TROP2 TOP1i ADC + PD-L1 mAb 1L PD-L1 CPS ≥10 TNBC
- *Datroway* + pembrolizumab TROPION-Lung08#
  TROP2 TOP1i ADC + PD-1 mAb 1L PD-L1 TPS ≥50% NSQ NSCLC
- *Datroway* +/- *Imfinzi* TROPION-Breast03#
  TROP2 TOP1i ADC +/- PD-L1 mAb post-neoadjuvant TNBC with residual disease
- *Enhertu* + rilvegostomig/pembrolizumab DESTINY-Endometrial01#
  HER2 TOP1i ADC + PD-1/TIGIT bispecific mAb/PD-1 mAb 1L HER2+ pMMR endometrial cancer
- *Imfinzi* + domvanalimab following cCRT PACIFIC-8#
  PD-L1 mAb + TIGIT following cCRT unresectable stage III NSCLC
- *Imfinzi* + *Imjudo* + SoC NILE
  PD-L1 mAb + CTLA-4 mAb + SoC 1L urothelial cancer
- *Imfinzi* +/- bevacizumab EMERALD-2
  PD-L1 mAb +/- VEGFi adjuvant HCC
- *Tagrisso* + *Orpathys* SAFFRON#
  EGFR TKI +METi advanced EGFRm NSCLC
- *Truqap* + *Faslodex* + palbociclib CAPItello-292
  AKTi + SERD + CDK4/6i 1L early relapse/ET resistant advanced HR+ breast cancer
- *Datroway* TROPION-Lung17 #
  TROP2 TOP1i ADC TROP2 QCS NMR+ non-squamous NSCLC 2L
- *Datroway* + *Imfinzi* TROPION-Breast04#
  TROP2 TOP1i ADC + PD-L1 mAb neo/adjuvant TNBC or HR-low/HER2- breast cancer
- *Datroway* + rilvegostomig TROPION-Lung10#
  TROP2 TOP1i ADC + PD-1/TIGIT bispecific mAb 1L PD-L1 ≥50% NSQ NSCLC
- *Datroway* + *Tagrisso* TROPION-Lung15#
  TROP2 TOP1i ADC + EGFR TKI 2L EGFRm NSCLC
- *Enhertu* DESTINY-Endometrial02#
  HER2 TOP1i ADC adjuvant endometrial cancer
- *Imfinzi* + CRT KUNLUN
  PD-L1 mAb + CRT locally advanced ESCC
- *Imfinzi* + *Imjudo* + TACE +/- lenvatinib EMERALD-3
  PD-L1 mAb +CTLA4 mAb +/- chemoembolisation +VEGFi locoregional HCC
- *Imfinzi* + VEGF + TACE EMERALD-1
  PD-L1 mAb +VEGFi +TACE locoregional HCC
- *Tagrisso* +/- CTx NeoADAURA
  EGFR TKI +/- CTx neoadjuvant stage II/III resectable EGFRm NSCLC
- *Datroway* + *Imfinzi* + CTx AVANZAR#
  TROP2 TOP1i ADC + PD-L1 mAb + CTx 1L NSQ/NSQ TROP2+ NSCLC
- *Datroway* + pembrolizumab TROPION-Lung07#
  TROP2 TOP1i ADC + PD-1 mAb 1L PD-L1 <50% NSQ NSCLC
- *Datroway* + *Tagrisso* TROPION-Lung14#
  TROP2 TOP1i ADC + EGFR TKI 1L EGFRm NSCLC
- *Enhertu* + rilvegostomig DESTINY-BTC01#
  HER2 TOP1i ADC + PD-1/TIGIT bispecific mAb 1L HER2+ biliary tract cancer
- *Enhertu* DESTINY-Lung04#
  HER2 TOP1i ADC 1L HER2m NSCLC
- *Imfinzi* + EV +/- *Imjudo* VOLGA
  PD-L1 mAb + nectin-4 targeting MMAE ADC +/- CTLA-4 mAb muscle invasive bladder cancer (cis-ineligible/refusal)
- *Imfinzi* + SBRT PACIFIC-4
  PD-L1 mAb + SBRT stage I/II NSCLC
- *Lynparza* MONO-OLA1#
  PARPi 1L BRCAwt ovarian cancer
- *Tagrisso* ADAURA2
  EGFR TKI EGFRm NSCLC stage Ia2-Ia3 following complete tumour resection

Under review
5 Projects

- *Datroway* TROPION-Breast02#
  TROP2 TOP1i ADC 1L TNBC not candidates for IO
- *Enhertu* DESTINY-PanTumor03 (China)#
  HER2 TOP1i ADC HER2 expressing solid tumours
- *Enhertu* DESTINY-Breast05#
  HER2 TOP1i ADC post-neoadjuvant high-risk HER2+ early breast cancer
- *Imfinzi* + BCG POTOMAC
  PD-L1 mAb + BCG non-muscle invasive bladder cancer
- *Truqap* + abiraterone CAPItello-281
  AKTi + NHA PTEN deficient mHSPC

Phase progressions based on first subject in achievement
1. Includes significant lifecycle management projects and parallel indications for assets beyond Phase III
Partnered and/or in collaboration
As of 29 April 2026.
Appendix: Glossary.

Q1 2026 BioPharmaceuticals new molecular entity[1] pipeline

Phase I
12 New Molecular Entities

- surovatamig
  CD19/CD3 TCE B-cell driven autoimmune disease
- AZD0120
  CD19/BCMA CAR-T systemic lupus erythematosus
- AZD0120
  CD19/BCMA CAR-T autoimmune diseases
- AZD0120
  CD19/BCMA CAR-T multiple sclerosis
- AZD1043
  mAb obesity
- AZD1613
  PAPPA-1 mAb ADPKD
- AZD3974
  anti-inflammatory and anti-fibrotic mechanism cirrhosis
- AZD4063
  PLN R14del dilated cardiomyopathy
- AZD4248
  NNMT inhibitor cardiorenal disease
- AZD4954
  Lp(a) inhibitor dyslipidaemia
- AZD5492
  CD20 TITAN T-cell engager systemic lupus erythematosus
- AZD8965
  inhibition of arginase enzyme idiopathic pulmonary fibrosis

Phase II
17 New Molecular Entities

- balcinrenone/dapagliflozin
  MR antagonist/modulator + SGLT2 inhibitor CKD
- opemalirsen
  podocyte health nephropathy
- tozorakimab
  IL-33 mAb asthma
- AZD1163
  anti-PAD2/4 bispecific antibody rheumatoid arthritis
- AZD4144
  NLRP3 cardiorenal disease
- AZD5148
  anti-clostridioides difficile TcdB mAb reduction of C.diff recurrence
- AZD6234
  peptide chronic weight management in overweight or obesity
- AZD7760
  mAb combination targeting S aureus virulence factors prevention of Staph aureus infection
- AZD8630#
  inhaled TSLP FAb asthma
- elecoglipron
  oral GLP-1 receptor agonist T2D/chronic weight management
- AZD0292
  pseudomonas Psl-PcrV bispecific mAb bronchiectasis
- AZD2389
  anti-fibrotic mechanism metabolic dysfunction-associated steatohepatitis
- AZD4604
  inhaled JAK1 inhibitor asthma
- AZD5462#
  RXFP1 agonist heart failure
- AZD6793
  IRAK4 inhibitor COPD
- AZD7798
  humanised monoclonal antibody targets T-cells subset Crohn's disease
- AZD9550 + AZD6234
  GLP-1R glucagon dual agonist obesity

Phase III
8 New Molecular Entities

- balcinrenone/dapagliflozin
  MR antagonist/modulator + SGLT2 inhibitor heart failure with CKD
- baxdrostat BaxPA
  aldosterone synthase inhibitor primary aldosteronism
- baxdrostat/dapagliflozin
  aldosterone synthase inhibitor and reversible inhibitor of SGLT2 CKD
- baxdrostat/dapagliflozin
  aldosterone synthase inhibitor and reversible inhibitor of SGLT2 prevention of heart failure
- laroprovstat AZURE
  PCSK9 dyslipidemia
- tozorakimab OBERON TITANIA PROSPERO MIRANDA
  IL-33 mAb COPD
- tozorakimab TILIA
  IL-33 mAb severe viral lower respiratory tract disease
- zibotentan/dapagliflozin
  endothelin A receptor antagonist/SGLT2i CKD with high proteinuria

Under review
1 New Molecular Entity

- baxdrostat BaxHTN Bax24 BaxAsia
  aldosterone synthase inhibitor hypertension

Phase progressions based on first subject in achievement
1. Includes additional indications for assets where the lead is not yet launched
Partnered and/or in collaboration
As of 29 April 2026.
Appendix: Glossary.

Q1 2026 BioPharmaceuticals life cycle management[1] pipeline

Phase I	Phase II	Phase III	Under review
0 Projects	0 Projects	8 Projects	1 Project
		Breztri/Trixeo THARROS# LABA/LAMA/ICS cardiopulmonary outcomes trial in COPD	*Fasenra* NATRON IL-5R mAb hypereosinophilic syndrome
		Saphnelo DAISY# type I IFN receptor mAb systemic sclerosis	
		Saphnelo IRIS# type I IFN receptor mAb lupus nephritis	
		Saphnelo JASMINE# type I IFN receptor mAb myositis	
		Saphnelo LAVENDER# type I IFN receptor mAb cutaneous lupus erythematosus	
		Tezspire CROSSING# TSLP mAb eosinophilic esophagitis	
		Tezspire EMBARK, JOURNEY# TSLP mAb chronic obstructive pulmonary disease	
		Wainua# ligand-conjugated antisense ATTR-cardiomyopathy	

Phase progressions based on first subject in achievement
1. Includes significant lifecycle management projects and parallel indications for assets beyond Phase III
Partnered and/or in collaboration
As of 29 April 2026.
Appendix: Glossary.

Q1 2026 Rare Disease pipeline[1]

Phase I
5 Projects

- ALXN2080
  oral factor D healthy participants
- ALXN2230
  healthy participants
- ALXN2350 DCMRestore
  AAV gene therapy BAG3-associated dilated cardiomyopathy
- AZD0120 ALACRITY
  CD19/BCMA CAR-T amyloid light-chain amyloidosis
- AZD1390 AGILE
  ATM inhibitor glioblastoma

Phase II
3 Projects

- tarperprumig I TRANSCEND
  anti-properdin (complement factor P), dual-binding, nanobody ANCA-associated vasculitis
- ALXN1920 AUTUMN
  kidney-targeted factor H fusion protein nephrology
- ALXN2030 CONCORD
  siRNA targeting complement C3 antibody mediated rejection

Phase III
6 Projects

- cliramitug DepleTTR-CM#
  TTR depleter transthyretin amyloid cardiomyopathy
- efzimfotase alfa Hickory (301), Mulberry (305), Chestnut (303)
  next generation TNSALP ERT hypophosphatasia
- eneboparatide CALYPSO
  parathyroid hormone receptor 1 hypoparathyroidism
- *Ultomiris*
  anti-complement C5 mAb haematopoietic stem cell transplant–associated thrombotic microangiopathy
- *Ultomiris* AWAKE
  anti-complement C5 mAb delayed graft function
- *Ultomiris* I CAN
  anti-complement C5 mAb immunoglobulin A nephropathy

Under review
2 Projects

- anselamimab CARES
  fibril-reactive mAb amyloid light-chain amyloidosis
- gefurulimab PREVAIL
  novel anti-C5, dual binding, nanobody generalised myasthenia gravis

Phase progressions based on first subject in achievement
1. Includes new molecular entities and significant lifecycle management projects
Partnered and/or in collaboration
As of 29 April 2026.
Appendix: Glossary.

Active designations in our pipeline

3

Priority Review

- baxdrostat HTN (US)
- Datroway 1L TNBC TROPION-Breast02 (US)
- cliramitug DepleTTR-CM (JP)

6

Breakthrough / PRIME[1] / Sakigake[2]

- AZD0292 Psl-PcrV N3Y NCFBE (EU)
- *Tezspire* COPD EMBARK, JOURNEY (US)
- tozorakimab severe viral LRTD TILIA (CN)
- camizestrant 1L HR+ HER2- *ESR1*m breast cancer SERENA-6 (US)
- *Enhertu* post-neoadjuvant high-risk HER2+ early breast cancer DESTINY-Breast05 (US)
- *Ultomiris* HSCT-TMA paed (US)

12

Fast Track

- AZD0292 Psl-PcrV N3Y NCFBE (US)
- AZD7760 Staph aureus mAbs-Hemodialysis (US)
- balci/dapa HF with CKD (US)
- tozorakimab COPD (US)
- tozorakimab severe viral LRTD (US)
- *Wainua* ATTR-Cardiomyopathy (US)
- camizestrant 1L HR+ HER2- *ESR1*m breast cancer SERENA-6 (US)
- *Orpathys* + *Tagrisso* NSCLC SAFFRON (US)
- anselamimab AL amyloidosis CAEL101-301/2 (US)
- cliramitug DepleTTR-CM (US)
- efzimfotase alfa s.c. HPP (US)
- eneboparatide HypoPT (US)

3

Qualified Infectious Disease product

- AZD0292 Psl-PcrV N3Y NCFBE (US)
- AZD5148 C. difficile mAb - Prevention of Recurrence (US)
- AZD7760 prevention of Staph aureus infection (US)

18

Orphan

- *Fasenra* HES NATRON (US)
- *Saphnelo* myositis JASMINE (US)
- *Saphnelo* systemic sclerosis DAISY (US)
- *Saphnelo* systemic sclerosis DAISY (JP)
- *Tezspire* EoE CROSSING (US)
- anselamimab AL amyloidosis CAEL101-301/2 (US)
- anselamimab AL amyloidosis CAEL101-301/2 (EU)
- AZD1390 Glioblastoma (US)
- cliramitug DepleTTR-CM (US)
- cliramitug DepleTTR-CM (EU)
- cliramitug DepleTTR-CM (JP)
- efzimfotase alfa s.c. HPP (US)
- efzimfotase alfa s.c. HPP (JP)
- eneboparatide HypoPT (EU)
- eneboparatide HypoPT (US)
- gefurulimab myasthenia gravis PREVAIL (US)
- *Ultomiris* HSCT-TMA ALXN1210-TM-313 (US)
- *Ultomiris* HSCT-TMA ALXN1210-TM-313 (JP)

ACCELERATED APPROVAL, these regulations allowed medicines for serious conditions that addressed an unmet medical need to be approved based on a surrogate endpoint
BREAKTHROUGH DESIGNATION is a process designed to expedite the development and review of medicines which may demonstrate substantial improvement over available therapy. 1PRIME is a scheme launched by the EMA to enhance support for the development of medicines that target an unmet medical need. 2SAKIGAKE is aimed at early introduction of innovative medicines, medical devices, etc. that are initially developed in Japan
FAST TRACK is a process designed to facilitate the development, and expedite the review of medicines to treat serious conditions and fill an unmet medical need
PRIORITY REVIEW DESIGNATION is the US FDA's goal to take action on an application within 6 months
ORPHAN DRUG DESIGNATION, intended for treatment, diagnosis or prevention of rare diseases/disorders that affect fewer than 200,000 patients in the US, or that affect more than 200,000 patients but are not expected to recover the costs of developing and marketing a treatment drug
QUALIFIED INFECTIOUS DISEASE PRODUCT designation confers particular advantages, including priority review by the US Food and Drug Administration (FDA) and fast-track designation, which can accelerate development of a product, as well as an additional five years' market exclusivity if a product is licensed.

Oncology BioPharmaceuticals Rare Disease

As of 29 April 2026.
Appendix: Glossary.



Oncology

Approved medicines and late-stage pipeline

Calquence (BTK inhibitor)

Blood cancers

Trial	Population	Patients	Design	Endpoints	Status
Phase III **AMPLIFY (ACE-CL-311)** **NCT03836261**	Previously untreated CLL	981	• Arm 1: *Calquence* + venetoclax • Arm 2: *Calquence* + venetoclax + obinutuzumab • Arm 3: FCR or BR	• Primary endpoint: PFS (IRC) (Arm 1 vs. Arm 3) • Secondary endpoints: PFS (IRC) (Arm 2 vs. Arm 3) and PFS (INV) (Arm 1 vs. Arm 3; Arm 2 vs. Arm 3)	• FPCD: Q1 2019 • LPCD: Q3 2023 • Data readout: Q3 2024 • Primary endpoint met
Phase III **ECHO (ACE-LY-308)** **NCT02972840**	Previously untreated MCL	634	• Arm 1: *Calquence* + bendamustine + rituximab • Arm 2: bendamustine + rituximab	• Primary endpoint: PFS by Lugano Classification for NHL • Secondary endpoints: IA, PFS, ORR, DoR, time to response and OS	• FPCD: Q2 2017 • LPCD: Q1 2023 • Data readout: Q2 2024 • Primary endpoint met
Phase III **ESCALADE** **NCT04529772**	DLBCL	600	• Arm 1: *Calquence* + rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone • Arm 2: rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone	• Primary endpoint: PFS	• FPCD: Q1 2021 • Data anticipated: 2027
Phase II **TrAVeRse** **NCT05951959**	Treatment-naïve MCL	100	• Open-label, single-arm trial • *Calquence* + venetoclax + rituximab	• Primary endpoint: MRD-negative CR at end of induction	• FPCD: Q1 2024 • Data anticipated: >2027

As of 29 April 2026.
Appendix: Glossary.

Datroway (datopotamab deruxtecan, TROP2 ADC)

Breast cancer

Trial	Population	Patients	Design	Endpoints	Status
Phase III **TROPION-Breast02** **NCT05374512** **Partnered (Daiichi Sankyo)**	Locally recurrent inoperable or metastatic TNBC not candidates for IO	600	• Open-label, randomised trial • Arm 1: *Datroway* • Arm 2: investigator's choice of chemotherapy (paclitaxel, nab-paclitaxel, carboplatin, capecitabine, eribulin mesylate)	• Primary endpoints: PFS (BICR) and OS • Secondary endpoints: PFS (INV), ORR, DoR, PK parameters and ADA	• FPCD: Q2 2022 • LPCD: Q2 2024 • Data readout: Q4 2025 • Dual primary endpoints met
Phase III **TROPION-Breast03** **NCT05629585** **Partnered (Daiichi Sankyo)**	Stage I-III TNBC without pathological complete response following neoadjuvant therapy	1075	• Open-label, randomised trial • Arm 1: *Datroway* + *Imfinzi* • Arm 2: *Datroway* • Arm 3: investigator's choice of therapy (capecitabine, pembrolizumab, or capecitabine + pembrolizumab)	• Primary endpoint: iDFS • Secondary endpoints: DDFS, OS, PK parameters and ADA	• FPCD: Q4 2022 • LPCD: Q4 2024 • Data anticipated: 2027
Phase III **TROPION-Breast04** **NCT06112379** **Partnered (Daiichi Sankyo)**	Perioperative triple-negative or HR-low/HER2-negative breast cancer	1900	• Open-label, randomised • Arm 1: *Datroway* + *Imfinzi* • Arm 2: pembrolizumab + chemotherapy	• Primary endpoint: EFS • Secondary endpoints: pCR, OS, DDFS and safety	• FPCD: Q4 2023 • LPCD: Q3 2025 • Data anticipated: >2027
Phase III **TROPION-Breast05** **NCT06103864** **Partnered (Daiichi Sankyo)**	Patients with PD-L1-positive locally recurrent inoperable or metastatic TNBC	625	• Open-label, randomised • Arm 1: *Datroway* + *Imfinzi* • Arm 2: investigator's choice of chemotherapy in combination with pembrolizumab (paclitaxel, nab-paclitaxel, or gemcitabine + carboplatin) • Arm 3: *Datroway*	• Primary endpoint: PFS (BICR) • Secondary endpoints: OS, PFS (INV), ORR, DoR, DCR and safety	• FPCD: Q4 2023 • Data anticipated: 2027

As of 29 April 2026.
Appendix: Glossary.

Datroway (datopotamab deruxtecan, TROP2 ADC)

NSCLC

Trial	Population	Patients	Design	Endpoints	Status
Phase III **AVANZAR** **NCT05687266**	1L locally advanced/metastatic NSCLC without actionable genomic alterations	1350	• Randomised, open-label • Arm 1: *Datroway* + *Imfinzi* + platinum-based CTx • Arm 2: pembrolizumab + platinum-based CTx	• Co-primary endpoints: PFS and OS in NSQ ITT and NSQ TROP2 biomarker-positive	• FPCD: Q1 2023 • Data anticipated: H2 2026
Phase III **TROPION-Lung07** **NCT05555732** **Partnered (Daiichi Sankyo)**	1L PD-L1 TC <50% locally advanced/metastatic NSCLC without actionable genomic alterations	1170	• Randomised, open-label • Arm 1: *Datroway* + pembrolizumab + platinum-based CTx • Arm 2: *Datroway* + pembrolizumab • Arm 3: pembrolizumab + pemetrexed + platinum-based CTx	• Primary endpoints: PFS and OS in NSQ ITT and NSQ TROP2 NMR+ for both doublet and triplet	• FPCD: Q1 2023 • LPCD: Q4 2025 • Data anticipated: 2027
Phase III **TROPION-Lung08** **NCT05215340** **Partnered (Daiichi Sankyo)**	1L PD-L1 TC ≥50% locally advanced/metastatic non-squamous NSCLC without actionable genomic alterations	740	• Randomised, open-label • Arm 1: *Datroway* + pembrolizumab • Arm 2: pembrolizumab	• Primary endpoints: PFS and OS • Key secondary endpoints: PFS and OS in TROP2 NMR+ population	• FPCD: Q1 2022 • Data anticipated: 2027
Phase III **TROPION-Lung10** **NCT06357533** **Partnered (Daiichi Sankyo)**	1L PD-L1 TC ≥50% locally advanced/metastatic non-squamous NSCLC without actionable genomic alterations	675	• Randomised, open-label • Arm 1: *Datroway* + rilvegostomig • Arm 2: rilvegostomig • Arm 3: pembrolizumab	• Primary endpoints: PFS and OS in TROP2 biomarker-positive participants • Secondary endpoints: PFS and OS in the ITT population, ORR, DoR, TTD, PK parameters, immunogenicity and PFS2	• FPCD: Q2 2024 • Data anticipated: >2027
Phase III **TROPION-Lung14** **NCT06350097** **Partnered (Daiichi Sankyo)**	1L *EGFR*m locally advanced/metastatic NSCLC	562	• Randomised, open-label study • Arm 1: *Tagrisso* + *Datroway* • Arm 2: *Tagrisso* monotherapy	• Primary endpoint: PFS (BICR) • Secondary endpoints: OS, PFS (INV), ORR, DoR, DCR, PFS of CNS met. patients, PFS2; safety, PK parameters and immunogenicity	• FPCD: Q2 2024 • Data anticipated: >2027
Phase III **TROPION-Lung15** **NCT06417814** **Partnered (Daiichi Sankyo)**	2L *EGFR*m locally advanced / metastatic EGFRm NSCLC (disease progressed on prior Tagrisso)	744	• Open-label, randomised trial • Arm 1: *Datroway* + *Tagrisso* • Arm 2: *Datroway* • Arm 3: Platinum-based CTx	• Primary endpoints: PFS (BICR) monotherapy vs CTx, PFS (BICR) combination vs CTx • Secondary endpoints: OS, CNS PFS, PFS (Inv.), PFS2, ORR, DoR, DCR, TTR, safety and PRO	• FPCD: Q4 2024 • Data anticipated: H2 2026
Phase III **TROPION-Lung17** **NCT07291037** **Partnered (Daiichi Sankyo)**	Non-squamous 2L+ TROP2 NMR+ NSCLC without actionable genomic alterations	400	• Randomised, open-label study • Arm 1: *Datroway* • Arm 2: docetaxel	• Primary endpoints: PFS (BICR), OS	• Data anticipated: >2027

As of 29 April 2026.
Appendix: Glossary.

Datroway (datopotamab deruxtecan, TROP2 ADC)

NSCLC

Trial	Population	Patients	Design	Endpoints	Status
Phase I **TROPION-Lung02** **NCT04526691** **Partnered (Daiichi Sankyo)**	Advanced or metastatic NSCLC	145	• Open-label, two-part (dose escalation and dose expansion), sequential assignment • *Datroway* + pembrolizumab +/- platinum chemotherapy	• Primary endpoints: DLT and safety • Secondary endpoints: ORR, DoR, PFS, OS, PK parameters and ADA	• FPCD: Q4 2020 • LPCD: Q2 2023 • Data readout: Q4 2024
Phase I **TROPION-Lung04** **NCT04612751** **Partnered (Daiichi Sankyo)**	Advanced or metastatic NSCLC	155	• Open-label, two-part (dose escalation, dose expansion), sequential assignment • *Datroway* + *Imfinzi* +/- platinum chemotherapy • Cohort 1 & 2: *Datroway* + *Imfinzi* • Cohort 3 & 4: *Datroway* + *Imfinzi* + carboplatin • Cohort 4a: *Datroway* + *Imfinzi* + carboplatin (SQ 1L only) • Cohort 5 & 6: *Datroway* + rilvegostomig • Cohort 7 & 8: *Datroway* + rilvegostomig + carboplatin • Cohort 9 & 10: *Datroway* + volrustomig + carboplatin • Cohort 11: *Datroway* + volrustomig	• Primary endpoints: DLT and safety • Secondary endpoints: ORR, DoR, PFS, OS, PK parameters and ADA	• FPCD: Q1 2021 • Data anticipated: H1 2026

As of 29 April 2026.
Appendix: Glossary.

Datroway (datopotamab deruxtecan, TROP2 ADC)

Other cancers

Trial	Population	Patients	Design	Endpoints	Status
Phase II **TROPION-PanTumor03** **NCT05489211** **Partnered (Daiichi Sankyo)**	Endometrial cancer, gastric cancer, mCRPC, ovarian cancer, CRC, bladder cancer and BTC	606	• Sub-study 1 (endometrial cancer); • Sub-study 1a: *Datroway* monotherapy • Sub-study 2 (gastric cancer); • Sub-study 2a: *Datroway* + capecitabine • Sub-study 2b: *Datroway* + 5-fluorouracil • Sub-study 3 (mCRPC); • Sub-study 3a: *Datroway* (post-NHA) • Sub-study 3c: *Datroway* + prednisone/prednisolone • Sub-study 4 (ovarian cancer); • Sub-study 4a: *Datroway* • Sub-study 4a (expansion): *Datroway* PSR/PRR (2-3L) • Sub-study 4c: *Datroway* + carboplatin + bevacizumab PSR (2-3L) • Sub-study 5 (CRC); • Sub-study 5a1: *Datroway* (TROP2+ 3L+) • Sub-study 5a2: *Datroway* (TROP2+ 2L+) • Sub-study 5b: *Datroway* + 5-FU/leucovorin or capecitabine + bevacizumab (TROP2+ 1L) • Sub-study 6 (bladder); • Sub-study 6d: *Datroway* (2L+) • Sub-study 6b: 1L cis-ineligible/2L *Datroway* + rilvegostomig (1L) • Sub-study 6c: post-pembro/EV - *Datroway* + carbo/cisplatin (2L) • Sub-Study 6E: 1L *Datroway* + rilvegostomig • Sub-study 7 (BTC) • Sub-study 7a: TROP2+ *Datroway* (2L+)	• Primary endpoints: ORR and safety	• FPCD: Q3 2022 • Data anticipated: 2027

As of 29 April 2026.
Appendix: Glossary.

Datroway (datopotamab deruxtecan, TROP2 ADC)

Other cancers

Trial	Population	Patients	Design	Endpoints	Status
Phase I/II **TROPION-PanTumor02** **NCT05460273** **Partnered (Daiichi Sankyo)**	NSCLC and TNBC and other solid tumours in Chinese patients	119	• Single-arm, multi-cohort trial with no blinding • *Datroway* • China only	• Primary endpoint: ORR • Secondary endpoints: DoR, DCR, BOR, TTR, PFS and OS	• FPCD: Q3 2022 • LPCD: Q2 2023 • Data readout: Q2 2024
Phase I **TROPION-PanTumor01** **NCT03401385** **Partnered (Daiichi Sankyo)**	Subjects with advanced solid tumours: NSCLC, TNBC, HR+ breast cancer, HER2-negative gastric/GEJ, oesophageal, urothelial, SCLC, CRPC, PDAC, HNSCC, HR+ HER2-low breast cancer and HER2-positive breast cancer	890	• Open-label, two-part (dose escalation, dose expansion), sequential assignment • *Datroway* • US and Japan	• Primary endpoints: DLT and safety • Secondary endpoints: PK parameters, anti-tumour activity and ADA	• FPCD: Q1 2018 • LPCD: Q4 2025 • Data anticipated: H1 2026

As of 29 April 2026.
Appendix: Glossary.

Enhertu (trastuzumab deruxtecan, HER2 ADC)

Breast cancer

Trial	Population	Patients	Design	Endpoints	Status
Phase III **DESTINY-Breast05** **NCT04622319** **Partnered (Daiichi Sankyo)**	High-risk HER2-positive with residual invasive breast cancer following neoadjuvant therapy	1600	• Randomised, open-label, parallel assignment • Arm 1: *Enhertu* • Arm 2: ado-trastuzumab emtansine	• Primary endpoint: IDFS • Secondary endpoints: DFS, OS, DRFI and BMFI	• FPCD: Q4 2020 • Data readout: Q3 2025 • Primary endpoint met
Phase III **DESTINY-Breast09** **NCT04784715** **Partnered (Daiichi Sankyo)**	HER2-positive, metastatic breast cancer with no prior therapy for advanced or metastatic disease	1157	• Randomised, parallel assignment • Arm 1: *Enhertu* + placebo • Arm 2: *Enhertu* + pertuzumab • Arm 3: SoC	• Primary endpoint: PFS • Secondary endpoints: OS, DoR and ORR	• FPCD: Q2 2021 • Data readout: Q2 2025 • Primary endpoint met for *Enhertu* + pertuzumab arm • Data anticipated for *Enhertu* monotherapy arm: H2 2026
Phase III **DESTINY-Breast11** **NCT05113251** **Partnered (Daiichi Sankyo)**	High-risk HER2-positive early non-metastatic breast cancer	927	• Randomised, open-label, parallel assignment • Arm 1: *Enhertu* • Arm 2: *Enhertu* followed by THP • Arm 3: doxorubicin and cyclophosphamide followed by THP	• Primary endpoint: pCR • Secondary endpoints: EFS, IDFS and OS	• FPCD: Q4 2021 • Data readout: Q2 2025 • Primary endpoint met
Phase Ib/II **DESTINY-Breast07** **NCT04538742** **Partnered (Daiichi Sankyo)**	HER2-positive metastatic breast cancer	245	• Randomised, open-label, sequential assignment • Arm 1: *Enhertu* • Arm 2: *Enhertu* + *Imfinzi* • Arm 3: *Enhertu* + pertuzumab • Arm 4: *Enhertu* + paclitaxel • Arm 5: *Enhertu* + *Imfinzi* + paclitaxel • Arm 6: *Enhertu* + tucatinib	• Primary endpoints: AE and SAE • Secondary endpoints: ORR, PFS, DoR and OS	• FPCD: Q1 2021 • Data readout: Q3 2025

As of 29 April 2026.
Appendix: Glossary.

Enhertu (trastuzumab deruxtecan, HER2 ADC)

Gastric cancer

Trial	Population	Patients	Design	Endpoints	Status
Phase III **DESTINY-Gastric04** **NCT04704934** **Partnered (Daiichi Sankyo)**	HER2-positive gastric cancer or GEJ adenocarcinoma patients who have progressed on or after a trastuzumab-containing regimen and have not received any additional systemic therapy	490	• Open-label, randomised, parallel group assignment • Arm 1: *Enhertu* • Arm 2: SoC chemotherapy	• Primary endpoint: OS • Secondary endpoints: ORR, DoR, PFS, DCR and safety	• FPCD: Q2 2021 • Data readout: Q1 2025
Phase III **DESTINY-Gastric05** **NCT06731478** **Partnered (Daiichi Sankyo)**	1L HER2-positive locally advanced or metastatic gastric cancer or GEJ adenocarcinoma	726	• Arm A (CPS ≥1): *Enhertu* + 5-FU or capecitabine + pembrolizumab • Arm B (CPS ≥1): *Enhertu* + 5-FU or capecitabine + cisplatin or oxaliplatin + pembrolizumab • Arm C (CPS <1): *Enhertu* + 5-FU or capecitabine • Arm D (CPS <1): ToGA	• Primary endpoint: PFS (BICR) in ITT • Secondary endpoints: OS, ORR, PFS (INV), DoR, safety and PRO	• FPCD: Q1 2025 • Data anticipated: >2027
Phase Ib/II **DESTINY-Gastric03** **NCT04379596** **Partnered (Daiichi Sankyo)**	Metastatic or unresectable HER2+ GC, GEJ, & esophageal adenocarcinoma Part 1: ≥ 2L following trastuzumab containing therapy Part 2, 3 and 4: Previously untreated metastatic or unresectable GC Part 3 and 4: HER2 expressing (IHC 3+,2+,1+) (local assess	447	• Open-label, parallel assignment • Part 1: to determine recommended Phase II combination dose • 5 Arms combining *Enhertu* with SoC chemotherapies (5-FU, capecitabine, oxaliplatin) and/or *Imfinzi* • Part 2 and 3: to assess efficacy of the selected combinations • Arm 2A: standard chemotherapy • Arm 2B: *Enhertu* monotherapy • Arm 2C: *Enhertu* with chemotherapy • Arm 2D: *Enhertu* with chemotherapy and pembrolizumab • Arm 2E: *Enhertu* and pembrolizumab • Arm 2F: *Enhertu*, chemotherapy and pembrolizumab • Arm 3A (HER2+): *Enhertu*, chemotherapy and volrustomig • Arm 3B (HER2low): *Enhertu*, chemotherapy and volrustomig • Arm 4A (HER2+): *Enhertu*, chemotherapy and rilvegostomig • Arm 4B (HER2low): *Enhertu*, chemotherapy and rilvegostomig • Arm 5 (HER2low): *Enhertu*, chemotherapy and volrustomig (priming dose)	• Primary endpoint (Part 1): safety, RP2D and ORR • Secondary endpoints: DoR, DCR, PFS, OS, PK parameters and presence of ADAs	• FPCD: Q2 2020 • Data anticipated: 2027

As of 29 April 2026.
Appendix: Glossary.

Enhertu (trastuzumab deruxtecan, HER2 ADC)

Other cancers

Trial	Population	Patients	Design	Endpoints	Status
Phase III **DESTINY-BTC01** **NCT06467357** **Partnered (Daiichi Sankyo)**	Advanced treatment-naïve HER2-expressing BTC	620	• Arm A: *Enhertu* + rilvegostomig • Arm B: *Enhertu* • Arm C: gemcitabine and cisplatin + *Imfinzi*	• Primary endpoint: OS • Secondary endpoint: OS (ITT), PFS (BICR and INV), ORR (BICR and INV), DoR (INV) Safety, PRO	• FPCD: Q3 2024 • Data anticipated: >2027
Phase III **DESTINY-Endometrial01** **NCT06989112** **Partnered (Daiichi Sankyo)**	Stage III, Stage IV, or recurrent, histologically-confirmed endometrial cancer	600	• Open label, randomized, global • Arm A: *Enhertu* + rilvegostomig • Arm B: *Enhertu* + pembrolizumab • Arm C: carboplatin/paclitaxel + pembrolizumab	• Primary: PFS (BICR) in ITT • Secondary: OS, PFS (Investigator), ORR	• FPCD: Q2 2025 • Data anticipated: >2027
Phase III **DESTINY-Endometrial02** **NCT07022483** **Partnered (Daiichi Sankyo)**	HER2-expressing (IHC 3+/2+) endometrial cancer	710	• Randomised, open label, parallel assignment • Arm 1: *Enhertu* +/- radiotherapy • Arm 2: SoC chemotherapy +/- radiotherapy	• Primary endpoints: DFS ITT (BICR or pathology) • Secondary endpoints: OS ITT, DFS ITT (INV), DDFS	• FPCD: Q4 2025 • Data anticipated: >2027
Phase III **DESTINY-Lung04** **NCT05048797** **Partnered (Daiichi Sankyo)**	HER2-mutated, unresectable, locally advanced/metastatic NSCLC	450	• Randomised, parallel group assignment • Arm 1: *Enhertu* • Arm 2: SoC (platinum, pemetrexed and pembrolizumab)	• Primary endpoint: PFS • Secondary endpoints: OS, CNS-PFS, PFS (INV), ORR, DoR, safety, PK parameters, ADA, PRO-tolerability and PRO- pulmonary symptoms	• FPCD: Q4 2021 • Data anticipated: H1 2026
Phase III **DESTINY-Lung06** **NCT06899126** **Partnered (Daiichi Sankyo)**	Locally advanced unresectable or metastatic NSCLC, no prior systemic treatment for advanced/metastatic disease, HER2-overexpressing and PD-L1 TPS <50% without AGA	686	• Arm A: *Enhertu* + pembrolizumab • Arm B: pembrolizumab + pemetrexed + platinum CTx (cisplatin or carboplatin)	• Primary endpoint: PFS by BICR • Secondary endpoint: OS, PFS (INV), ORR per RECIST v1.1, DoR, safety and tolerability, PROs	• FPCD: Q4 2025 • Data anticipated: >2027
Phase III **DESTINY-Ovarian01** **NCT06819007** **Partnered (Daiichi Sankyo)**	HER2-expressing (IHC 3+/2+/1+) advanced high-grade epithelial ovarian cancer	582	• DS-unilateral • Phase 3, open label, randomised • Arm 1: *Enhertu* + bevacizumab • Arm 2: bevacizumab	• Primary: PFS (BICR) in IHC 2+/3+ • Secondary: PFS (BICR) in ITT (3/2/1+), OS ICH 2+/3+, OS ITT	• FPCD: Q2 2025 • Data anticipated: >2027

As of 29 April 2026.
Appendix: Glossary.

Enhertu (trastuzumab deruxtecan, HER2 ADC)

Other cancers

Trial	Population	Patients	Design	Endpoints	Status
Phase II **DESTINY-PanTumor03** **NCT06271837** **Partnered (Daiichi Sankyo)**	HER2 expressing tumours	125	• Non-randomised single group assignment • *Enhertu* • China only	• Primary endpoint: ORR • Secondary endpoints: DoR, DCR, PFS, OS, safety and tolerability, PK	• FPCD: Q3 2024 • Data readout: Q1 2026
Phase Ib **DESTINY-Lung03** **NCT04686305** **Partnered (Daiichi Sankyo)**	HER2-overexpressing, unresectable and/or metastatic NSCLC Part 1: 2L/3L advanced Parts 2/3/4/5: 1L advanced	244	• Non-randomised, parallel group assignment • Part 1: to determine recommended combination dose • 3 arms combine *Enhertu* with SoC chemotherapies (cisplatin, carboplatin or pemetrexed) and *Imfinzi*; Arm 1D: *Enhertu* monotherapy arm • Part 2: to assess efficacy of the selected combinations with chemotherapies (cisplatin, carboplatin or pemetrexed) and *Imfinzi* not initiated • Part 3 (2 arms): dose confirmation to assess safety and efficacy with volrustomig and volrustomig and chemotherapy (carboplatin) • Part 4 (2 arms): dose confirmation to assess safety and efficacy with rilvegostomig and rilvegostomig and chemotherapy (carboplatin) • Part 5: to evaluate priming approach (*Enhertu*+ volrustomig (500mg) followed by 250mg until progression)	• Primary endpoint: safety and RP2D • Secondary endpoints: ORR, DoR, DCR, PFS, OS and PK parameters	• FPCD: Q4 2021 • Data anticipated: 2027
Phase I **Enhertu SubQ** **NCT07015697** **Partnered (Daiichi Sankyo)**	Part 1: pre-treated mBC Part 2: HER2-low mBC	76	• Non-randomised, sequential assignment • Part 1: Dose escalation, subcutaneous *Enhertu* with hyaluronidase co-mixed • Part 2: Expansion, subcutaneous *Enhertu* with hyaluronidase co-mixed flat dose	• Part 1: DLT incidence, safety, PK • Part 2: Primary endpoint: PK; Secondary endpoints: ORR, safety, tolerability	• FPCD: Q4 2025 • Data anticipated: >2027

As of 29 April 2026.
Appendix: Glossary.

Imfinzi (durvalumab, PD-L1 mAb)

Gastrointestinal cancers

Trial	Population	Patients	Design	Endpoints	Status
Phase III **EMERALD-1** **NCT03778957**	Locoregional HCC	710	• Arm 1: TACE in combination with *Imfinzi* • Arm 2: TACE in combination with *Imfinzi* + bevacizumab • Arm 3: TACE in combination with placebo	• Primary endpoint: PFS (Arm 2 vs. Arm 3) • Secondary endpoints: PFS (Arm 1 vs. Arm 3) and OS	• FPCD: Q1 2019 • LPCD: Q3 2021 • Data readout: Q4 2023 • Primary endpoint met
Phase III **EMERALD-2** **NCT03847428**	Adjuvant HCC	908	• Arm 1: *Imfinzi* + bevacizumab • Arm 2: *Imfinzi* + placebo • Arm 3: placebo + placebo	• Primary endpoint: RFS (Arm 1 vs. Arm 3) • Secondary endpoints: RFS (Arm 2 vs. Arm 3), OS and RFS at 24 months	• FPCD: Q2 2019 • LPCD: Q2 2022 • Data anticipated: H2 2026
Phase III **EMERALD-3** **NCT05301842**	Locoregional HCC	725	• Arm 1: *Imfinzi* + *Imjudo* + TACE + lenvatanib • Arm 2: *Imfinzi* + *Imjudo* + TACE • Arm 3: TACE	• Primary endpoint: PFS • Secondary endpoint: OS	• FPCD: Q2 2022 • Data readout: Q1 2026 • Primary endpoint met
Phase III **HIMALAYA** **NCT03298451**	1L HCC	1324	• Arm 1: *Imfinzi* + *Imjudo* • Arm 2: *Imfinzi* • Arm 3: sorafenib	• Primary endpoint: OS • Secondary endpoints: PFS, TTP and ORR	• FPCD: Q4 2017 • LPCD: Q4 2019 • Data readout: Q4 2021
Phase III **KUNLUN** **NCT04550260**	Locally advanced, unresectable ESCC	640	• Arm 1: *Imfinzi* + definitive CRT • Arm 2: placebo + definitive CRT	• Primary endpoint: PFS • Secondary endpoint: OS	• FPCD: Q4 2020 • LPCD: Q3 2023 • Data anticipated: 2027
Phase III **MATTERHORN** **NCT04592913**	Resectable GC/GEJC	900	• Arm 1: *Imfinzi* + FLOT • Arm 2: placebo + FLOT	• Primary endpoint: EFS • Secondary endpoints: OS (Arm 1 vs. Arm 2) and pCR (Arm 1 vs. Arm 2)	• FPCD: Q4 2020 • LPCD: Q3 2022 • Data readout: Q1 2025 • Primary endpoint met

As of 29 April 2026.
Appendix: Glossary.

Imfinzi (durvalumab, PD-L1 mAb)

Lung cancer

Trial	Population	Patients	Design	Endpoints	Status
Phase III PACIFIC-4 NCT03833154	Unresected Stage I/II NSCLC	662	• Arm 1: *Imfinzi* i.v. Q4W with definitive SBRT • Arm 2: placebo with definitive SBRT	• Primary endpoint: PFS • Secondary endpoint: OS	• FPCD: Q2 2019 • Data anticipated: >2027
Phase III PACIFIC-5 NCT03706690	Unresected, locally advanced NSCLC	407	• Arm 1: *Imfinzi* i.v. Q4W following chemotherapy/RT • Arm 2: placebo following chemotherapy/RT • Global trial (ex-US with China focus)	• Primary endpoint: PFS • Secondary endpoint: OS	• FPCD: Q1 2019 • LPCD: Q2 2022 • Data readout: Q3 2024 • Primary endpoint met
Phase III PACIFIC-8 NCT05211895 Partnered (Arcus Biosciences)	Unresected locally advanced NSCLC	860	• Arm 1: *Imfinzi* + domvanalimab following chemotherapy/RT • Arm 2: *Imfinzi* + placebo following chemotherapy/RT	• Primary endpoint: PFS • Secondary endpoint: OS	• FPCD: Q1 2022 • Data anticipated: >2027
Phase III PACIFIC-9 NCT05221840 Partnered (Innate Pharma)	Patients with locally advanced (Stage III), unresectable NSCLC who have not progressed following platinum-based CRT	1051	• Arm 1: *Imfinzi* + oleclumab • Arm 2: *Imfinzi* + monalizumab + placebo • Arm 3: *Imfinzi* + placebo	• Primary endpoint: PFS • Secondary endpoints: OS, ORR, DoR, PFS2 and TFST	• FPCD: Q2 2022 • Data anticipated: H2 2026
Phase II NeoCOAST-2 NCT05061550	Early-stage, resectable NSCLC (Stage II to Stage IIIA)	630	• Open-label trial • Arm 1: *Imfinzi* + oleclumab + platinum doublet chemotherapy • Arm 2: *Imfinzi* + monalizumab + platinum doublet chemotherapy • Arm 3: volrustomig + platinum doublet chemotherapy • Arm 4: *Datroway* + single agent platinum chemotherapy • Arm 5: AZD0171 + platinum doublet chemotherapy • Arm 6: rilvegostomig + platinum doublet chemotherapy • Arm 7: *Datroway* + rilvegostomig + single agent platinum chemotherapy	• Primary endpoints: pCR and safety	• FPCD: Q2 2022 • Data anticipated: 2027

As of 29 April 2026.
Appendix: Glossary.

Imfinzi (durvalumab, PD-L1 mAb)

Other cancers

Trial	Population	Patients	Design	Endpoints	Status
Phase III **NIAGARA** **NCT03732677**	Muscle-invasive bladder cancer eligible for cisplatin	1063	• Arm 1: *Imfinzi* in combination with gemcitabine + cisplatin, *Imfinzi* maintenance • Arm 2: gemcitabine + cisplatin	• Co-primary endpoints: pCR and EFS	• FPCD: Q4 2018 • LPCD: Q3 2021 • Data readout: Q2 2024
Phase III **NILE** **NCT03682068**	1L bladder cancer	1246	• Arm 1: *Imfinzi* + *Imjudo* + SoC • Arm 2: *Imfinzi* + SoC • Arm 3: SoC	• Primary endpoint: OS	• FPCD: Q4 2018 • LPCD: Q2 2021 • Data anticipated: H1 2026
Phase III **POTOMAC** **NCT03528694**	Non-muscle-invasive bladder cancer	1018	• Arm 1: BCG (induction + maintenance) • Arm 2: *Imfinzi* + BCG (induction only) • Arm 3: *Imfinzi* + BCG (induction + maintenance)	• Primary endpoint: DFS	• FPCD: Q2 2018 • LPCD: Q4 2020 • Data readout: Q2 2025
Phase III **SAMETA** **NCT05043090** **Partnered (HUTCHMED)**	MET-driven, unresectable and locally advanced or metastatic papillary renal cell carcinoma	200	• Arm 1: *Orpathys* + *Imfinzi* • Arm 2: sunitinib • Arm 3: *Imfinzi* monotherapy	• Primary endpoint: PFS • Secondary endpoints: OS, ORR, DoR and DCR	• FPCD: Q4 2021 • Data readout: Q1 2026 • Primary endpoint not met
Phase III **VOLGA** **NCT04960709**	Muscle-invasive bladder cancer ineligible to cisplatin	712	• Arm 1: *Imfinzi* + *Imjudo* + enfortumab vedotin • Arm 2: *Imfinzi* + enfortumab vedotin • Arm 3: SoC cystectomy	• Primary endpoints: safety, EFS and pCR • Secondary endpoint: OS	• FPCD: Q4 2021 • LPCD: Q1 2025 • Data anticipated: H1 2026
Phase II **BEGONIA** **NCT03742102**	1L mTNBC	243	• Arm 1: *Imfinzi* + paclitaxel • Arm 2: *Imfinzi* + paclitaxel + *Truqap* • Arm 5: *Imfinzi* + paclitaxel + oleclumab • Arm 6: *Imfinzi* + *Enhertu* • Arm 7: *Imfinzi* + *Datroway* • Arm 8: *Imfinzi* + *Datroway* (PD-L1-high)	• Primary endpoints: safety and tolerability • Secondary endpoints: ORR, PFS, DoR, OS, PK and ADA	• FPCD: Q1 2019 • Data readout: Q2 2025
Phase I **IMFINZI-subQ** **NCT07391670**	Part 1: Solid tumours - NSCLC, limited-stage SCLC or HCC Part 2: unresectable HCC	40	• Part 1 (dose finding): subcutaneous *Imfinzi*, 2 planned dose levels (DL1and DL2) • Part 2 (dose expansion): subcutaneous *Imfinzi*, dose based on Part 1	• Primary endpoint: AUC and Ctrough of subcutaneous Imfinzi • Secondary endpoints: Safety, AUClast, Cmax, tmax, terminal elimination half-life, CL(/F), VZ(/F), Cavg, serum concentration of imfinzi	• Data anticipated: 2027

As of 29 April 2026.
Appendix: Glossary.

Lynparza (PARP inhibitor)

Ovarian, endometrial and breast cancers

Trial	Population	Patients	Design	Endpoints	Status
Phase III **MONO-OLA1** **NCT04884360**	BRCAwt advanced ovarian cancer, 1L maintenance	366	• Global trial – 12 countries • Arm 1: *Lynparza* BID 24-month duration • Arm 2: placebo BID 24-month duration	• Primary endpoints: PFS (BRCAwt HRD-positive) and PFS (BRCAwt) • Secondary endpoints: OS, TFST and PFS2	• FPCD: Q3 2021 • LPCD: Q1 2024 • Data anticipated: H2 2026
Phase III **DUO-E** **NCT04269200**	1L advanced and recurrent endometrial cancer	805	• Global trial • Arm 1: CTx + *Imfinzi* placebo followed by *Imfinzi* placebo + *Lynparza* placebo • Arm 2: CTx + *Imfinzi* followed by *Imfinzi* + *Lynparza* placebo • Arm 3: CTx + *Imfinzi* followed by *Imfinzi* + *Lynparza*	• Primary endpoint: PFS • Secondary endpoints: OS, PFS2, ORR and DoR	• FPCD: Q2 2020 • LPCD: Q2 2023 • Data readout: Q2 2023 • Primary endpoint met
Phase II **OlympiaN** **NCT05498155**	HER2 negative BRCAm neoadjuvant breast cancer	50	• Non-randomised 2 cohort study • Cohort A: lower-risk population receive neoadjuvant *Lynparza* monotherapy for 4-6 cycles • Cohort B: higher-risk population receive neoadjuvant *Lynparza* + *Imfinzi* for 4-6 cycles	• Primary endpoint: pCR (central review) • Secondary endpoints: pCR (local pathology review), RCB, percentage change in tumour volume, EFS, safety and tolerability	• FPCD: Q4 2022 • LPCD: Q2 2024 • Data readout: Q3 2025 • Primary endpoint met.

As of 29 April 2026.
Appendix: Glossary.

Orpathys (savolitinib, MET inhibitor)

Gastric cancer

Trial	Population	Patients	Design	Endpoints	Status
Phase II **NCT04923932** **Partnered (HUTCHMED)**	Locally advanced or metastatic gastric cancer and esophagogastric junction adenocarcinoma patients with MET gene amplifications	75	• Single-arm, multi-cohort, multi-centre, open-label trial • *Orpathys*	• Primary endpoint: ORR • Secondary endpoints: PFS and safety	• FPCD: Q3 2021 • LPCD: Q2 2025 • Data readout: Q4 2025

As of 29 April 2026.
Appendix: Glossary.

Tagrisso (highly-selective, irreversible EGFR inhibitor)

NSCLC

Trial	Population	Patients	Design	Endpoints	Status
Phase III **ADAURA2** **NCT05120349**	Adjuvant EGFRm NSCLC Stage IA2 to IA3 following complete tumour resection	380	• Arm 1: *Tagrisso* • Arm 2: placebo	• Primary endpoint: DFS • Secondary endpoints: DFS rate, OS, OS rate and QoL	• FPCD: Q2 2022 • LPCD: Q4 2024 • Data anticipated: 2027
Phase III **NeoADAURA** **NCT04351555**	Neoadjuvant EGFRm NSCLC	351	• Arm 1: placebo + pemetrexed/carboplatin or pemetrexed/cisplatin • Arm 2: *Tagrisso* + pemetrexed/carboplatin or pemetrexed/cisplatin • Arm 3: *Tagrisso*	• Primary endpoint: mPR • Secondary endpoints: cPR, EFS, DFS and OS	• FPCD: Q1 2021 • LPCD: Q4 2023 • Data readout: Q4 2024 • Primary endpoint met
Phase III **SACHI** **NCT05015608** **Partnered (HUTCHMED)**	Locally advanced or metastatic NSCLC with MET amplification after failure of the first-line EGFR inhibitor therapy	250	• Arm 1: *Tagrisso* + *Orpathys* • Arm 2: pemetrexed + platinum • China only	• Primary endpoint: PFS	• FPCD: Q3 2021 • Data readout: Q3 2024 • Primary endpoint met
Phase III **SAFFRON** **NCT05261399** **Partnered (HUTCHMED)**	Locally advanced or metastatic EGFRm, MET-overexpressed and/or amplified NSCLC progressed on first- or second-line treatment with Tagrisso	324	• Arm 1: *Tagrisso* + *Orpathys* • Arm2: pemetrexed with either cisplatin or carboplatin	• Primary endpoint: PFS • Secondary endpoints: OS, ORR, PK, DCR and DoR	• FPCD: Q3 2022 • Data anticipated: H2 2026
Phase III **SANOVO** **NCT05009836** **Partnered (HUTCHMED)**	1L EGFRm, MET+ locally advanced or metastatic NSCLC	320	• Arm 1: *Tagrisso* + *Orpathys* • Arm 2: *Tagrisso* + placebo	• Primary endpoint: PFS	• FPCD: Q3 2021 • Data anticipated: H2 2026
Phase II **ORCHARD** **NCT03944772**	Advanced EGFRm NSCLC patients who have progressed on first-line Tagrisso treatment	250	• Modular design platform trial: • Module 1: *Tagrisso* + *Orpathys* (cMET) • Module 2: *Tagrisso* + gefitinib (EGFRm) • Module 3: *Tagrisso* + necitumumab (EGFRm) • Module 4: carboplatin + pemetrexed + *Imfinzi* • Module 5: *Tagrisso* + alectinib (ALK) • Module 6: *Tagrisso* + selpercatinib (RET fusion) • Module 7: *Imfinzi* + etoposide + carboplatin or cisplatin • Module 8: *Tagrisso* + pemetrexed + carboplatin or cisplatin • Module 9: *Tagrisso* + *Koselugo* • Module 10: *Tagrisso* + *Datroway* • No intervention: observational cohort	• Primary endpoint: ORR • Secondary endpoints: PFS, DoR, OS, safety and tolerability	• FPCD: Q3 2019 • LPCD: Q4 2023 • Data readout: Q4 2025

As of 29 April 2026.
Appendix: Glossary.

Truqap (capivasertib, AKT inhibitor)

Breast cancer and prostate cancer

Trial	Population	Patients	Design	Endpoints	Status
Phase III **CAPItello-281** **NCT04493853**	De novo PTEN deficient metastatic hormone sensitive prostate cancer	1012	• Double-blind, randomised, comparative trial • Arm 1: *Truqap* + abiraterone • Arm 2: placebo + abiraterone	• Primary endpoint: rPFS	• FPCD: Q3 2020 • LPCD: Q1 2024 • Data readout: Q4 2024 • Primary endpoint met
Phase Ib/III **CAPItello-292** **NCT04862663**	1L early relapse/endocrine-resistant locally advanced (inoperable) or metastatic HR+/HER2-negative breast cancer	793	• Double-blind, randomised, comparative trial • Arm 1: *Truqap* + palbociclib + *Faslodex* • Arm 2: placebo + palbociclib + *Faslodex*	• Primary endpoint: PFS	• FPCD: Q2 2021 • Data anticipated: 2027

As of 29 April 2026.
Appendix: Glossary.

camizestrant (next-generation oral SERD)

Breast cancer

Trial	Population	Patients	Design	Endpoints	Status
Phase III **CAMBRIA-1** **NCT05774951**	ER+/HER2-negative early breast cancer patients who completed definitive locoregional therapy and standard adjuvant ET for at least 2 years and up to 5 years	4300	• Arm 1: camizestrant • Arm 2: continue standard ET of investigator's choice	• Primary endpoint: IBCFS • Secondary endpoints: IDFS, DRFS and OS	• FPCD: Q1 2023 • Data anticipated: 2027
Phase III **CAMBRIA-2** **NCT05952557**	ER+/HER2-negative early breast cancer with intermediate-high or high risk of recurrence that has completed definitive locoregional therapy and have no evidence of disease	5500	• Arm 1: camizestrant ± abemaciclib • Arm 2: standard endocrine therapy of investigator's choice (aromatase inhibitors [exemestane, letrozole, anastrozole] or tamoxifen) ± abemaciclib	• Primary endpoint: IBCFS • Secondary endpoints: IDFS, DRFS and OS	• FPCD: Q4 2023 • Data anticipated: >2027
Phase III **SERENA-4** **NCT04711252**	HR+ HER2-negative advanced breast cancer	1370	• Randomised, double-blind, comparative trial • Arm 1: camizestrant + palbociclib • Arm 2: anastrozole + palbociclib	• Primary endpoint: PFS • Secondary endpoints: OS and PFS2	• FPCD: Q1 2021 • LPCD: Q4 2023 • Data anticipated: H2 2026
Phase III **SERENA-6** **NCT04964934**	HR+ HER2-negative advanced breast cancer	312	• Randomised, double-blind, comparator trial • Arm 1: camizestrant + palbociclib or abemaciclib or ribociclib • Arm 2: anastrozole or letrozole + palbociclib or abemaciclib or ribociclib	• Primary endpoint: PFS • Secondary endpoint: OS and PFS2	• FPCD: Q3 2021 • LPCD: Q3 2024 • Data readout: Q1 2025 • Primary endpoint met
Phase I **SERENA-1** **NCT03616587**	HR+ HER2-negative advanced breast cancer	396	• Escalation phase: open-label multi-centre trial • Cohort 1: camizestrant • Cohort 2: camizestrant + palbociclib, everolimus, abemeciclib (+/- anastrozole), *Truqap*, ribociclib (+/- anastrozole) or anastrozole • Expansion phase: randomised expansion cohort(s) • Cohort 1: camizestrant • Cohort 2: camizestrant + palbociclib, everolimus, abemeciclib (+/- anastrozole), *Truqap*, ribociclib (+/- anastrozole) or anastrozole	• Primary endpoints: safety and tolerability • Secondary endpoints: PK parameters and anti-tumour activity	• FPCD: Q4 2018 • LPCD: Q1 2024 • Data readout: Q1 2025

As of 29 April 2026.
Appendix: Glossary.

puxitatug samrotecan (AZD8205, B7H4 TOP1i ADC)

Solid tumours

Trial	Population	Patients	Design	Endpoints	Status
Phase III **Bluestar-Endometrial01** **NCT07044336**	2-3L B7-H4 selected endometrial cancer	700	• Randomised, single-open label • Arm 1: puxitatug samrotecan 2.4mg/kg Q3W • Arm 2: docetaxel/paclitxel	• Primary endpoints: PFS, OS • Secondary endpoints: ORR, DoR, PFS2, TFST, TSST, TDT	• FPCD: Q4 2025 • Data anticipated: 2027
Phase I/II **BLUESTAR** **NCT05123482**	Breast cancer, ovarian cancer, endometrial cancer, squamous NSCLC	370	• Open-label dose escalation and expansion trial • Sub-study 1: puxitatug samrotecan monotherapy • Sub-study 2: puxitatug samrotecan + rilvegostomig • Sub-study 4: puxitatug samrotecan + rilvegostomig + palacaparib	• Primary endpoints: AE, SAE, DLTs, changes in lab and preliminary efficacy parameters • Secondary endpoints: ORR, DCR, DoR, PFS, OS, PK parameters and ADA	• FPCD: Q1 2022 • Data anticipated: 2027

As of 29 April 2026.
Appendix: Glossary.

rilvegostomig (PD-1/TIGIT bispecific mAb)

Gastrointestinal cancers

Trial	Population	Patients	Design	Endpoints	Status
Phase III **ARTEMIDE-Biliary01** **NCT06109779** **Partnered (Compugen)**	Adjuvant BTC with curative intent	750	• Randomised, double-blind, placebo-controlled, multicentre trial • Arm 1: rilvegostomig + investigator's choice of CTx (capecitabine, S-1 (tegafur/gimeracil/oteracil) or gemcitabine/cisplatin) • Arm 2: placebo + investigator's choice of CTx (capecitabine, S-1 (tegafur/gimeracil/oteracil) or gemcitabine/cisplatin)	• Primary endpoint: RFS • Secondary endpoint: OS	• FPCD: Q4 2023 • LPCD: Q1 2026 • Data anticipated: >2027
Phase III **ARTEMIDE-Biliary02** **NCT07221253** **Partnered (Compugen)**	1L advanced BTC	1100	• Randomised, open label, global, multicentre • Arm 1: rilvegostomig + gemcitabine/cisplatin • Arm 2: *Imfinzi* + gemcitabine/cisplatin	• Primary endpoint: OS • Secondary endpoints: PFS, ORR, DoR	• FPCD: Q4 2025 • Data anticipated: >2027
Phase III **ARTEMIDE-Gastric01** **NCT06764875** **Partnered (Compugen)**	HER2-positive PD-L1 CPS ≥ 1 locally advanced or metastatic gastric or GEJ adenocarcinoma	840	• Randomised, multicentre • Arm A: rilvegostomig + *Enhertu* + fluoropyrimidine • Arm B: trastuzumab + CTx + pembrolizumab • Arm C: trastuzumab + chemotherapy + rilvegostomig	• Primary endpoints: PFS, OS • Secondary endpoints: ORR, DoR	• FPCD: Q1 2025 • Data anticipated: >2027
Phase III **ARTEMIDE-HCC01** **NCT06921785** **Partnered (Compugen)**	Advanced HCC not amenable to curative therapy or locoregional therapy	1220	• Randomised, open-label, multicentre, global trial • Arm A: *Imjudo*, rilvegostomig + bevacizumab • Arm B: rilvegostomig + bevacizumab • Arm C: atezolizumab + bevacizumab	• Primary endpoint: OS • Secondary endpoints: PFS, ORR, DoR	• FPCD: Q2 2025 • Data anticipated: >2027
Phase IIb **GEMINI-Gastric** **NCT05702229** **Partnered (Compugen)**	Gastric cancer	360	• Open-label gastric platform trial • Sub-study 1: volrustomig + XELOX or FOLFOX • Sub-study 2: rilvegostomig + XELOX or FOLFOX • Sub-study 3: sonesitatug vedotin + volrustomig plus fluorouracil or capecitabine • Sub-study 4: sonesitatug vedotin + fluorouracil or capecitabine with or without rilvegostomig	• Primary endpoints: safety and efficacy (ORR and PFS6) • Secondary endpoints: DoR, OS, PK, ADA and safety	• FPCD: Q1 2023 • Data anticipated: >2027
Phase IIb **GEMINI-PeriOp Gastric** **NCT07069712** **Partnered (Compugen)**	Gastroesophageal adenocarcinoma	150	• Open-label platform study • Substudy 1: sonesitatug vedotin + rilvegostomig and 5-FU or capecitabine • Substudy 2: *Enhertu* + rilvegostomig and 5-FU or capecitabine • Substudy 3: rilvegostomig + FLOT chemotherapy	• Primary endpoints: safety, pCR rate	• FPCD: Q3 2025 • Data anticipated: >2027

As of 29 April 2026.
Appendix: Glossary.

rilvegostomig (PD-1/TIGIT bispecific mAb)

Lung cancer

Trial	Population	Patients	Design	Endpoints	Status
Phase III **ARTEMIDE-Lung02** **NCT06692738** **Partnered (Compugen)**	1L PD-L1 TC ≥1% squamous NSCLC	880	• Randomised, double-blind, multicentre • Arm 1: rilvegostomig + platinum-based CTx followed by maintenance rilvegostomig • Arm 2: pembrolizumab + platinum-based CTx followed by maintenance pembrolizumab	• Primary endpoints: PFS, OS • Secondary endpoint: OS, ORR, DoR	• FPCD: Q4 2024 • Data anticipated: >2027
Phase III **ARTEMIDE-Lung03** **NCT06627647** **Partnered (Compugen)**	1L PD-L1 TC ≥1% non-squamous NSCLC	878	• Randomised, double-blind, multicentre trial • Arm 1: rilvegostomig + platinum-based CTx followed by maitenance rilvegostomig monotherapy + pemetrexed • Arm 2: pembrolizumab + platinum-based CTx followed by maintenance pembrolizumab monotherapy + pemetrexed in maintenance	• Primary endpoints: PFS and OS • Secondary endpoints: OS, ORR and DoR	• FPCD: Q4 2024 • Data anticipated: >2027
Phase III **ARTEMIDE-Lung04** **NCT06868277** **Partnered (Compugen)**	1L PD-L1 TC ≥50% NSCLC	830	• Randomised, double-blind, multicentre • Arm A: rilvegostomig • Arm B: pembrolizumab	• Primary endpoints: PFS, OS • Secondary endpoints: ORR, DoR	• FPCD: Q3 2025 • Data anticipated: >2027 • Initiating
Phase II **LIBRA** **NCT07098338** **Partnered (Daiichi Sankyo)**	Locally advanced or metstatic NSCLC Sub-study 1- 1L non-AGA, PD-L1 ≥50% Sub-study 2 - 1L non-AGA, PD-L1 1-49% Sub-study 3 - 2/L AGA+	278	• Non-Randomised, Sequential Assignment, Open Label • Sub-study 1: rilvegostomig ± ramucirumab, i.v. • Sub-study 2: rilvegostomig + ramucirumab, i.v. • Sub-study 3: *Datroway* + ramucirumab ± rilvegostomig, i.v.	• Primary endpoints: safety and ORR • Secondary endpoints: BOR, PFS, DCR, DoR, OS, PK parameters and ADA	• FPCD: Q3 2025 • Data anticipated: >2027

As of 29 April 2026.
Appendix: Glossary.

rilvegostomig (PD-1/TIGIT bispecific mAb)

Lung cancer

Trial	Population	Patients	Design	Endpoints	Status
Phase I/II **ALTAIR** **NCT06996782**	Advanced or metastatic NSCLC	116	• Part A (safety run in): rilvegostomig + platinum-based CTx +/- ramucirumab • Part B (dose expansion): rilvegostomig + platinum-based CTx +/- ramucirumab	• Primary endpoints: safety and tolerabilty, R2PD, DLT (Part A), OR (Part B) • Secondary endpoints: DoR, TTR, DC, PFS, OS, PK meansures, OR (Part A)	• FPCD: Q4 2025 • Data anticipated: >2027
Phase I/II **ARTEMIDE-01** **NCT04995523** **Partnered (Compugen)**	NSCLC	210	• Global, open-label, dose escalation and dose expansion trial • Part A: dose escalation in CPI-experienced NSCLC patients with rilvegostomig i.v. monotherapy • Part B: dose expansion in CPI-experienced NSCLC patients with rilvegostomig i.v. monotherapy • Part C: dose expansion in CPI-naive NSCLC patients with rilvegostomig i.v. monotherapy • Part D: randomised dose expansion in CPI-naive NSCLC patients with rilvegostomig i.v. monotherapy • Part E: dose expansion in CPI-naive stage IV squamous NSCLC patients with rilvegostomig i.v. monotherapy	• Primary endpoints (Part A): safety, RP2D and MTD • Primary endpoints (Part B): safety and efficacy (ORR) • Primary endpoints (Part C): safety and efficacy (ORR) • Primary endpoints (Part D): safety and efficacy (ORR) • Primary endpoints (Part E): safety and efficacy (ORR) • Secondary endpoints: PK parameters, PD (receptor occupancy), efficacy (DCR, DoR, DRR, PFS)	• FPCD: Q4 2021 • LPCD: Q1 2026 • Data anticipated: H2 2026
Phase I **ARTEMIDE-subQ** **NCT07161414** **Partnered (Compugen)**	Solid tumours	40	• Part 1 (dose finding): subcutaneous rilvegostomig, 2 planned dose levels (DL1, DL2) • Part 2: (dose confirmation): subcutaneous rilvegostomig, dose selected in Part 1	• Primary endpoint: AUCtau • Secondary endpoint: safety, Ctrough, Cavg, serum rilvegostomig concentration	• FPCD: Q4 2025 • Data anticipated: 2027

As of 29 April 2026.
Appendix: Glossary.

rilvegostomig (PD-1/TIGIT bispecific mAb)

Solid tumours

Trial	Population	Patients	Design	Endpoints	Status
Phase IIb **GEMINI-Hepatobiliary** **NCT05775159** **Partnered (Compugen)**	HCC, BTC	294	• Open-label platform trial • HCC sub-study: • Cohort 1A: volrustomig monotherapy • Cohort 1B: volrustomig + bevacizumab • Cohort 1C: volrustomig + lenvatinib • Cohort 1D: volrustomig + rilvegostomig + bevacizumab • Cohort 1E: rilvegostomig + bevacizumab • BTC sub-study: • Cohort 2A: rilvegostomig + gemcitabine + cisplatin • Cohort 2B: volrustomig + gemcitabine + cisplatin	• Primary endpoints (HCC sub-study): safety and efficacy (ORR) • Primary endpoints (BTC sub-study): safety and efficacy (PFS6) • Secondary endpoints: DoR, OS, PK and ADA	• FPCD: Q2 2023 • Data anticipated: 2027

As of 29 April 2026.
Appendix: Glossary.

saruparib (AZD5305, PARP1 inhibitor)

Solid tumours

Trial	Population	Patients	Design	Endpoints	Status
Phase III **EvoPAR-Breast01** **NCT06380751**	BRCA1, BRCA2, or PALB2m, HR-positive, HER2-negative advanced breast cancer	500	• Randomised, open-label trial • Arm 1: saruparib + camizestrant • Arm 2: physician's choice CDK4/6i + physician's choice ET • Arm 3: physician's choice CDK4/6i + camizestrant	• Primary endpoint: PFS (BICR) • Secondary endpoints: PFS2 and OS	• FPCD: Q3 2024 • Data anticipated: >2027
Phase III **EvoPAR-Prostate01** **NCT06120491**	HRRm and non-HRRm mCSPC	1800	• Randomised, placebo-controlled trial • Arm 1: saruparib + physician's choice NHA (abiraterone, darolutamide or enzalutamide) • Arm 2: placebo + physician's choice NHA (abiraterone, darolutamide or enzalutamide)	• Primary endpoint: rPFS • Secondary endpoints: OS and PFS2	• FPCD: Q4 2023 • Data anticipated: 2027
Phase III **EvoPAR-Prostate02** **NCT06952803**	High-risk BRCAm prostate cancer patients (adjuvant setting)	700	• Randomised, double-blind trial • Cohort A: • Arm 1: saruparib + ADT • Arm 2: placebo + ADT • Cohort B: • Arm 1: saruparib + ADT + abiraterone + prednisolone/prednisone • Arm 2: placebo + ADT + abiraterone + prednisolone/prednisone	• Primary: Metastasis-free survival • Key secondary: OS	• Data anticipated: >2027
Phase I/IIa **PETRA** **NCT04644068**	Advanced solid tumours	702	• Modular, open-label, multi-centre dose escalation and expansion trial • Module 1: saruparib • Module 2: saruparib + paclitaxel • Module 3: saruparib + carboplatin +/- paclitaxel • Module 4: saruparib + *Enhertu* • Module 5: saruparib + *Datroway* • Module 6: saruparib + camizestrant	• Primary endpoints: safety, tolerability and PK parameters • Secondary endpoint: efficacy	• FPCD: Q4 2020 • LPCD: Q3 2025 • Data anticipated: 2027
Phase I/IIa **PETRANHA** **NCT05367440**	Metastatic prostate cancer	175	• Multi-arm, open-label, non-randomised, multi-centre trial • Arm 1: saruparib + enzalutamide • Arm 2: saruparib + abiraterone acetate • Arm 3: saruparib + darolutamide • Arm 4: saruparib + apalutamide	• Primary endpoints: safety and tolerability • Secondary endpoints: PK parameters and efficacy	• FPCD: Q2 2022 • LPCD: Q3 2025 • Data anticipated: >2027

As of 29 April 2026.
Appendix: Glossary.

saruparib (AZD5305, PARP1 inhibitor)

Solid tumours

Trial	Population	Patients	Design	Endpoints	Status
Phase I **ASCERTAIN** NCT05938270	Newly diagnosed prostate cancer	120	• Open-label, randomised, multi-centre trial	• Primary endpoint: effects of treatment on γH2AX change • Secondary endpoints: safety and tolerability, impact on surgical feasibility and change in Ki67	• FPCD: Q3 2023 • Data anticipated: H2 2026

As of 29 April 2026.
Appendix: Glossary.

sonesitatug vedotin (AZD0901, CLDN18.2 MMAE ADC)

Solid tumours

Trial	Population	Patients	Design	Endpoints	Status
Phase III **CLARITY-Gastric01** **NCT06346392**	2L+ advanced or metastatic gastric or GEJ adenocarcinoma expressing CLDN18.2	572	• Multi-centre, open-label, sponsor-blinded, randomised trial • Arm 1: sonesitatug vedotin dose level 1 via i.v. infusion treatment • Arm 2: sonesitatug vedotin dose level 2 via i.v. infusion treatment • Arm 3: investigator's choice CTx	• Primary endpoints: PFS and OS • Secondary endpoints: OS, PFS for 3L+, ORR, ORR for 3L+, DoR, MMAE, safety and tolerability, PK parameters and prevalence of ADAs	• FPCD: Q2 2024 • Data anticipated: H2 2026
Phase III **CLARITY-Gastric02** **NCT07431281**	1L advanced or metastatic gastric or GEJ adenocarcinoma expressing CLDN18.2	2130	• Cohort 1: • sonesitatug vedotin in combination with rilvegostomig and capecitabine • sonesitatug vedotin in combination with nivolumab and capecitabine • SoC nivolumab plus capecitabine plus oxaliplatin (CAPOX) or folinic acid, 5-fluorouracil, and oxaliplatin (FOLFOX) • • Cohort 2: • sonesitatug vedotin in combination with capecitabine • CAPOX or FOLFOX alone or in combination with zolbetuximab	• Primary endpoints: PFS (Cohort 1 and Cohort 2) and OS (Cohort 1) • Secondary endpoints: OS (Cohort 2); ORR, DoR, PK, Immunogenicity, safety & tolerability	• FPCD: Q1 2026 • Data anticipated: >2027
Phase II **CLARITY-PanTumour01** **NCT06219941**	Locally advanced unresectable or metastatic solid tumours expressing CLDN18.2	224	• Open-label, multi-centre trial • Sub-study 1: sonesitatug vedotin monotherapy (gastric cancer) • Sub-study 2: sonesitatug vedotin and anti-cancer agents (pancreatic cancer) • Sub-study 3: sonesitatug vedotin monotherapy (BTC)	• Primary endpoints: AEs, SAEs and ORR • Secondary endpoints: OS, PFS, DoR, DCR, PK parameters and prevalence of ADAs	• FPCD: Q1 2024 • Data anticipated: 2027

As of 29 April 2026.
Appendix: Glossary.

surovatamig (CD19/CD3 T-cell engager)

Haematologic malignancies

Trial	Population	Patients	Design	Endpoints	Status
Phase III **SOUNDTRACK-D2** NCT07215585	B-cell non-Hodgkin lymphoma, diffuse large B-cell lymphoma (elderly)	420	• Multi-centre, randomised • Safety run-in • Arm 1: R-mini-CHOP followed by surovatamig • Arm 2: R-mini-CHOP	• Primary: PFS • Key secondary: OS	• Data anticipated: >2027
Phase III **SOUNDTRACK-F1** NCT06549595	Previously untreated follicular lymphoma	1015	• Multi-centre, randomised, open-label trial • Arm 1: rituximab + surovatamig followed by observation • Arm 2: rituximab + surovatamig followed by maintenance AZD0486 • Arm 3: Investigator's choice of RCHOP/RCVP/BR followed by standard of care maintenance or observation	• Primary endpoint: PFS • Secondary endpoint: CR	• FPCD: Q3 2024 • Data anticipated: >2027
Phase II **SOUNDTRACK-B** NCT06526793	B-cell non-Hodgkin lymphoma, follicular lymphoma and diffuse large B-cell lymphoma	240	• Multi-centre, single-arm, open-label trial • Module 1: follicular lymphoma • Module 2 diffuse large B-cell lymphoma	• Primary endpoint: ORR • Secondary endpoints: DoR, CR and PFS	• FPCD: Q4 2024 • Data anticipated: 2027
Phase I/IIb **SYRUS** NCT06137118	R/R B-ALL	163	• Multi-centre, open-label, single-arm dose escalation and dose optimisation trial	• Ph1 primary endpoints: DLT, and safety • Ph2 primary endpoint: CR • Secondary endpoints: ORR, DoR, CR rate at any time during trial, EFS, OS, subsequent alloSCT, CR MRD-negative rate, PK parameters and ADA	• FPCD: Q1 2024 • Data anticipated: 2027
Phase I/II **SOUNDTRACK-E** NCT06564038	Mature B-cell malignancies (chronic lymphocytic leukaemia/small lymphocytic leukaemia, mantle-cell lymphoma, and large B-cell lymphoma)	180	• Multi-centre, open-label trial • Sub-study 1 (RR CLL/SLL): surovatamig in IV or SC • Sub-study 2 (RR MCL): surovatamig in IV or SC • Sub-study 3 (RR LBCL): surovatamig IV + R-CHOP	• Primary endpoints: DLT and safety • Secondary endpoints: ORR, CR rate, DoR, Cmax, AUC, Cmin, Tmax, Ctrough, half-life of AZD0486, clearance of AZD0486 and ADA	• FPCD: Q1 2025 • Data anticipated: H2 2026
Phase I NCT04594642	R/R B-cell non-Hodgkin lymphoma	317	• Multi-centre, open-label, dose escalation and dose expansion trial	• Primary endpoints: safety and tolerability, MTD and/or RP2D and PK parameters • Secondary endpoints: clinical activity of AZD0486 monotherapy and ADA titers for AZD0486 monotherapy	• FPCD: Q1 2021 • Data anticipated: H2 2026

As of 29 April 2026.
Appendix: Glossary.

torvutatug samrotecan (AZD5335, anti-FRα TOP1i ADC)

Ovarian cancer, solid tumours

Trial	Population	Patients	Design	Endpoints	Status
Phase III **TREVI-OC-01** **NCT07218809**	Previously treated FRα-expressing platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer	1100	• Randomised, open-label • FRα-high cohort: • Arm 1: torvu-sam • Arm 2: mirvetuximab soravtansine • FRα-low cohort: • Arm 1: torvu-sam • Arm 2: investigator's choice single-agent CTx	• Primary endpoint: PFS • Secondary endpoint: OS, ORR, safety & tolerability, HRQoL	• Data anticipated: >2027 • Initiating
Phase I/II **FONTANA** **NCT05797168**	Advanced solid tumour malignancies	506	• Module 1: torvu-sam monotherapy • Module 2: torvu-sam + saruparib • Module 3: torvu-sam + bevacizumab • Module 4: torvu-sam + carboplatin +/- bevacizumab • Module 5: torvu-sam + palacaparib	• Primary endpoints: safety and tolerability • Secondary endpoints: efficacy and PK parameters	• FPCD: Q3 2023 • Data anticipated: >2027

As of 29 April 2026.
Appendix: Glossary.

volrustomig (PD-1/CTLA-4 bispecific mAb)

Solid tumours

Trial	Population	Patients	Design	Endpoints	Status
Phase III **eVOLVE-Cervical** **NCT06079671**	High-risk locally advanced cervical cancer with no progression following platinum-based cCRT	800	• Randomised, double-blind, placebo-controlled, multi-centre trial • Arm 1: volrustomig • Arm 2: placebo	• Primary endpoint: PFS (INV, ITT) • Secondary endpoints: OS, ORR, DoR	• FPCD: Q4 2023 • Data anticipated: 2027
Phase III **eVOLVE-HNSCC** **NCT06129864**	Unresected locally advanced HNSCC	1145	• Randomised, double-blind, placebo-controlled, multicentre trial • Arm 1: volrustomig • Arm 2: observational	• Primary endpoint: PFS (BICR, PD-L1 expressing tumours) • Secondary endpoints: PFS (BICR, ITT), landmark PFS, OS (PD-L1 expressing tumours), landmark OS and OS (ITT)	• FPCD: Q1 2024 • Data anticipated: >2027
Phase III **eVOLVE-Lung02** **NCT05984277**	1L PD-L1 <50% mNSCLC	1200	• Double-arm randomised, open-label trial • Arm 1: volrustomig + CTx • Arm 2: pembrolizumab + CTx	• Primary endpoints: OS and PFS (PD-L1 < 1%) • Secondary endpoints: PFS (ITT), ORR and DoR • •	• FPCD: Q4 2023 • Data anticipated: 2027
Phase III **eVOLVE-Meso** **NCT06097728**	1L unresectable malignant pleural mesothelioma	825	• Double-arm, randomised, open-label trial • Arm 1: volrustomig + CTx • Arm 2: CTx or nivolumab + ipilimumab	• Primary endpoint: OS • Secondary endpoints: PFS, landmark OS, landmark PFS and ORR	• FPCD: Q4 2023 • Data anticipated: >2027
Phase IIb **eVOLVE-01** **NCT06448754**	Metastatic NSCLC	180	• Platform, randomised, open-label, multicentre, global trial • Substudy 1: mNSCLC (non-squamous) • Arm 1A: volrustomig dose regimen 1 + CTx • Arm 1B: volrustomig dose regimen 2 + CTx • Substudy 2: mNSCLC (non-squamous or squamous) • Arm 2A: volrustomig dose regimen 2 + ramucirumab + CTx	• Primary endpoints: safety, & tolerability, ORR • Secondary endpoints: DCR, DoR, PFS, OS	• FPCD: Q3 2024 • Data anticipated: 2027
Phase II **CANTOR** **NCT06792695**	Metastatic colorectal cancer	120	• Platform, randomised, open-label, multicentre, global trial • Arm A: volrustomig + FOLFIRI + bevacizumab • Arm B: FOLFIRI + bevacizumab	• Primary endpoints: PFS, safety • Secondary endpoints: OS, ORR, DCR, DoR	• FPCD: Q1 2025 • Data anticipated: 2027

As of 29 April 2026.
Appendix: Glossary.

volrustomig (PD-1/CTLA-4 bispecific mAb)

Solid tumours

Trial	Population	Patients	Design	Endpoints	Status
Phase II **eVOLVE-02** **NCT06535607**	Advanced/metastatic solid tumours	257	• Platform, multicentre trial • Sub-study 1: volrustomig monotherapy in cervical cancer • Sub-study 2: volrustomig monotherapy in head and neck squamous cell carcinoma • Sub-study 3: volrustomig + CTx in head and neck squamous cell carcinoma • Sub-study 4: volrustomig + CTx in esophageal squamous cell carcinoma • Sub-study 5: volrustomig monotherapy in unresectable pleural mesothelioma	• Primary endpoints: ORR and safety • Secondary endpoints: DoR, PFS, TTR, OS, DCR, PK parameters and immunogenicity	• FPCD: Q3 2024 • Data anticipated: >2027
Phase Ib/III **eVOLVE-RCC02** **NCT07000149** **Partnered (Arcus Biosciences)**	1L advanced clear cell renal cell carcinoma	9	• Randomised, open-label, multicenter, global trial • Phase Ib: • Arm 1: volrustomig Dose 1 + casdatifan • Arm 2: volrustomig Dose 2 + casdatifan	• Primary endpoints: AEs, SAEs • Secondary endpoints: ORR, DoR, PFS, DCR, PK parameters and immunogenicity, TTR	• FPCD: Q3 2025 • Trial discontinued due to strategic portfolio prioritisation
Phase Ib **NCT04522323**	Advanced renal cell carcinoma	67	• Open-label, dose escalation and dose expansion trial • Arm 1: volrustomig + axitinib • Arm 2: volrustomig + lenvatanib	• Primary endpoints (escalation): safety, MTD, RP2D, tolerability and anti-tumour activity of combination (ORR) • Secondary endpoints: PK parameters, ADA and anti-tumour activity (PFS, OR, DoR, DCR, TTR, OS)	• FPCD: Q3 2020 • LPCD: Q2 2023 • Data anticipated: H1 2026
Phase I **NCT03530397**	Advanced solid tumours	400	• Open-label, dose escalation and dose expansion trial • Dose escalation: volrustomig i.v. • Dose expansion: volrustomig i.v. as monotherapy and + CTx • Arm 1: volrustomig i.v. • Arm 2: volrustomig i.v., pemetrexed + carboplatin • Arm 3: pembrolizumab, pemetrexed + carboplatin • Arm 4: volrustomig i.v., taxane (paclitaxel or nab-paclitaxel) + carboplatin	• Primary endpoints (escalation): safety and tolerability, MTD, OBD and HPDD • Primary endpoint (expansion): antitumour activity based on ORR • Secondary endpoints: PK parameters, ADA, tumoural baseline PD-L1, anti-tumour activity (OR, DoR, DCR, PFS, OS)	• FPCD: Q2 2018 • LPCD: Q4 2023 • Data readout: Q1 2026

As of 29 April 2026.
Appendix: Glossary.

AZD0120 (autologous anti-CD19 and anti-BCMA CAR-T)

Blood cancers

Trial	Population	Patients	Design	Endpoints	Status
Phase III **DURGA-4** **NCT07391657**	Relapsed/refractory multiple myeloma	508	• Randomised, multicentre, controlled, open-label, global trial • Arm 1: AZD0120 • Arm 2: Standard regimens (DKd, DPd, PVd or Kd)	• Primary: PFS, MRD negativity rate at 9 months • Secondary: CRR, ORR, OS	• FPCD: Q1 2026 • Data anticipated: >2027
Phase II **DURGA-3** **NCT06235229**	Relapsed/refractory multiple myeloma	20	• Open-label, multi-centre, non-randomised trial • Phase II dose expansion • China only	• Primary endpoint (Phase Ib): safety and tolerability measures • Secondary endpoints (Phase Ib): PK parameters • Primary endpoint (Phase II): ORR • Secondary endpoints (Phase II): PFS, OS, MRD, DoR, TTR	• FPCD: Q3 2025 • Data anticipated: 2027
Phase I/II **DURGA-1** **NCT05850234**	Relapsed/refractory multiple myeloma	182	• Open-label, single-arm, multi-centre trial	• Primary endpoints: ORR • Secondary endpoints: DoR, PFS, OS, MRD negative rate, AEs	• FPCD: Q3 2023 • Data anticipated: 2027
Phase I **DURGA-2** **NCT07073547**	Newly diagnosed multiple myeloma, early relapsed or primary refractory multiple myeloma	40	• Open-label, single-arm, multi-centre trial	• Primary endpoints: incidence of AEs, SAEs and DLTs • Secondary endpoints: ORR, CRR, DoR, TTR, MRD negative status at 9 months, AEs and PK parameters	• FPCD: Q3 2025 • Data anticipated: H2 2026

As of 29 April 2026.
Appendix: Glossary.



Oncology

Early-stage development

IPH5201 (CD39 mAb)

Solid tumours

Trial	Population	Patients	Design	Endpoints	Status
Phase I **NCT04261075** **Partnered (Innate Pharma)**	Advanced solid tumours	57	• Open-label, dose escalation trial to determine MTD of IPH5201 as monotherapy, or in combination with *Imfinzi* +/- oleclumab • Part 1: IPH5201 monotherapy dose escalation to MTD • Part 2: IPH5201 + *Imfinzi* dose escalation to MTD • Part 3: IPH5201 + *Imfinzi* + oleclumab dose escalation to MTD • Route of administration: i.v. • Global trial – US and EU	• Primary endpoints: AE, SAE and DLT • Secondary endpoints: OR, DC, PK parameters and ADA	• FPCD: Q1 2020 • LPCD: Q2 2022 • Data readout: Q2 2023

As of 29 April 2026.
Appendix: Glossary.

NT-112 (KRAS G12D specific TCR-T)

Solid tumours

Trial	Population	Patients	Design	Endpoints	Status
Phase I **NCT06218914**	Unresectable, advanced/metastatic NSCLC, colorectal adenocarcinoma, pancreatic adenocarcinoma, endometrial cancer or any solid tumour histology positive for KRAS G12D mutation	24	• Open-label, single-arm, multi-centre trial with dose escalation	• Primary endpoints: incidence of DLTs, TEAEs and SAEs • Secondary endpoints: ORR per RECIST v.1.1, BOR, DoR, CBR (CR, PR, SD), TTR, PFS and OS	• FPCD: Q1 2024 • LPCD: Q2 2026 • Data anticipated: H2 2026

As of 29 April 2026.
Appendix: Glossary.

NT-175 (TP53 R175H armoured TCR-T)

Solid tumours

Trial	Population	Patients	Design	Endpoints	Status
Phase I **NCT05877599**	Unresectable, advanced, and/or metastatic solid tumours positive for HLA-A*02:01 and TP53 R175H mutation	45	• Open-label, single-arm, multi-centre trial with dose escalation and dose expansion components	• Primary endpoint: Incidence of DLTs, TEAEs and SAEs • Secondary endpoints: ORR per RECIST v.1.1, BOR, DoR, CBR (CR, PR, SD), TTR, PFS and OS	• FPCD: Q3 2023 • Data anticipated: >2027

As of 29 April 2026.
Appendix: Glossary.

tilatamig samrotecan (EGFR-cMET TOP1i ADC)

Lung cancer

Trial	Population	Patients	Design	Endpoints	Status
Phase I **EGRET** **NCT05647122**	Advanced solid tumours including NSCLC, HNSCC and CRC	403	• Escalation phase, open-label, multi-centre trial • Arm 1: tilatamig samrotecan • Arm 2: tilatamig samrotecan + *Tagrisso* • Arm 3: tilatamig samrotecan + 5FU + bevacizumab	• Primary endpoints (escalation): safety and tolerability • Primary endpoints (expansion): safety, tolerability and anti-tumour activity • Secondary endpoints (escalation): PK parameters, immunogenicity and anti-tumour activity • Secondary endpoints (expansion): PK parameters and immunogenicity	• FPCD: Q1 2023 • Data anticipated: 2027

As of 29 April 2026.
Appendix: Glossary.

vemzatatug vedotin (AZD0305, GPRC5D MMAE ADC)

Blood cancers

Trial	Population	Patients	Design	Endpoints	Status
Phase I/II **NCT06106945**	R/R multiple myeloma	226	• Open-label, dose escalation and dose expansion trial • Phase I: AZD0305 in monotherapy or in combination with other anticancer agents, prescribed at specified dose levels • Phase II: AZD0305 monotherapy prescribed as RP2D	• Primary endpoints: occurrence of dose-limiting toxicities and incidence and severity of AEs and SAEs • Secondary endpoints: ORR, DoR, PFS, OS, PK parameters and immunogenicity	• FPCD: Q4 2023 • Data anticipated: 2027

As of 29 April 2026.
Appendix: Glossary.

AZD0516 (STEAP2 ADC)

Prostate cancer

Trial	Population	Patients	Design	Endpoints	Status
Phase I/II SEACLIFF NCT07181161	mCRPC	177	• Open-label multi-centre, modular dose escalation and dose optimisation trial	• Primary endpoint: safety and tolerability • Secondary endpoints: efficacy, PK and immunogenicity	• FPCD: Q4 2025 • Data anticipated: >2027

As of 29 April 2026.
Appendix: Glossary.

AZD0754 (STEAP2 dnTGFβRII-armoured CAR-T)

Solid tumours

Trial	Population	Patients	Design	Endpoints	Status
Phase I/II **APOLLO** **NCT06267729**	mCRPC with prior NHA and taxane exposure	60	• Open-label, single-arm, multi-centre trial with dose escalation and dose expansion components	• Primary endpoints (Phase I): DLT, AEs (including AESI and SAEs), determination of recommended dose for expansion phase • Secondary endpoints (Phase I): PSA related changes (PSA50, PSA90), radiological assesssment according to RECIST v1.1 and PCWG3 (ORR, BOR, DRR, DCR, TTR, rPFS, OS), PK parameters (Cmax, Tmax, Tlast, AUC)	• FPCD: Q2 2024 • Data anticipated: 2027

As of 29 April 2026.
Appendix: Glossary.

AZD2068 (FPI-2068, EGFR cMET radioconjugate)

Solid tumours

Trial	Population	Patients	Design	Endpoints	Status
Phase I **NCT06147037**	Advanced solid tumours	110	• Multicentre, open-label dose escalation trial • Part 1: optimisation of FPI-2053 dose (treatment with dose level 1 of [225Ac]-AZD2068 - fixed dose) • Part 2: dose escalation of [225Ac]-AZD2068 with optimal FPI-2053	• Primary endpoints: safety and tolerability • Secondary endpoints: anti-tumour activity, immunogenicity and PK parameters	• FPCD: Q3 2024 • Data anticipated: 2027

As of 29 April 2026.
Appendix: Glossary.

(225Ac) zadavotide guraxetan (AZD2265, PSMA radioconjugate)

Prostate cancer

Trial	Population	Patients	Design	Endpoints	Status
Phase II **AlphaBreak** **NCT06402331** **Partnered (Fusion)**	PSMA-positive mCRPC previously treated with lutetium-PSMA therapy	100	• Open-label, randomised, multi-centre trial	• Primary endpoints: PSA50 and safety	• FPCD: Q2 2024 • Data anticipated: H2 2026

As of 29 April 2026.
Appendix: Glossary.

AZD2284 (STEAP2 radioconjugate)

Prostate cancer

Trial	Population	Patients	Design	Endpoints	Status
Phase I **NCT06879041**	mCRPC	134	• Part A (imaging): • Part A (cold antibody exploration, optimal dosing exploration): AZD2284 +/- AZD2275 • Part A (expansion): prevalence of PSMA and STEAP2 expression by imaging • • Part B (therapeutic): • Part B (actinium-225 dose escalation): AZD2284 dose escalation informed by Part A • Part B (expansion cohorts 1, 2): AZD2284	• Primary endpoints: safety and tolerability • Secondary endpoints: anti-tumour activity, PK parameters and immunogenicity	• FPCD: Q1 2025 • Data anticipated: 2027

As of 29 April 2026.
Appendix: Glossary.

AZD2962 (IRAK4 inhibitor)

Blood cancers

Trial	Population	Patients	Design	Endpoints	Status
Phase I **NCT07064122**	Haematologic neoplasms	72	• Modular, open-label, multicentre • AZD2962 dose escalation	• Primary endpoints: DLT, AEs, duration of exposure, relative dose intensity • Secondary endpoints: OR, DoR, TTR, OS, time to progression, PK measures	• Data anticipated: >2027 • Initiating

As of 29 April 2026.
Appendix: Glossary.

AZD3470 (PRMT5 inhibitor)

Solid tumours and blood cancers

Trial	Population	Patients	Design	Endpoints	Status
Phase I/II **PRIMROSE** **NCT06130553**	MTAP-deficient advanced solid tumours	234	• Open-label, multicentre • Part 1 (dose excalation): AZD3470 • Part 2 (dose optimisation and expansion): AZD3470	• Arm 1: Primary endpoints: safety and tolerability • Secondary endpoints: PK parameters and clinical efficacy	• FPCD: Q1 2024 • Data anticipated: 2027
Phase I **PRIMAVERA** **NCT06137144**	R/R haematologic malignancies	110	• Modular Phase I/II open-label dose escalation and expansion trial • Module 1 – Part A (dose escalation): AZD3470 monotherapy • Module 1 – Part B (dose expansion/optimisation): AZD3470 monotherapy	• Primary endpoints: safety and tolerability • Secondary endpoints: PK parameters and clinical effacacy	• FPCD: Q1 2024 • Data anticipated: H2 2026

As of 29 April 2026.
Appendix: Glossary.

AZD3632 (menin inhibitor)

Blood cancers

Trial	Population	Patients	Design	Endpoints	Status
Phase I/II MOMENTUM NCT07155226	R/R AML, ALL and HR MDS with KMT2Ar, NPM1m, or other genotypes associated with homeobox (HOX) overexpression	84	• Module 1 (dose escalation): AZD3632 • Module 2: AZD3632 + posaconazole	• Primary endpoints: safety and tolerability • Secondary endpoints: preliminary efficacy (CR, CRh, TTR, DoR, TI, EFS, OS), PK parameters	• FPCD: Q1 2026 • Data anticipated: >2027

As of 29 April 2026.
Appendix: Glossary.

AZD4360 (CLDN18.2 TOP1i ADC)

Solid tumours

Trial	Population	Patients	Design	Endpoints	Status
Phase I/II **CONCLUDE** **NCT06921928**	Advanced or metastatic Claudin 18.2-expressing pancreatic ductal adenocarcinoma, gastric/gastroesophageal junction cancer and biliary tract cancer	117	• Open-label, multicentre trial with FIH modular protocol design • Module 1: AZD4360 monotherapy	• Primary endpoints: safety • Secondary endpoints: efficacy, PK, immunogenicity	• FPCD: Q2 2025 • Data anticipated: 2027

As of 29 April 2026.
Appendix: Glossary.

AZD4512 (CD22 TOP1i ADC)

Blood cancers

Trial	Population	Patients	Design	Endpoints	Status
Phase I/II ALLight NCT07109219	Acute Lymphoblastic Leukemia	83	• Modular phase I/II, open-label multi-centre study • Module 1 (dose escalation): AZD4512 • Module 2 (dose expansion): AZD4512	• Module 1: • Primary endpoints: safety • Secondary endpoints: PK, safety, ORR, DoR, EFS, OS • Module 2: • Primary endpoints: ORR, safety • Secondary endpoints: DoR, EFS, OS, PK, safety	• FPCD: Q4 2025 • Data anticipated: >2027
Phase I/II Lumi-NHL NCT07123454	Relapsed/refractory B-cell Non-Hodgkin Lymphoma	91	• Module 1: AZD4512	• Primary endpoints: safety measures • Secondary endpoints: ORR, CR, DoR, PFS, OS	• FPCD: Q4 2025 • Data anticipated: >2027

As of 29 April 2026.
Appendix: Glossary.

AZD4956 (POLQ inhibitor)

Solid tumours

Trial	Population	Patients	Design	Endpoints	Status
Phase I/II **PARTHENON** **NCT07446855** -	HRRm solid tumours	180	• Module 1: AZD4956 monotherapy • Module 2: AZD4956 + saruparib • Each module may further contain 2 parts Part A (dose escalation/dose finding) and Part B (dose expansion)	• Primary endpoints: safety and tolerability • Secondary: PFS, ORR, DoR,BOR •	• FPCD: Q1 2026 • Data anticipated: >2027

As of 29 April 2026.
Appendix: Glossary.

AZD5492 (CD20 TITAN TCE)

Blood cancers

Trial	Population	Patients	Design	Endpoints	Status
Phase I **TITANIUM** **NCT06542250**	Relapsed/refractory B-Cell malignancies	176	• Module 1: AZD5492 monotherapy	• Primary endpoints: safety and tolerability • Secondary endpoints: preliminary efficacy (ORR, CRR, DoR, PFS, OS), PK parameters and immunogenicity	• FPCD: Q3 2024 • Data anticipated: H2 2026

As of 29 April 2026.
Appendix: Glossary.

AZD5863 (CLDN18.2 CD3 bispecific antibody)

Solid tumours

Trial	Population	Patients	Design	Endpoints	Status
Phase I **NCT06005493**	Advanced or metastatic Claudin 18.2-expressing solid tumours	280	• Part A: AZD5863 dose escalation • Part B: AZD5863 dose expansion	• Primary endpoints (Part A): safety and tolerability • Primary endpoints (Part B): safety, tolerability and preliminary anti-tumour activity • Secondary endpoints: preliminary anti-cancer activity, PK parameters and immunogenicity	• FPCD: Q4 2023 • Data anticipated: H2 2026

As of 29 April 2026.
Appendix: Glossary.

AZD6621 (STEAP2 T-cell engager)

Prostate cancer

Trial	Population	Patients	Design	Endpoints	Status
Phase I/II **ACTIVATED-4-PC** **NCT07192614** -	mCRPC	52	• Open-label, multi-centre, modular design • Part 1 (dose escalation): AZD6621 • Part 2 (dose expansion): AZD6621	• Primary: safety, tolerability • Secondary: efficacy, PK, immunogenicity	• FPCD: Q4 2025 • Data anticipated: >2027

As of 29 April 2026.
Appendix: Glossary.

AZD6750 (CD8 guided IL-2)

Solid tumours

Trial	Population	Patients	Design	Endpoints	Status
Phase I/II **NCT07115043**	Select advanced or metastatic solid tumours	60	• Open-label, dose escalation and expansion study • Module 1: AZD6750 monotherapy • Module 2: AZD6750 + rilvegostomig	• Primary endpoints: Safety and efficacy measures • Secondary endpoints: PK/PD parameters, immunogenecity, efficacy	• FPCD: Q3 2025 • Data anticipated: >2027

As of 29 April 2026.
Appendix: Glossary.

AZD7003 (GPC3 CAR-T)

Hepatocellular carcinoma (HCC)

Trial	Population	Patients	Design	Endpoints	Status
Phase I/II **STARLIGHT** **NCT06590246**	GPC3-positive advanced/recurrent HCC	121	• Open-label, single-arm, multicentre trial • Part A1 (dose escalation): AZD7003 • Part A2 (dose expansion): AZD7003 • Part B: AZD7003 at RP2D • China only	• Primary endpoints (Part A): DLT, AEs (including AESI and SAEs), determination of recommended dose for expansion phase • Secondary endpoints (Part B): ORR per RECIST v. 1.1, TTR, DCR, DRR, BoR, DoR, PFS and OS; PK parameters (Cmax, Tmax, Tlast, AUC)	• FPCD: Q4 2024 • Data anticipated: >2027

As of 29 April 2026.
Appendix: Glossary.

AZD8421 (CDK2 inhibitor)

Breast cancer

Trial	Population	Patients	Design	Endpoints	Status
Phase I/II **CYCAD-1** **NCT06188520**	ER+ HER2-negative advanced breast cancer	204	• Module 1: AZD8421 • Module 2: AZD8421+ camizestrant + one or more of abemaciclib or ribociclib or palbociclib	• Primary endpoints: safety and tolerablility • Secondary endpoints: PK parameters	• FPCD: Q4 2023 • Data anticipated: H2 2026

As of 29 April 2026.
Appendix: Glossary.

palacaparib (AZD9574, PARP1-sel BBB inhibitor)

Solid tumours

Trial	Population	Patients	Design	Endpoints	Status
Phase I/IIa **CERTIS-1** **NCT05417594**	Advanced solid malignancies	695	• Modular, open-label, multi-centre dose escalation and expansion trial • Module 1: palacaparib monotherapy • Module 2: palacaparib + temozolomide • Module 3: [11C]AZ14193391 + palacaparib or [11C]AZ14193391 + palacaparib + temozolomide • Module 4: palacaparib + *Enhertu* • Module 5: palacaparib + *Datroway*	• Primary endpoints: safety and tolerability of palacaparib as monotherapy and in combination with anti-cancer agents, determination of PARP1 occupancy in brain by palacaparib at examined doses and plasma concentration and evaluation of safety of radioligand [11C]AZ14193391 • Secondary endpoints: PK parameters and efficacy of palacaparib as monotherapy and in combination with anti-cancer agents	• FPCD: Q3 2022 • Data anticipated: 2027

As of 29 April 2026.
Appendix: Glossary.

AZD9750 (AR PROTAC)

Prostate cancer

Trial	Population	Patients	Design	Endpoints	Status
Phase I/II ANDROMEDA NCT07336446	Metastatic prostate cancer	300	• Open-label, multicenter • Module 1, Part A (dose escalation): AZD9750 • Module 1, Part B (dose optimisation and expansion): AZD9750 • Module 2, Part A (dose escalation): AZD9750 + saruparib • Module 2, Part B (dose expansion): AZD9750 + saruparib	• Primary endpoints: safety and tolerability, clinical efficacy (Part B)	• FPCD: Q1 2026 • Data anticipated: >2027

As of 29 April 2026.
Appendix: Glossary.

AZD9793 (GPC3 TITAN T-cell engager)

Solid tumours

Trial	Population	Patients	Design	Endpoints	Status
Phase I/II **RHEA-1** **NCT06795022**	Metastatic solid tumours	304	• Open label, non randomised, multi-centre, dose escalation and expansion • Module 1: intravenous AZD9793 • Module 2: subcutaneous AZD9793	• Primary endpoint: safety and tolerability • Secondary endpoints: ORR, BOR, DRR, DoR, TTR, PFS, OS, PK parameters	• Data anticipated: >2027 • Active

As of 29 April 2026.
Appendix: Glossary.



BioPharmaceuticals

Approved medicines and late-stage pipeline

Wainua (eplontersen, ligand-conjugated antisense)

ATTR

Trial	Population	Patients	Design	Endpoints	Status
Phase III **CARDIO-TTRansform** **NCT04136171** **Partnered (Ionis Pharmaceuticals, Inc.)**	Hereditary or wild-type transthyretin-mediated amyloid cardiomyopathy (ATTR-CM)	1438	• Arm 1: *Wainua* s.c. • Arm 2: placebo	• Primary endpoints: composite outcome of CV mortality and recurrent CV clinical events at Week 140 • Secondary endpoints: 6MWT, KCCQ, CV events and CV mortality, all cause mortality, composite outcome of CV mortality and recurrent CV clinical events in subgroup of patients treated with tafamidis at baseline	• FPCD: Q1 2020 • Data anticipated: H2 2026
Phase III **EPIC-ATTR** **NCT06194825**	Hereditary or wild-type transthyretin-mediated amyloid cardiomyopathy (ATTR-CM)	64	• Arm 1: *Wainua* s.c. Q4W • Arm 2: placebo • China only	• Primary endpoint (at week 24): percent change from baseline in serum TTR concentration • Secondary endpoints: PK, immunogenicity, disease biomarkers (NT pro-BNP, hsTnT)	• FPCD: Q4 2023 • Data anticipated: H1 2026
Phase III **NEURO-TTRansform** **NCT04136184** **Partnered (Ionis Pharmaceuticals, Inc.)**	Hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN)	168	• Arm 1: *Wainua* s.c. • Arm 2: inotersen s.c.	• Primary endpoints (at Week 35): change from baseline in mNIS+7 and percent change from baseline in TTR concentration • Secondary endpoint (Week 35): changes from baseline in Norfolk QOL • Primary endpoints (at Week 66): change from baseline in mNIS+7, change from baseline in the Norfolk QoL-DN Questionnaire and percent change from baseline in TTR concentration	• FPCD: Q1 2020 • LPCD: Q3 2023 • Data readout: Q2 2022 • Co-primary endpoints met at Week 35 and Week 66

As of 29 April 2026.
Appendix: Glossary.

balcinrenone/dapagliflozin (MR antagonist/modulator + SGLT2 inhibitor)

Heart failure, CKD

Trial	Population	Patients	Design	Endpoints	Status
Phase III **BalanceD-HF** **NCT06307652** -	Heart failure patients with renal impairment (eGFR 20-60 ml/min) with heart failure event within the last 6 months	4800	• Randomised, double-blind, parallel-group, double-dummy, active-controlled, event-driven trial • Arm 1: balcinrenone/dapagliflozin 15mg/10mg • Arm 2: balcinrenone/dapagliflozin 40mg/10mg • Arm 3: dapagliflozin 10mg	• Primary endpoints: time to first occurrences of any the components of the composite of CV death, HF hospitalisation and HF event without hospitalisation • Secondary endpoints: total occurrences (first and recurrent) of the components of the composite of CV death, HF hospitalisation and HF event without hospitalisation; total occurrences (first and recurrent) of HF hospitalisations; time to CV death; the hierarchical composite endpoint of death from any cause, total HF events, and change from baseline in KCCQ total symptom score to 24-week post-randomisation; time to death from any cause	• FPCD: Q2 2024 • Data anticipated: 2027
Phase IIb **MIRO-CKD** **NCT06350123** -	CKD	300	• Multicentre, randomised, double-blind, dose-finding, parallel group, double-dummy trial • Arm 1: balcinrenone/dapagliflozin 15 mg/10 mg once daily • Arm 2: balcinrenone/dapagliflozin 40 mg/10 mg once daily • Arm 3: dapagliflozin 10 mg once daily	• Primary endpoint: Relative change in UACR from baseline to Week 12	• FPCD: Q2 2024 • LPCD: Q4 2024 • Data readout: Q3 2025 • Primary endpoint met

As of 29 April 2026.
Appendix: Glossary.

baxdrostat (selective aldosterone synthase inhibitor)

Hypertension

Trial	Population	Patients	Design	Endpoints	Status
Phase III **Bax24** **NCT06168409**	Patients with resistant hypertension on three or more antihypertensive medications	218	• Arm 1: baxdrostat 2mg QD • Arm 2: placebo QD	• Primary endpoint: effect of baxdrostat vs. placebo on ambulatory 24-hour average systolic blood pressure at Week 12	• FPCD: Q2 2024 • LPCD: Q2 2025 • Data readout: Q4 2025 • Primary endpoint met
Phase III **BaxAsia** **NCT06344104**	Patients with uncontrolled hypertension on two or more antihypertensive medications including patients with resistant hypertension	326	• Arm 1: baxdrostat 1mg QD • Arm 2 baxdrostat 2mg QD • Arm 3: placebo QD	• Primary endpoint: effect of baxdrostat vs. placebo on seated systolic blood pressure at Week 12 • Secondary endpoints: effect of baxdrostat vs. placebo on seated systolic blood pressure at 8 weeks after randomised withdrawal, safety and tolerability	• FPCD: Q2 2024 • LPCD: Q1 2025 • Data readout: Q1 2026 • Primary endpoint met
Phase III **BaxHTN** **NCT06034743**	Patients with uncontrolled hypertension on two or more antihypertensive medications including patients with resistant hypertension	796	• Arm 1: baxdrostat 1mg QD • Arm 2: baxdrostat 2mg QD • Arm 3: placebo QD	• Primary endpoint: effect of baxdrostat vs. placebo on seated systolic blood pressure at Week 12 • Secondary endpoints: effect of baxdrostat vs. placebo on seated systolic blood pressure at 8 weeks after randomised withdrawal, safety and tolerability	• FPCD: Q1 2024 • LPCD: Q1 2025 • Data readout: Q3 2025 • Primary endpoint met
Phase II **FigHTN** **NCT05432167**	Patients with uncontrolled hypertension and CKD	194	• Arm 1: baxdrostat (low dose) • Arm 2: baxdrostat (high dose) • Arm 3: placebo • US only	• Primary endpoint: change from baseline in mean seated systolic blood pressure vs. placebo at Week 26 • Secondary endpoint: to evaluate the treatment effect on SBP at Week 26 by dosing strategy	• FPCD: Q2 2022 • LPCD: Q2 2024 • Data readout: Q3 2024

As of 29 April 2026.
Appendix: Glossary.

baxdrostat (selective aldosterone synthase inhibitor)

Hypertension, primary aldosteronism

Trial	Population	Patients	Design	Endpoints	Status
Phase II **NCT06336356**	Patients with uncontrolled hypertension on one or more antihypertensive medications	45	• Arm 1: baxdrostat 2mg QD • Arm 2: placebo	• Primary endpoint: individual cortisol level before and after ACTH stimulation test at baseline and Week 8	• FPCD: Q2 2024 • LPCD: Q3 2024 • Data readout: Q1 2025
Phase I **NCT06194032**	Healthy volunteers	28	• Arm 1: baxdrostat 16mg (single dose) • Arm 2: baxdrostat 32mg (single dose) • Arm 3: placebo (single dose) • Arm 4: moxifloxacin 400mg (single dose)	• Primary endpoint: placebo-corrected change from baseline QTcF	• FPCD: Q1 2024 • LPCD: Q2 2024 • Data readout: Q3 2024
Phase I **NCT06357520**	Healthy volunteers	14	• Arm 1: baxdrostat 2mg and itraconazole 200mg • US only	• Primary endpoint: AUCinf and Cmax	• FPCD: Q2 2024 • LPCD: Q2 2024 • Data readout: Q3 2024
Phase I **NCT06657105**	Healthy volunteers	22	• Arm1: baxdrostat 2mg and ethiny estradiol/levonorgestrel 0.06/0.3mg	• Primary endpoints: AUCinf, AUClast and Cmax	• FPCD: Q4 2024 • LPCD: Q4 2024 • Data readout: Q2 2025
Phase III **BaxPA** **NCT07007793**	Primary aldosteronism	250	• Multicentre, randomised, double-blind, placebo-controlled, parallel-group • Arm 1: baxdrostat QD • Arm 2: placebo QD	• Primary endpoints: change from baseline in seated systolic blood pressure and achieving normalisation of the renin angiotensin aldosterone system at week 8	• FPCD: Q4 2025 • Data anticipated: >2027
Phase II **SPARK** **NCT04605549**	Patients with primary aldosteronism	18	• Arm 1: baxdrostat 2-8mg QD • US only	• Primary endpoints: safety and tolerability in patients with PA at doses from 2 to 8mg per day for 12 weeks and the reduction in SBP patients with PA after 12 weeks • Secondary endpoints: reduction in DBP as a function of dose in patients with PA after 12 weeks of treatment, change in serum potassium and requirement for potassium supplementation and change in serum sodium and requirement for fluid or mineral replacement	• FPCD: Q3 2022 • LPCD: Q2 2023 • Data readout: Q1 2025

As of 29 April 2026.
Appendix: Glossary.

baxdrostat/dapagliflozin (selective ASI/SGLT2)

CKD/Prevention of heart failure

Trial	Population	Patients	Design	Endpoints	Status
Phase III **BaxDuo-Arctic** **NCT06268873**	CKD and high blood pressure	2500	• Arm 1: baxdrostat/dapagliflozin QD • Arm 2: dapagliflozin/placebo QD	• Primary endpoint: change from baseline in eGFR to post-treatment • Secondary endpoints: change from baseline in SBP and UACR, kidney HCE and eGFR	• FPCD: Q2 2024 • Data anticipated: >2027
Phase III **BaxDuo-Pacific** **NCT06742723**	CKD and high blood pressure	5000	• Arm 1: baxdrostat/dapagliflozin QD • Arm 2: dapagliflozin/placebo QD	• Primary endpoint: Time to the first occurrence of any of the components of the composite of Kidney disease progression (≥ 50% sustained decline in eGFR, Onset of kidney failure), CV events (HF with or without hospitalisation CV death)	• FPCD: Q1 2025 • Data anticipated: >2027
Phase III **PREVENT-HF** **NCT06677060**	T2D, history of hypertension and established CVD and risk factor(s)	11300	• Arm 1: baxdrostat/dapagliflozin QD • Arm 2: dapagliflozin/placebo QD	• Primary endpoint: Time to first occurrence of any of the components of the composite of: Hospitalisation for HF, HF without hospitalisation, CV death •	• FPCD: Q1 2025 • Data anticipated: >2027
Phase II **BaxDuo-Baltic** **NCT07222917** -	CKD and high blood pressure	218	• Arm 1: baxdrostat/dapagliflozin • Arm 2: baxdrostat/Placebo	• Primary endpoint: change from baseline in UACR at 12 weeks	• FPCD: Q4 2025 • Data anticipated: 2027

As of 29 April 2026.
Appendix: Glossary.

laroprovstat (AZD0780, PCSK9 inhibitor)

Dyslipidaemia

Trial	Population	Patients	Design	Endpoints	Status
Phase III **AZURE-HeFH** **NCT07000136**	Heterozygos familial hypercholesterolemia	405	• Randomised, double-blind, placebo-controlled, parallel-group trial • Arm 1: laroprovstat • Arm 2: placebo	• Primary endpoint: Relative change in LDL-C from baseline to 12 weeks • Secondary endpoint: Relative change in LDL-C from baseline to 12 weeks in patients on a statin, indicator for LDL-C < 70 mg/dL (< 1.8 mmol/L) at 12 weeks	• FPCD: Q2 2025 • Data anticipated: 2027
Phase III **AZURE-LDL** **NCT07000123**	Patients with dyslipidaemia and history of clinical ASCVD or at risk for a first ASCVD event	2800	• Randomised, double-Blind, placebo-controlled, parallel-group trial • Arm 1: laroprovstat • Arm 2: placebo	• Primary endpoint: • Relative change in LDL-C from baseline to 12 weeks • Secondary endpoints: • Relative change in LDL-C from baseline to 12 weeks in patients on statins • Indicator for LDL-C < 70 mg/dL (< 1.8 mmol/L) at 12 weeks	• FPCD: Q2 2025 • Data anticipated: 2027
Phase III **AZURE-Outcomes** **NCT07000357**	Patients with dyslipidaemia and established ASCVD or at high risk for a first ASCVD event	15100	• Randomised, double-blind, placebo-controlled, parallel-group trial • Arm 1: laroprovstat • Arm 2: placebo	• Primary endpoint: Time to first event of any component of MACE-PLUS • Secondary endpoints: Time to first event of any component of 3P MACE, Time to first event of any component of MACE PLUS in patients with a history of ASCVD	• FPCD: Q2 2025 • Data anticipated: >2027
Phase II/III **AZURE-China** **NCT06834932**	Participants with elevated LDL-C	360	• Randomised, double-blind, placebo-controlled, multi-centre • China only	• Primary endpoint (Part A) : PK parameters • Secondary endpoint: (Part A) LDL-C at Week 4, To evaluate the effect of treatment with AZD0780 versus placebo on LDL-C at Week 4 • • Primary endpoint (Part B): To compare the effect of treatment with AZD0780 versus placebo on LDL-C at 12 weeks • Secondary endpoint (Part B):To evaluate the effect of treatment with AZD0780 versus placebo on LDL-C at Week 12	• FPCD: Q4 2024 • Data anticipated: 2027

As of 29 April 2026.
Appendix: Glossary.

laroprovstat (AZD0780, PCSK9 inhibitor)

Dyslipidaemia

Trial	Population	Patients	Design	Endpoints	Status
Phase II **PURSUIT** **NCT06173570**	Dyslipidaemia	428	• Randomised trial with equal distribution across five parallel treatment arms to either placebo or one of four AZD0780 doses	• Primary endpoint: percent change in LDL-C level from baseline to Week 12 • Secondary endpoints: percent change from baseline of LDL-C at Week 12, plasma concentrations summarised by sampling timepoint, percent change from baseline at Week 12 in other lipid parameters and inflammatory markers and safety and tolerability	• FPCD: Q1 2024 • LPCD: Q2 2025 • Data readout: Q1 2025 • Primary endpoint met
Phase II **NCT06692764**	Participants with ASCVD or risk equivalents and LDL-C ≥70 mg/dL on stable medication	172	• Multi-centre, randomised, double-blind, placebo-controlled, crossover trial	• Primary endpoint: ambulatory 24-hour average systolic blood pressure at Week 4 • Secondary endpoint: ambulatory 24-hour average diastolic blood pressure at Week 4	• FPCD: Q4 2024 • Data anticipated: H2 2026
Phase I **NCT06576765**	Hepatic impairment and matched healthy controls	32	• Multi-centre, single-dose, non-randomised, open-label, parallel-group trial	• Primary endpoint: PK parameters • Secondary endpoints: safety and tolerability	• FPCD: Q3 2024 • LPCD: Q4 2024 • Data readout: Q2 2025
Phase I **NCT06592482**	Renal impairment and matched healthy controls	30	• Multi-centre, single-dose, non-randomised, open-label, parallel-group trial	• Primary endpoint: PK parameters • Secondary endpoints: safety and tolerability	• FPCD: Q3 2024 • LPCD: Q4 2024 • Data readout: Q2 2025
Phase I **NCT06671405**	Healthy volunteers	78	• Open-label, fixed sequence trial to assess the PK of AZD0780 when administered in combination with itraconazole, carbamazepine, and the PK of midazolam and EE/LNG when administered with AZD0780	• Primary endpoint: PK parameters • Secondary endpoints: safety and PK parameters	• FPCD: Q4 2024 • LPCD: Q1 2025 • Data readout: Q4 2025
Phase I **NCT06742853**	Healthy volunteers with elevated LDL-C	120	• Randomised, single-blind, placebo-controlled trial	• Primary endpoints: percent change in LDL-C at Week-4 and safety and tolerability	• FPCD: Q4 2024 • LPCD: Q3 2025 • Data readout: Q4 2025
Phase I **NCT07216131**	Healthy volunteers	14	• Fixed-sequence, open-label PK trial of laroprovstat effect on metformin	• Primary endpoint: PK measures • Secondary endpoint: safety and tolerability measures	• FPCD: Q4 2025 • LPCD: Q4 2025 • Data anticipated: H1 2026

As of 29 April 2026.
Appendix: Glossary.

laroprovstat (AZD0780, PCSK9 inhibitor)

Dyslipidaemia

Trial	Population	Patients	Design	Endpoints	Status
Phase I **NCT07423598**	Healthy volunteers	40	• Phase I, randomised, single-blind, placebo-controlled study	• Primary endpoint: PK measures • Secondary endpoint: safety and tolerability measures	• FPCD: Q1 2026 • Data anticipated: H2 2026

As of 29 April 2026.
Appendix: Glossary.

laroprovstat + rosuvastatin (PCSK9 inhibitor + HMG-CoA reductase inhibitor)

Dyslipidaemia

Trial	Population	Patients	Design	Endpoints	Status
Phase I NCT07316608 -	Healthy adults	44	• Randomised, open-label, 3 or 4-period, single-dose, two-cohort, multi-centre, crossover study with oral dosing • US only	• Primary: relative bioavailability between FCDP and the STPs • Secondary: PK profile	• Data anticipated: H1 2026

As of 29 April 2026.
Appendix: Glossary.

zibotentan/dapagliflozin (ETA receptor antagonist/SGLT2 inhibitor)

Chronic kidney disease

Trial	Population	Patients	Design	Endpoints	Status
Phase III **ZENITH High Proteinuria** **NCT06087835** -	CKD and high proteinuria	1835	• Randomised, parallel, multi-centre, double-blind trial • Arm 1: zibotentan/dapagliflozin dose A or dose B • Arm 2: dapagliflozin	• Primary endpoint: change in eGFR from baseline • Secondary endpoints: Change in Urine Albumin to Creatinine Ratio (UACR) from baseline; Time to the first occurrence of any of the components of the renal composite endpoint of 40% sustained decline in eGFR or End Stage Kidney Disease (ESKD) or renal death; Change in Urine Protein to Creatinine Ratio (UPCR) from baseline in the biopsy-confirmed IgAN subgroup	• FPCD: Q4 2023 • LPCD: Q4 2024 • Data anticipated: 2027

As of 29 April 2026.
Appendix: Glossary.

Airsupra (PT027, SABA/ICS, pMDI)

Asthma

Trial	Population	Patients	Design	Endpoints	Status
Phase IIIb **ACADIA** **NCT06307665** -	Adolescents with asthma	440	• Randomised, double-blind, multi-centre, parallel-group • Arm 1: BDA MDI 160/180µg prn • Arm 2: AS MDI 180µg prn	• Primary endpoint: severe asthma exacerbation rate (annualised) • Secondary endpoints: time to first severe exacerbation, annualised total systemic corticosteroid exposure, safety (AEs and SAEs), PK sub-study (including Cmax, AUClast and AUCinf)	• FPCD: Q2 2024 • Data anticipated: 2027
Phase IIIb **BATURA** **NCT05505734** **Managed by Avillion (Avillion)**	Adults and adolescents with mild asthma	2517	• Randomised, double-blind, multi-centre, parallel-group, decentralised • 12 to 52-week treatment period • Arm 1: *Airsupra* MDI 160/180µg • Arm 2: AS MDI 180µg • US only	• Primary endpoint: time to first severe asthma exacerbation	• FPCD: Q3 2022 • LPCD: Q1 2024 • Data readout: Q4 2024 • Primary endpoint met
Phase III **BAIYUN** **NCT06471257**	Adult patients with asthma	790	• Randomised, double-blind, multi-centre, event-driven, parallel-group • Arm 1: BDA MDI 160/180µg prn • Arm 2: AS MDI 180µg prn • China only	• Primary endpoint: time to first severe exacerbation • Secondary endpoints: severe exacerbation rate (annualised), total systemic corticosteroid exposure, ACQ-5 responder, AQLQ+12 responder	• FPCD: Q3 2024 • Data anticipated: H2 2026
Phase II **MITCHELL** **NCT06644924** -	Adults with asthma	102	• Randomised, single-dose, double-blind, placebo-controlled, 3-period, 3-treatment, crossover, multicentre • Arm 1: AS MDI 180µg (double-blind) • Arm 2: placebo MDI (double-blind) • Arm 3: Ventolin Evohaler 200µg (open-label) • US Only	• Primary endpoint: Mean change from baseline in FEV1 AUC0-6 (Non-inferiority of AS MDI relative to Ventolin Evohaler) • Secondary endpoints: FEV1 AUC0-6, Mean change from baseline in FEV1 AUC0-4, Safety (AEs and SAEs)	• FPCD: Q1 2025 • LPCD: Q2 2025 • Data readout: Q3 2025 • Primary endpoint met
Phase I **PUTUO** **NCT06514157**	Healthy volunteers	14	• Open-label, single-dose, single-centre trial • Treatment: BDA MDI 160µg/180µg (single dose)	• Primary endpoints: PK parameters for budesonide and albuterol include AUClast, AUCinf, Cmax, tmax, tlast, t½λz, CL/F and Vz/F	• FPCD: Q3 2024 • LPCD: Q3 2024 • Data readout: Q1 2025

As of 29 April 2026.
Appendix: Glossary.

Breztri, Trixeo (LAMA/LABA/ICS)

Asthma

Trial	Population	Patients	Design	Endpoints	Status
Phase III **KALOS** **NCT04609878**	Uncontrolled asthma	2266	• Randomised, double-blind, double-dummy, parallel group and multi-centre trial • Treatments (24- to 52-week variable length) • Arm 1: BGF 320/28.8/9.6µg BID MDI • Arm 2: BGF 320/14.4/9.6µg BID MDI • Arm 3: *Symbicort* Aerosphere 320/9.6µg BID MDI • Arm 4: *Symbicort* 320/9µg BID pMDI	• Primary endpoint: change from baseline in FEV1 AUC0-3 at Week 24 • Secondary endpoint: change from baseline in morning pre-dose trough FEV1 at Week 24	• FPCD: Q1 2021 • Data readout: Q2 2025 • Primary endpoint met
Phase III **LITHOS** **NCT05755906**	Inadequately controlled asthma despite treatment with low dose ICS or ICS/LABA	373	• Randomised, double-blind, parallel group and multi-centre • Treatments (12-week) • Arm 1: PT009 160/9.6µg BID MDI • Arm 2: BD 160µg BID MDI	• Primary endpoint: Change from baseline in forced expiratory volume in 1 second (FEV1) area under the curve 0 to 3 hours (AUC0-3) at Week 12	• FPCD: Q1 2023 • Data readout: Q1 2025 • Primary endpoint met
Phase III **LOGOS** **NCT04609904**	Uncontrolled asthma	2182	• Randomised, double-blind, double dummy, parallel group and multi-centre trial • Treatments (24- to 52-week variable length) • Arm 1: BGF 320/28.8/9.6µg BID MDI • Arm 2: BGF 320/14.4/9.6µg BID MDI • Arm 3: *Symbicort* Aerosphere 320/9.6µg BID MDI • Arm 4: *Symbicort* 320/9µg BID pMDI	• Primary endpoint: change from baseline in FEV1 AUC0-3 at Week 24 • Secondary endpoint: change from baseline in morning pre-dose trough FEV1 at Week 24	• FPCD: Q1 2021 • Data readout: Q2 2025 • Primary endpoint met
Phase III **VATHOS** **NCT05202262**	Inadequately controlled asthma despite treatment with medium dose ICS or ICS/LABA	645	• Randomised, double-blind, parallel group, multi-centre trial • Treatments (24-week) • Arm 1: *Symbicort* Aerosphere 320/9.6µg BID MDI • Arm 2: PT009 160/9.6µg BID MDI • Arm 3: BD 320µg BID MDI • Arm 4:open-label *Symbicort* Turbuhaler 320/9µg BID	• Primary endpoint: change from baseline in FEV1 AUC0-3 at Week 24	• FPCD: Q1 2022 • Data readout: Q2 2025 • Primary endpoint met

As of 29 April 2026.
Appendix: Glossary.

Breztri, Trixeo (LAMA/LABA/ICS)

COPD

Trial	Population	Patients	Design	Endpoints	Status
Phase III **ATHLOS** **NCT06067828**	COPD	180	• Randomised, double-blind, three-treatment, three-period, crossover trial • Treatments (2-week treatment periods, 2-week washout between treatments) • Arm 1: *Breztri* 320/14.4/9.6µg BID MDI • Arm 2: *Symbicort* Aerosphere 320/9.6µg BID MDI • Arm 3: placebo BID MDI	• Primary endpoint: change from baseline in isotime IC • Secondary endpoint: change from baseline in constant work rate cycle ergometry endurance time	• FPCD: Q4 2023 • Data readout: Q1 2026 • Primary endpoint met
Phase III **THARROS** **NCT06283966**	COPD who are at risk of cardiopulmonary event	5000	• Randomised, double blind, event-driven trial • Arm 1: BGF MDI 320/14.4/9.6µg BID • Arm 2: GFF MDI 14.4/9.6µg BID	• Primary endpoint: time to first severe cardiac or COPD event • Secondary endpoints: time to first severe COPD exacerbation event, time to first severe cardiac event, time to cardiopulmonary death, moderate/severe COPD exacerbation rate, time to MI hospitalisation or cardiac death and time to HF acute healthcare visit/hospitalisation or cardiac death	• FPCD: Q1 2024 • Data anticipated: >2027

As of 29 April 2026.
Appendix: Glossary.

Fasenra (IL-5R mAb)

Other eosinophilic diseases

Trial	Population	Patients	Design	Endpoints	Status
Phase III **MANDARA** **NCT04157348**	Patients with r/r EGPA on corticosteroid therapy with or without stable immunosuppressive therapy; age 18 years and older	140	• Arm 1: *Fasenra* 30mg Q4W s.c. • Arm 2: mepolizumab 300mg Q4W s.c. • 52-week trial with a minimum 1-year open label extension	• Primary endpoint: proportion of patients achieving remission (BVAS=0 and OCS dose ≤4mg/day) at Week 36 and Week 48	• FPCD: Q4 2019 • LPCD: Q3 2022 • Data readout: Q3 2023 • Primary endpoint met
Phase III **NATRON** **NCT04191304**	Patients with HES (history of persistent eosinophilia >1500 cells/µL with evidence of end organ manifestations attributable to eosinophilia) and signs or symptoms of HES worsening/flare at Visit 1; age 12 years and older	134	• Randomised, double-blind, placebo controlled • Arm 1: *Fasenra* 30mg Q4W s.c. • Arm 2: placebo Q4W s.c. • 24-week trial with a minimum 1-year open label extension	• Primary endpoint: time to first HES worsening/flare	• FPCD: Q3 2020 • LPCD: Q4 2024 • Data readout: Q2 2025 • Primary endpoint met

As of 29 April 2026.
Appendix: Glossary.

Saphnelo (type I interferon receptor mAb)

Lupus (SLE/LN), sclerosis and other myopathies

Trial	Population	Patients	Design	Endpoints	Status
Phase III **AZALEA-SLE** **NCT04931563** **Partnered (BMS)**	Moderate to severe SLE	276	• Randomised, double-blind, placebo-controlled • Arm 1: 300mg *Saphnelo* i.v. Q4W • Arm 2: placebo i.v. Q4W • Asia only	• Primary endpoint: BICLA at Week 52	• FPCD: Q4 2021 • LPCD: Q2 2024 • Data readout: Q2 2025 • Primary endpoint met
Phase III **IRIS** **NCT05138133** **Partnered (BMS)**	Active, proliferative LN	363	• Randomised, double-blind, placebo-controlled • Arm 1: *Saphnelo* i.v. • Arm 2: placebo i.v.	• Primary endpoint: CRR at Week 52	• FPCD: Q2 2022 • LPCD: Q1 2026 • Data anticipated: 2027
Phase III **LAVENDER** **NCT06015737** **Partnered (BMS)**	Chronic and/or subacute CLE	302	• Randomised, double-blind, placebo-controlled • Arm 1: *Saphnelo* s.c. • Arm 2: placebo s.c.	• Primary endpoint: Clinical response based on CLASI-70 at week 24	• FPCD: Q4 2024 • Data anticipated: 2027
Phase III **TULIP-SC** **NCT04877691** **Partnered (BMS)**	Moderate to severe SLE	367	• Randomised, double-blind, placebo-controlled • Arm 1: *Saphnelo* s.c. • Arm 2: placebo s.c.	• Primary endpoint: BICLA at Week 52	• FPCD: Q3 2021 • LPCD: Q3 2024 • Data readout: Q3 2025 • Primary endpoint met
Phase III **DAISY** **NCT05925803** **Partnered (BMS)**	Systemic sclerosis	306	• Randomised, double-blind, placebo-controlled • Arm 1: *Saphnelo* s.c. • Arm 2: placebo s.c.	• Primary endpoint: CRISS-25 at Week 52	• FPCD: Q4 2023 • LPCD: Q1 2026 • Data anticipated: 2027
Phase III **JASMINE** **NCT06455449** **Partnered (BMS)**	Idiopathic inflammatory myopathies	240	• Randomised, double-blind, placebo-controlled • Arm 1: *Saphnelo* s.c. • Arm 2: placebo s.c.	• Primary endpoint: Total Improvement Score ≥40 at Week 52	• FPCD: Q4 2024 • Data anticipated: 2027

As of 29 April 2026.
Appendix: Glossary.

Tezspire (TSLP mAb)

CRSwNP, COPD, EoE and severe, uncontrolled asthma

Trial	Population	Patients	Design	Endpoints	Status
Phase III **CROSSING** **NCT05583227** **Partnered (AMGEN)**	Adult and paediatric aged 12 years and older with eosinophilic esophagitis	360	• Arm 1: *Tezspire* s.c. low dose • Arm 2: *Tezspire* s.c. high dose • Arm 3: placebo • 52-week trial	• Co-primary endpoints: histologic response of peak esophageal eosinophil per HPF count of ≤6 across all available esophageal levels and change from baseline in Dysphagia Symptom Questionnaire score	• FPCD: Q1 2023 • LPCD: Q3 2025 • Data anticipated: H2 2026
Phase III **EMBARK** **NCT06883305** **Partnered (Amgen)**	Adults with moderate to very severe COPD	990	• Randomised, double-blind, placebo-controlled • Arm 1: *Tezspire* s.c. dose 1 • Arm 2: *Tezspire* s.c. dose 2 • Arm 3: placebo • 52-week treatment minimum	• Primary endpoint: Annualized moderate to severe COPD exacerbations.	• FPCD: Q2 2025 • Data anticipated: >2027
Phase III **JOURNEY** **NCT06878261** **Partnered (Amgen)**	Adults with moderate to very severe COPD	990	• Randomised, double-blind, placebo-controlled • Arm 1: *Tezspire* s.c. dose 1 • Arm 2: *Tezspire* s.c. dose 2 • Arm 3: placebo • 52-week treatment minimum	• Primary endpoint: Annualized moderate to severe COPD exacerbations	• FPCD: Q2 2025 • Data anticipated: >2027
Phase III **WAYPOINT** **NCT04851964** **Partnered (AMGEN)**	Severe chronic rhinosinusitis with nasal polyps; age 18 years and older	416	• Arm 1: *Tezspire* s.c. • Arm 2: placebo s.c. • 52-week trial	• Co-primary endpoint: nasal polyp score and participant reported nasal congestion	• FPCD: Q2 2021 • LPCD: Q4 2023 • Data readout: Q4 2024 • Co-primary endpoints met
Phase III **DIRECTION** **NCT03927157** **Partnered (AMGEN)**	Severe asthma; age 18 to 80 years	405	• Randomised, double-blind, placebo controlled • Arm 1: *Tezspire* s.c. • Arm 2: placebo s.c. • 52-week trial • Regional trial (Asia) – 3 countries	• Primary endpoint: annual asthma exacerbation rate • Secondary endpoints: change from baseline in pre-BD FEV1, asthma related QoL (AQLQ(S)+12) and asthma control (ACQ-6)	• FPCD: Q3 2019 • LPCD: Q2 2023 • Data readout: Q3 2024 • Primary endpoint met
Phase III **NAVIGATOR** **NCT03347279** **Partnered (AMGEN)**	Severe asthma; age 12 to 80 years	1061	• Randomised, double-blind, placebo controlled • Arm 1: *Tezspire* s.c. • Arm 2: placebo s.c. • 52-week trial	• Primary endpoint: annual asthma exacerbation rate • Secondary endpoints: change from baseline in pre-BD FEV1, asthma related QoL (AQLQ(S)+12) and asthma control (ACQ-6)	• FPCD: Q1 2018 • LPCD: Q3 2019 • Data readout: Q4 2020 • Primary endpoint met

As of 29 April 2026.
Appendix: Glossary.

tozorakimab (IL-33 ligand mAb)

COPD

Trial	Population	Patients	Design	Endpoints	Status
Phase III **OBERON** **NCT05166889**	Adults with symptomatic COPD with a history of exacerbations	1132	• Randomised, double-blind, placebo-controlled, parallel-group • Treatment: 52-week • Arm 1: tozorakimab dose 1 s.c. + SoC • Arm 2: tozorakimab dose 2 s.c. + SoC • Arm 3: placebo s.c. + SoC	• Primary endpoint: annualised rate of moderate to severe COPD exacerbations (former smokers) • Secondary endpoints: annualised rate of moderate to severe COPD exacerbations (former or current smokers), annualised rate of COPD exacerbations requiring hospitalisation and/or ER/ED visits and change in pre/post-BD FEV1, E-RS:COPD and SGRQ	• FPCD: Q1 2022 • Data readout: Q1 2026 • Primary endpoint met
Phase III **TITANIA** **NCT05158387**	Adults with symptomatic COPD with a history of exacerbations	1174	• Randomised, double-blind, placebo-controlled, parallel-group • Treatment: 52-week • Arm 1: tozorakimab dose 1 s.c. + SoC • Arm 2: tozorakimab dose 2 s.c. + SoC • Arm 3: placebo s.c. + SoC	• Primary endpoint: annualised rate of moderate to severe COPD exacerbations (former smokers) • Secondary endpoints: annualised rate of moderate to severe COPD exacerbations (former or current smokers), annualized COPD exacerbations requiring • hospitalisation and/or Emergency Room/Emergency Department and change in pre/post-BD FEV1, E-RS:COPD and SGRQ	• FPCD: Q1 2022 • Data readout: Q1 2026 • Primary endpoint met

As of 29 April 2026.
Appendix: Glossary.

tozorakimab (IL-33 ligand mAb)

COPD

Trial	Population	Patients	Design	Endpoints	Status
Phase III **MIRANDA** **NCT06040086**	Adults with symptomatic COPD with a history of exacerbations	1454	• Randomised, double-blind, placebo-controlled, parallel group • Arm 1: tozorakimab dose s.c. + SoC • Arm 2: placebo s.c. + SoC	• Primary endpoint: annualised rate of moderate to severe COPD exacerbations (former smokers) • Secondary endpoints: annualised rate of moderate to severe COPD exacerbations (former or current smokers), annualised rate of severe COPD exacerbations (former and former or current smokers), COPD exacerbations requiring hospitalisation and/or Emergency Room (ER)/ Emergency Department (ED) visits and change in pre/post-BD FEV1, E-RS:COPD and SGRQ	• FPCD: Q4 2023 • Data readout: Q1 2026 • Primary endpoint met
Phase III **PROSPERO** **NCT05742802**	Subjects who completed either OBERON or TITANIA will be offered the opportunity to consent (adults with symptomatic COPD with a history of exacerbations)	1713	• Randomised, double-blind, placebo-controlled, parallel-group, long-term extension trial • Treatment: 52-weeks • Arm 1: tozorakimab dose 1 s.c. + SoC • Arm 2: tozorakimab dose 2 s.c. + SoC • Arm 3: placebo s.c. + SoC	• Primary endpoint: annualised rate of severe COPD exacerbation in primary population of former smokers over the treatment period incorporating both the predecessor studies and PROSPERO • Secondary endpoint: annualised rate of severe COPD exacerbation in the overall population of current and former smokers, time to first severe COPD exacerbation in former smokers, annualised rate of COPD exacerbations requiring hospitalisation and/or ER/ED visits in former smokers.	• FPCD: Q1 2023 • Data readout: Q1 2026 • Primary endpoint not met

As of 29 April 2026.
Appendix: Glossary.

tozorakimab (IL-33 ligand mAb)

Severe viral LRTD, asthma

Trial	Population	Patients	Design	Endpoints	Status
Phase III **TILIA** **NCT05624450**	Adults hospitalised for viral lung infection requiring supplemental oxygen	2870	• Randomised, double-blind, placebo-controlled, parallel group • Arm 1: tozorakimab dose i.v. + SoC • Arm 2: placebo i.v. + SoC	• Primary endpoint: progression to death or to invasive mechanical ventilation/extracorporeal membrane oxygenation • Secondary endpoints: safety and other efficacy measures	• FPCD: Q4 2022 • Data anticipated: H2 2026
Phase II **UMBRIEL** **NCT06932263**	Adult participants with uncontrolled asthma on medium-to-high dose inhaled corticosteroids	540	• Multi-centre, double-blind, placebo-controlled dose range finding • Arm 1: tozorakimab dose 1 s.c. • Arm 2: tozorakimab dose 2 s.c. • Arm 3: placebo s.c.	• Primary endpoint: annualised rate of severe asthma exacerbations • Secondary endpoints: annualised rate of severe asthma exacerbations, time-to-first severe asthma exacerbation; pre and post BD FEV1, change in baseline ACQ- 6 and AQLQ(S), safety and other efficacy measures	• FPCD: Q2 2025 • Data anticipated: 2027

As of 29 April 2026.
Appendix: Glossary.

Next-generation propellant

pMDI

Trial	Population	Patients	Design	Endpoints	Status
Phase III **NCT05755932**	Mucociliary clearance in healthy volunteers	30	• Randomised, double-blind, multi-site, two-way crossover trial with propellant only • Arm 1: NGP pMDI; 6 inhalations BID for 7 days • Arm 2: HFA pMDI; 6 inhalations BID for 7 days	• Primary endpoint: change from baseline in MCC through 60 minutes following inhalation of 99m technetium sulfur colloid and gamma camera imaging • Secondary endpoint: change from baseline in MCC at 3 hours following inhalation of 99m technetium sulfur colloid and gamma camera imaging	• FPCD: Q2 2023 • Data readout: Q4 2024
Phase III **NCT05573464**	Moderate to very severe COPD	542	• Randomised, double-blind, 12-week (with an extension to 52 weeks in a subset of participants), parallel-group, multi-centre trial • Arm 1: *Breztri* MDI NGP 160/7.2/4.8µg (2 inhalations BID) • Arm 2: *Breztri* MDI HFA 160/7.2/4.8µg (2 inhalations BID)	• Primary endpoints: number of participants with AEs/SAEs and potentially clinically significant changes in Digital 12-lead Holter ECG, laboratory values, blood pressure, pulse rate, respiratory rate and body temperature	• FPCD: Q3 2022 • Data readout: Q4 2024
Phase III **NCT05850494**	Well-controlled or partially-controlled asthma	52	• Randomised, mulit-centre double-blind, single-dose crossover trial • Arm 1: NGP propellant only pMDI; 4 inhalations per dose • Arm 2: HFA propellant only pMDI; 4 inhalations per dose	• Primary endpoints: change from baseline FEV1 0 to 15 minutes post-dose, cumulative incidence of bronchospasm events and safety and tolerability	• FPCD: Q2 2023 • Data readout: Q1 2024 • Primary endpoint met
Phase III **NCT06075095**	COPD	300	• Randomised, placebo-controlled, double-blind, multi-centre, 4-week, 3-way crossover pharmacodynamic trial to assess the equivalence of *Breztri* delivered by pMDI NGP vs. with *Breztri* delivered by MDI HFA • Arm 1: *Breztri* pMDI NGP 320/14.4/9.6µg • Arm 2: *Breztri* pMDI HFA 320/14.4/9.6µg • Placebo: MDI HFA	• Primary endpoints: changes in FEV1 AUC (0-4) and change in morning pre-dose trough FEV1 • Secondary endpoints: safety and efficacy	• FPCD: Q1 2024 • Data readout: Q3 2025 • Primary endpoint met
Phase III **NCT06502366**	Asthma	398	• Randomised, placebo-controlled, double-blind, multi-centre, 12-week, 3-way, partial-replicate crossover trial • BDA MDI NGP 160/180µg • BDA MDI HFA 160/180µg • Placebo: MDI HFA	• Primary endpoint: change from baseline in peak FEV1 in 0-60 minutes after dosing at Day 29 • Secondary endpoint: change from baseline in morning pre-dose trough FEV1	• FPCD: Q3 2024 • Data anticipated: H1 2026

As of 29 April 2026.
Appendix: Glossary.

Next-generation propellant

pMDI

Trial	Population	Patients	Design	Endpoints	Status
Phase I **NCT05477108**	Healthy volunteers	108	• Randomised, double-blind, single-dose, single-centre, partial-replicate, 3-way crossover trial • Arm 1: *Breztri* pMDI NGP 160/7.2/4.8µg (single dose of 4 inhalations) • Arm 2: *Breztri* pMDI HFA 160/7.2/4.8µg (single dose of 4 inhalations)	• Primary endpoints: AUCinf, AUClast and Cmax	• FPCD: Q3 2022 • LPCD: Q1 2023 • Data readout: Q4 2023 • Primary endpoint met
Phase I **NCT05569421**	Healthy volunteers	108	• Randomised, double-blind, single-dose, single-centre, partial-replicate, 3-way crossover trial • Arm 1: *Breztri* pMDI NGP 160/7.2/4.8µg (single dose of 4 inhalations) • Arm 2: *Breztri* pMDI HFA 160/7.2/4.8µg (single dose of 4 inhalations)	• Primary endpoints: AUCinf, AUClast and Cmax	• FPCD: Q4 2022 • LPCD: Q2 2023 • Data readout: Q1 2024 • Primary endpoint met
Phase I **NCT06139991**	Healthy volunteers	66	• Randomised, double-blind, single-dose, crossover trial to assess the equivalence of *Airsupra* delivered by pMDI NGP vs. with *Airsupra* delivered by pMDI HFA • Arm A: *Airsupra* pMDI NGP 80/90µg (single dose of 2 inhalations) • Arm B: *Airsupra* pMDI HFA 80/90µg (single dose of 2 inhalations)	• Primary endpoints: AUClast and Cmax	• FPCD: Q4 2023 • LPCD: Q2 2024 • Data readout: Q4 2024
Phase I **NCT06297668**	Healthy volunteers	42	• Randomised, partial double-blind, single dose, three-way crossover trial • Arm 1: BGF MDI HFA 160/7.2/4.8µg with spacer • Arm 2: BGF MDI NGP 160/7.2/4.8µg with spacer • Arm 3: BGF MDI NGP 160/7.2/4.8µg without spacer	• Primary endpoints: AUClast of BGF MDI and Cmax of BGF MDI	• FPCD: Q2 2024 • LPCD: Q2 2024 • Data readout: Q4 2024 • Primary endpoint met
Phase I **NCT06723756**	Healthy volunteers	105	• Randomised, double-blind, single-dose, single-centre, 3-way crossover trial • Arm 1: *Breztri* pMDI NGP 160/14.4/4.8µg (single dose of 2 inhalations) • Arm 2: *Breztri* pMDI HFA 160/14.4/4.8µg (single dose of 2 inhalations)	• Primary endpoints: AUClast and Cmax	• FPCD: Q1 2025 • Data readout: Q3 2025 • Primary endpoint met

As of 29 April 2026.
Appendix: Glossary.



BioPharmaceuticals

Early-stage development

elecoglipron (AZD5004, oral GLP-1 RA)

Type 2 diabetes, obesity

Trial	Population	Patients	Design	Endpoints	Status
Phase IIb **SOLSTICE** **NCT06579105** -	Type 2 diabetes	406	• Arm 1: AZD5004 tablet • Arm 2: AZD5004 tablet • Arm 3: AZD5004 tablet • Arm 4: AZD5004 tablet • Arm 5: AZD5004 tablet • Arm 6: AZD5004 tablet • Arm 7: active comparator semaglutide tablet • Arm 8: placebo matching AZD5004 tablet	• Primary endpoint: change in HbA1c from baseline at 26 weeks • Secondary endpoints: change in fasting glucose from baseline, proportion of participants achieving HbA1c ≤6.5% and baseline HbA1c ≥7% and achieving <7.0% and percent change in body weight from baseline	• FPCD: Q4 2024 • LPCD: Q2 2025 • Data readout: Q1 2026 • Primary endpoint met
Phase IIb **VISTA** **NCT06579092**	Obesity or overweight who have at least one weight-related comorbidity	310	• Arm 1: AZD5004 tablet • Arm 2: AZD5004 tablet • Arm 3: AZD5004 tablet • Arm 4: AZD5004 tablet • Arm 5: AZD5004 tablet • Arm 6: placebo matching AZD5004 tablet	• Primary endpoints: change in body weight from baseline at 26 weeks, proportion of participants with weight loss ≥5% from baseline weight at 26 weeks • Secondary endpoints: change in body weight from baseline at 36 weeks, proportion of participants with weight loss ≥5% and absolute change from baseline in body weight at 26 and 36 weeks •	• FPCD: Q4 2024 • LPCD: Q1 2025 • Data readout: Q1 2026 • Primary endpoints met
Phase I **NCT06555822**	Healthy volunteers	31	• Part A – Arm 1: AZD5004 oral tablet • Part A – Arm 2: placebo oral tablet • Part B: single dose, open label crossover	• Primary endpoints (Part A): safety and tolerability • Secondary endpoints (Part A): PK and PD parameters • Primary endpoint (Part B): PK parameters • Secondary endpoints (Part B): safety and tolerability	• FPCD: Q3 2024 • LPCD: Q1 2025 • Data readout: Q2 2025
Phase I **NCT06703658**	Healthy volunteers or participants with type 2 diabetes mellitus	35	• SAD: 3 cohorts to receive AZD5004 or placebo tablet • MAD: 1 cohort to receive AZD5004 or placebo tablet • Japan only	• Primary endpoints: safety and tolerability • Secondary endpoints: PK and PD parameters	• FPCD: Q4 2024 • LPCD: Q1 2025 • Data readout: Q3 2025

As of 29 April 2026.
Appendix: Glossary.

elecoglipron (AZD5004, oral GLP-1 RA)

Type 2 diabetes, obesity

Trial	Population	Patients	Design	Endpoints	Status
Phase I **NCT06742762**	Healthy volunteers or participants with renal impairment	16	• Multi-centre, single-dose, non-randomised, open-label, parallel-group trial, single oral dose of AZD5004 •	• Primary endpoint: PK parameters • Secondary endpoints: safety and tolerability	• FPCD: Q1 2025 • LPCD: Q2 2025 • Data readout: Q3 2025
Phase I **NCT06813781**	Healthy volunteers or participants with hepatic impairment	33	• Multi-centre, single-dose, non-randomised, open-label, parallel-group trial, single oral dose of AZD5004 •	• Primary endpoint: PK parameters • Secondary endpoints: safety and tolerability	• FPCD: Q1 2025 • LPCD: Q3 2025 • Data readout: Q1 2026
Phase I **NCT06857695**	Healthy volunteers	8	• Part 1: A single dose of AZD5004 film-coated tablet and a single dose of AZD5004 solution for infusion • Part 2: A single dose of AZD5004 oral solution	• Part 1: absolute bioavailability • Part 2: amount of AZD5004 excreted	• FPCD: Q1 2025 • LPCD: Q1 2025 • Data readout: Q3 2025
Phase I **NCT06988553** **Partnered (Eccogene)**	Participants with overweight/obesity with/without T2D	45	• Randomized, parallel group, double-blind trial • AZD5004 or placebo tablet • China only	• Primary endpoints: safety and tolerability	• FPCD: Q2 2025 • LPCD: Q3 2025 • Data readout: Q1 2026
Phase I **NCT06996886**	Healthy volunteers	16	• Open-label, randomised, 4-period, 4-treatment, single-dose crossover trial • Different formulations as single dose of AZD5004	• Primary endpoint: PK profile (relative bioavailability) • Secondary endpoints: PK profile (food effect) • Safety endpoints: safety and tolerability	• FPCD: Q2 2025 • LPCD: Q2 2025 • Data readout: Q4 2025
Phase I **NCT06948747**	Healthy volunteers	49	• Open-label, fixed-sequence, single-centre trial • Part A: AZD5004, Rosuvastatin and Erythromycin tablets • Part B: AZD5004, Atorvastatin and Simvastatin tablets • Part C: AZD5004 and Repaglinide tablets	• Part A, B and C: • Primary endpoints: PK profile • Safety endpoints: safety and tolerability	• FPCD: Q2 2025 • LPCD: Q3 2025 • Data readout: Q4 2025
Phase I **NCT06942936**	Healthy volunteers	51	• Open-label, fixed-sequence, two-part study • Part A: AZD5004 tablet and Itraconazole capsule • Part B: AZD5004 and estradiol/ levonorgestrel tablets	• Primary endpoint: PK profile • Safety endpoints: safety and tolerability	• FPCD: Q2 2025 • LPCD: Q4 2025 • Data readout: Q1 2026
Phase I **NCT07455825**	Healthy volunteers	64	• Open-label, randomised, 2 part, 3-period, single-dose trial • Different formulations as single dose of AZD5004	• Part A and B: • Primary endpoint: PK profile (relative bioavailability) • Secondary endpoints: PK profile (food effect) • Safety endpoints: safety and tolerability	• FPCD: Q2 2026 • Data anticipated: H2 2026

As of 29 April 2026.
Appendix: Glossary.

elecoglipron (AZD5004, oral GLP-1 RA)

Type 2 diabetes, obesity

Trial	Population	Patients	Design	Endpoints	Status
Phase I **NCT07444424**	Healthy volunteers	32	• Open-label, fixed-sequence, two-part, single-centre trial • Part A and Part B are 2 independent and non-sequential parts in this study • Part A: elecoglipron + mitiglinide tablets • Part B: elecoglipron + pioglitazone tablets	• Part A and B: • Primary endpoint: PK profile • Safety endpoints: safety and tolerability	• FPCD: Q2 2026 • Data anticipated: H2 2026

As of 29 April 2026.
Appendix: Glossary.

opemalirsen (AZD2373, APOL1)

Chronic kidney disease

Trial	Population	Patients	Design	Endpoints	Status
Phase IIb **APPRECIATE** **NCT06824987** **Partnered with Ionis Pharmaceuticals Inc (x)**	Participants diagnosed with APOL1 mediated kidney disease (AMKD), proteinuria	96	• Randomised, multi-centre, double-blind trial in US and UK followed by OLE • Arm 1: opemalirsen dose A • Arm 2: opemalirsen dose B • Arm 3: placebo	• Primary endpoint: Dose-response effect of AZD2373 on placebo corrected percentage change in uACR from baseline to Week 30 • Secondary endpoints: Safety and tolerability, proportion of patients achieving a 45% or greater reduction in uACR	• FPCD: Q2 2025 • Data anticipated: 2027
Phase I **NCT07154901** **Partnered (with Ionis Pharmaceuticals Inc)**	Healthy participants/renal impairment	50	• Multicentre, single-dose, non-randomised, open-label, parallel-group	• Primary endpoints: PK measures • Secondary endpoints: PK/PD, safety measures	• FPCD: Q3 2025 • Data anticipated: H2 2026

As of 29 April 2026.
Appendix: Glossary.

AZD1043 (mAb)

Weight management

Trial	Population	Patients	Design	Endpoints	Status
Phase I **D9740C00001** **NCT07511205** -	Healthy participants living with overweight and/or obesity	104	• Randomised, single-blind, placebo-controlled trial • Part A (single ascending doses): • Part A1 (Global SAD, 6 cohorts): AZD1043 • Part A2 (Japanese SAD, 2 cohorts): AZD0143 • Part A1 (Chinese SAD, 1 cohort): AZD1043 • Part B (multiple ascending doses): • Part B1 (Global MAD, 3 cohorts): AZD1043 • Part B2 (Japanese MAD, 1 cohort): AZD1043	• Primary endpoints: Adverse events and serious adverse events • Secondary endpoints: PK and ADA	• Initiating

As of 29 April 2026.
Appendix: Glossary.

AZD1613 (PAPPA-1 mAb)

ADPKD

Trial	Population	Patients	Design	Endpoints	Status
Phase I **NCT06995820**	Healthy volunteers	136	• Randomised, single-blind, placebo-controlled single and multiple ascending dose	• Primary endpoint: safety and tolerability • Secondary endpoints: PK parameters, changes in plasma PD biomarkers	• FPCD: Q2 2025 • Data anticipated: H2 2026
Phase I **NCT07228364**	ADPKD Patients	40	• Single-blind, placebo-controlled, randomised	• Primary endpoints: Safety, PK, PD biomarkers of PAPPA-1 inhibition	• FPCD: Q1 2026 • Data anticipated: 2027

As of 29 April 2026.
Appendix: Glossary.

AZD1705 (Angptl3 inhibitor)

Dyslipidaemia

Trial	Population	Patients	Design	Endpoints	Status
Phase I **NCT06238466**	Dyslipidaemia	112	• Part A: single dose of AZD1705 with an in-clinic period of 3 days followed by an outpatient follow-up period of approximately 16 weeks • Part B: 2 doses of AZD1705 given 28 days apart with an in-clinic period followed by an outpatient follow-up period of approximately 20 weeks	• Primary endpoints: AEs and SAEs • Secondary endpoints: AUCinf, AUClast, Cmax, Ae, fe, CLR, LDL-C, ApoB, triglycerides and target plasma protein	• FPCD: Q1 2024 • LPCD: Q2 2025 • Trial discontinued due to strategic portfolio priorisation

As of 29 April 2026.
Appendix: Glossary.

AZD2389 (anti-fibrotic mechanism)

MASH

Trial	Population	Patients	Design	Endpoints	Status
Phase II **BORANA** **NCT06750276**	Participants with liver fibrosis and compensated cirrhosis	40	• Randomised, single-blind, placebo-controlled trial	• Primary endpoints: safety and tolerability	• FPCD: Q4 2024 • LPCD: Q3 2025 • Data readout: Q4 2025
Phase I **NCT06138795**	Healthy volunteers	128	• Randomised, placebo-controlled SAD/MAD trial	• Primary endpoints: safety and tolerability	• FPCD: Q4 2023 • LPCD: Q2 2025 • Data readout: Q4 2025
Phase I **NCT06812780** -	Healthy volunteers or participants with hepatic impairment	36	• Multi-centre, single-dose, non-randomised, open-label, parallel-group trial	• Primary endpoint: PK parameters • Secondary endpoints: safety and tolerability	• FPCD: Q1 2025 • LPCD: Q3 2025 • Data readout: Q1 2026
Phase I **NCT06846528**	Healthy volunteers	16	• Open-label, fixed-sequence trial • AZD2389 • AZD2389 + itraconazole	• Primary endpoints: PK parameters, safety and tolerability	• FPCD: Q1 2025 • LPCD: Q2 2025 • Data readout: Q3 2025
Phase I **NCT06974565**	Healthy Volunteers	24	• Open-label, randomised, single dose, 2-way crossover	• Pharmacokinetics, safety and tolerability	• FPCD: Q2 2025 • LPCD: Q3 2025 • Data readout: Q4 2025
Phase I **NCT06973005**	Healthy Volunteers	8	• Open label, fixed sequence, 3 period	• Pharmacokinetics, safety and tolerability	• FPCD: Q2 2025 • LPCD: Q3 2025 • Data readout: Q4 2025

As of 29 April 2026.
Appendix: Glossary.

AZD3974 (anti-inflammatory and anti-fibrotic mechanism)

Cirrhosis

Trial	Population	Patients	Design	Endpoints	Status
Phase I **NCT07290283**	Healthy volunteers	176	• Single-blind, placebo-controlled, randomised	• Primary endpoints: Safety/tolerability, PK	• FPCD: Q1 2026 • Data anticipated: H2 2026

As of 29 April 2026.
Appendix: Glossary.

AZD4063 (PLN siRNA)

Dilated cardiomyopathy

Trial	Population	Patients	Design	Endpoints	Status
Phase I **PULSE** **NCT07241104** **Partnered with Ionis Pharmaceuticals Inc (Ionis Pharmaceuticals Inc)**	R14del dilated cardiomyopathy	31	• Unblinded, SAD/MAD with 3 cohorts	• Primary endpoints: Safety and tolerability measures	• FPCD: Q4 2025 • Data anticipated: 2027

As of 29 April 2026.
Appendix: Glossary.

AZD4144 (NLRP3)

Cardiorenal disease

Trial	Population	Patients	Design	Endpoints	Status
Phase IIa SERENIA NCT07215702	Participants with Sepsis-associated Acute Kidney Injury (SA-AKI)	124	• Phase IIa, randomised, double-blind, placebo-controlled study.	• Primary endpoint: AUC 24-hour CrCl • Secondary endpoints: Days alive and free of KRT up to Day 30, Days alive and free of modified KDIGO AKI Stage 2 or 3 up to Days 7, 15, and 30, AUC(D1-7): Serum creatinine, PK/PD measures, safety and tolerability measures	• FPCD: Q1 2026 • Data anticipated: 2027
Phase I NCT06122714	Healthy participants	95	• Randomised, single-blind, placebo-controlled, SAD/MAD sequential group trial	• Primary endpoints: safety and tolerability • Secondary endpoints: PK parameters	• FPCD: Q4 2023 • LPCD: Q4 2024 • Data readout: Q1 2025
Phase I NCT06491550	Healthy participants	92	• Randomised, single-blind, placebo-controlled, SAD/MAD sequential group trial	• Primary endpoints: safety and tolerability • Secondary endpoints: PK parameters	• FPCD: Q3 2024 • LPCD: Q2 2025 • Data readout: Q3 2025
Phase I NCT06693765	Participants with renal impairment, end-stage kidney disease and healthy volunteers	41	• Single-dose, non-randomised, open-label, parallel-group trial	• Primary endpoints: safety, tolerability and PK parameters	• FPCD: Q4 2024 • LPCD: Q2 2025 • Data readout: Q4 2025
Phase I NCT06675175	Participants with established ASCVD	28	• Randomised, double-blind, placebo-controlled, parallel group trial	• Primary endpoints: safety, tolerability and PD parameters • Secondary endpoints: PK and PD parameters	• FPCD: Q1 2025 • LPCD: Q1 2026 • Data readout: Q1 2026
Phase I NCT06948006	Healthy participants	32	• Open-label, randomized, single-dose, crossover trial	• Primary endpoints: PK and safety	• FPCD: Q2 2025 • LPCD: Q2 2025 • Data readout: Q3 2025
Phase I NCT06925854	Healthy participants	12	• Open-label, 2-period, 2-sequence cross over trial • Treatment A: single dose of rosuvastatin • Treatment B: single dose of rosuvastatin in combination with AZD4144 • Participants will be randomized 1:1 ratio to receive treatment sequence AB or BA.	• Primary endpoints: PK and safety	• FPCD: Q2 2025 • LPCD: Q2 2025 • Data readout: Q3 2025

As of 29 April 2026.
Appendix: Glossary.

AZD4144 (NLRP3)

Cardiorenal disease

Trial	Population	Patients	Design	Endpoints	Status
Phase I **NCT06942923**	Healthy participants with obesity	28	• Placebo-controlled, parallel group study	• Primary endpoints: safety, tolerability and PD parameters • Secondary endpoints: PK and PD parameters	• FPCD: Q2 2025 • LPCD: Q3 2025 • Data readout: Q4 2025
Phase I **NCT07518459**	Healthy participants	16	• Open-label, non-randomised, single dose study	• Mass balance recovery, rates and routes of elimination • Metabolite profiling • PK	• FPCD: Q1 2026 • Data anticipated: H1 2026

As of 29 April 2026.
Appendix: Glossary.

AZD4248 (NNMT)

CKD

Trial	Population	Patients	Design	Endpoints	Status
Phase I **NCT07024823**	Healthy volunteers	164	• Randomised, single-blind, placebo-controlled • Part A: SAD in healthy volunteers • Part B: MAD in healthy volunteers • Part C: multiple dosing DKD • Part D: observational cohort	• Primary endpoints: Safety and tolerability measures • Secondary endpoints: PK parameters	• FPCD: Q3 2025 • Data anticipated: H2 2026

As of 29 April 2026.
Appendix: Glossary.

AZD4954 (Lp(a) inhibitor)

Dyslipidaemia

Trial	Population	Patients	Design	Endpoints	Status
Phase I **NCT06980428**	Healthy volunteers	120	• Randomised, placebo-controlled SAD/MAD trial	• Primary endpoints: safety and tolerability	• FPCD: Q2 2025 • Data anticipated: H2 2026
Phase I **NCT07513571**	Healthy participants	32	• Treatment A: single dose of AZD4954 alone • Treatment B: single dose of laroprovstat alone • Treatment C: single doses of laroprovstat + AZD4954 • Cohort 1: Treatment A followed by Treatment C. • Cohort 2: Treatment B followed by Treatment C	• To assess the effect of a single dose of oral laroprovstat on the PK of a single dose of oral AZD4954 in healthy participants.	• FPCD: Q2 2026

As of 29 April 2026.
Appendix: Glossary.

AZD5462 (oral relaxin)

Heart failure

Trial	Population	Patients	Design	Endpoints	Status
Phase IIb **LUMINARA** **NCT06299826**	Stable patients with chronic heart failure	375	• Two cohort, randomised, double-blind, placebo-controlled, multi-centre trial • Arm 1: AZD5462 (high dose) • Arm 2: AZD5462 (medium dose) • Arm 3: AZD5462 (low dose) • Arm 4: placebo	• Primary endpoint: change in heart function from baseline to Week 25 compared to placebo	• FPCD: Q3 2024 • LPCD: Q3 2025 • Data anticipated: H2 2026
Phase Ib **AURORA** **NCT06639087**	Stable patients with heart failure and moderately impaired renal function	8	• Randomised, double-blind, placebo-controlled, multi-centre mechanistic trial • Arm 1: AZD5462 + dapagliflozin • Arm 2: placebo + dapagliflozin	• Primary endpoint: change in fractional excretion of sodium from baseline to Day 1	• FPCD: Q4 2024 • LPCD: Q2 2025 • Data readout: Q1 2026
Phase I **GLITTER** **NCT06661733**	Participants with severe renal impairment and participants with normal renal function	16	• Single centre, non-randomised, open-label, parallel group trial • Cohort 1: AZD5462 • Cohort 2: AZD5462	• Primary endpoints: PK parameters, safety and tolerability	• FPCD: Q4 2024 • LPCD: Q4 2024 • Data readout: Q3 2025
Phase I **PHOTON** **NCT06989983**	Healthy volunteers	8	• Open-label, two-part sequential human ADME trial	• Primary endpoints: mass balance recovery, absorption, metabolism, excretion of [14C]AZD5462 and absolute bioavailability of AZD5462 • Secondary endpoints: safety and tolerability	• FPCD: Q2 2025 • LPCD: Q2 2025 • Data readout: Q1 2026

As of 29 April 2026.
Appendix: Glossary.

AZD6234 (selective amylin receptor agonist)

Obesity with related co-morbidities

Trial	Population	Patients	Design	Endpoints	Status
Phase II **APRICUS** **NCT06595238**	Participants living with obesity or overweight with co-morbidity	231	• Randomised, double-blind, placebo-controlled trial	• Primary endpoints: percent change in body weight from baseline to Week 26 and weight loss ≥5% from baseline weight to Week 26	• FPCD: Q4 2024 • LPCD: Q4 2025 • Data anticipated: H1 2026
Phase II **ARAY** **NCT06851858**	Adults with overweight or obesity and type 2 diabetes on stable GLP-1 RA therapy	69	• Randomised, parallel-group, double-blind, placebo-controlled trial •	• Primary endpoints: Percent change in body weight from baseline at Study Week 2; Weight loss ≥ 5% from baseline at Study Week 26 • Secondary endpoints: Weight loss, HbA1c, PK measures	• FPCD: Q2 2025 • Data anticipated: H2 2026
Phase I/II **AGLOW** **NCT07017179**	Chinese participants with obesity/overweight	48	• Sub study 1: 3 periods totalling up to approximately 23 weeks • Sub study 2: 3 periods totalling up to approximately 36 weeks	• Sub study 1 - To assess the safety and tolerability, PK, efficacy and immunogenicity of repeated subcutaneous (s.c.) doses of AZD6234 compared to placebo • Sub study 2 - To assess the safety and tolerability PK, efficacy and immunogenicity of repeated subcutaneous (s.c.) doses of AZD9550 and of AZD6234 in combination with AZD9550 compared to placebo	• FPCD: Q2 2022 • LPCD: Q1 2026 • Data anticipated: 2027
Phase I **NCT05511025**	Healthy participants who are overweight or obese	64	• SAD trial	• Primary endpoint: safety	• FPCD: Q4 2022 • LPCD: Q4 2023 • Data readout: Q1 2024
Phase I **NCT06132841**	Overweight or obese participants	142	• Randomised, single-blind, placebo-controlled trial with repeated doses of AZD6234 or placebo via s.c. injection	• Primary endpoints: safety and tolerability of repeat doses	• FPCD: Q4 2023 • Data anticipated: H1 2026

As of 29 April 2026.
Appendix: Glossary.

AZD6234 (selective amylin receptor agonist)

Obesity with related co-morbidities

Trial	Population	Patients	Design	Endpoints	Status
Phase I **NCT06845813**	Participants include those with end-stage renal disease (ESRD) on intermittent haemodialysis (HD), severe renal impairment not on dialysis, and optional groups for moderate and mild renal impairment.	48	• Phase I multicentre, single-dose, non-randomised, open-label, parallel-group study aims to examine the pharmacokinetics, safety, and tolerability of AZD6234 in both male and female participants.	• compare the plasma PK of a single SC dose of AZD6234 in participants with ESRD on HD, severe renal impairment (not on dialysis), moderate (optional), and mild (optional) renal impairment to those with normal renal function	• FPCD: Q1 2025 • LPCD: Q3 2025 • Data readout: Q1 2026
Phase I **NCT07013643**	Healthy females of childbearing and non-childbearing potential	50	• Open-label, single-sequence, multiple-cohort study	• To assess the effect of multiple doses of AZD6234 (cohort 1) and AZD6234 and AZD9550 in combination (cohort 2) on the PK of single doses of combined oral contraceptive EE/LEVO	• FPCD: Q3 2025 • Data anticipated: H2 2026

As of 29 April 2026.
Appendix: Glossary.

AZD9550 (GLP-1-glucagon receptor agonist)

MASH, Obesity

Trial	Population	Patients	Design	Endpoints	Status
Phase I/II **CONTEMPO** **NCT06151964**	Overweight and obese participants with T2DM or without T2DM	118	• Randomised, single-blind, placebo-controlled, MAD trial with 4 parts (A to D) • Part A: multiple repeat doses of AZD9550 or placebo given as 4 QW s.c. doses for 4 weeks to 2 sequential cohorts evaluating 2 low dose levels of AZD9550 or placebo • Part B: QW up-titration over 5 doses of AZD9550 or placebo • Part C: bi-weekly/monthly up-titration of AZD9550 or placebo for 24 weeks • Part D: bi-weekly/monthly up-titration of AZD9550 or placebo for 24 weeks (Japan only) • Part E: bi-weekly/monthly up-titration of AZD9550 and AZD6234 or placebo for 24 weeks	• Primary endpoints: safety, tolerability and PK parameters	• FPCD: Q4 2023 • Data anticipated: 2027
Phase I **NCT05848440**	Healthy volunteers	64	• SAD trial	• Primary endpoints: safety and tolerability	• FPCD: Q2 2023 • LPCD: Q4 2023 • Data readout: Q2 2024

As of 29 April 2026.
Appendix: Glossary.

AZD9550+AZD6234 (GLP-1-glucagon receptor agonist + selective amylin receptor agonist)

Obesity

Trial	Population	Patients	Design	Endpoints	Status
Phase IIb **ASCEND** **NCT06862791**	Adults who are living with obesity or overweight with at least one of the following weight-related co-morbidities: hypertension, dyslipidemia or obstructive sleep apnoea	360	• Randomised, parallel-group, double-blind, placebo-controlled, multi-centre, reduced factorial design • IMP injected subcutaneous, once weekly • Arm 1: AZD9550 low dose + AZD6234 low dose or placebos • Arm 2: AZD9550 medium dose + AZD6234 medium dose or placebos • Arm 3: AZD9550 high dose + AZD6234 high dose or placebos • Arm 4: AZD9550 low dose + AZD6234 medium dose or placebos • Arm 5: AZD9550 medium dose + AZD6234 low dose or placebos • Arm 6: AZD9550 high dose + AZD6234 medium dose or placebos • Arm 7: AZD9550 medium dose + AZD6234 high dose or placebos • Arm 8: AZD9550 high dose or placebo • Arm 9: AZD6234 high dose or placebo	• Primary endpoints: percent change in body weight from baseline after 36 weeks of treatment, weight loss ≥ 5% from baseline after 36 weeks of treatment • Secondary endpoints: absolute body weight change, weight loss ≥5%/10%/15% from baseline, ADA incidence/prevalence/titres	• FPCD: Q1 2025 • Data anticipated: H2 2026
Phase I **NCT07546760**	Severe and moderate hepatic impairment and healthy volunteers	28	• Open-label, parallel group trial	• AEs, SAEs and PK	• FPCD: Q2 2026 • Data anticipated: 2027

As of 29 April 2026.
Appendix: Glossary.

atuliflapon (FLAP inhibitor)

Asthma

Trial	Population	Patients	Design	Endpoints	Status
Phase IIa **FLASH** NCT05251259	Patients with moderate-to-severe uncontrolled asthma	666	• Randomised, placebo-controlled, double-blind, multi-centre trial with a lead-in PK cohort • Experimental lead-in PK cohort,: Arm 1: atuliflapon; Arm 2: placebo • Experimental Part 1: Arm 1: atuliflapon; Arm 2: placebo	• Primary endpoint: time to first CompEx asthma event	• FPCD: Q2 2022 • Discontinued due to efficacy

As of 29 April 2026.
Appendix: Glossary.

surovatamig (CD19/CD3 T-cell engager)

RA, SLE

Trial	Population	Patients	Design	Endpoints	Status
Phase I **NCT07201558**	Adult Participants With Rheumatoid Arthritis or Systemic Lupus Erythematosus	48	• Open-label, multicentre • Part 1: SAD • Part 2: SUD	• Primary endpoints: safety and tolerability measures	• FPCD: Q1 2026 • Data anticipated: >2027

As of 29 April 2026.
Appendix: Glossary.

AZD0120 (autologous anti-CD19 and anti-BCMA CAR-T)

Autoimmune conditions, neurology and SLE

Trial	Population	Patients	Design	Endpoints	Status
Phase Ib **AURORA** **NCT07295847**	Adult participants with systemic sclerosis (SSc), idiopathic inflammatory myopathies (IIM), or difficult-to-treat rheumatoid arthritis (D2T RA)	27	• Open-label multi-cohort • Regimen 1: Infusion of AZD0120 regimen 1 • Regimen 2: Infusion of AZD0120 regimen 2	• Primary: Incidence and severity of DLTs (over 28 days) and TEAS (over the study duration) • • Secondary: Cellular kinetics, DAS28-CRP (RA), mRSS (SSc), TIS (IIM), ADA, RCL	• FPCD: Q1 2026 • Data anticipated: >2027
Phase Ib **ZENITH** **NCT07224373**	Adults with refractory active relapsing or progressive multiple sclerosis	24	• Open-label, randomised • Group 1 (RMS): Regimen 1 of AZD0120 • Group 1 (RMS): Regimen 2 of AZD0120 • Group 2 (PMS): Regimen 1 of AZD0120 • Group 2 (PMS): Regimen 2 of AZD0120	• Primary: Incidence and severity of DLTs, AEs, SAEs, and TEAEs • Secondary: B-cell counts, Cellular Kinetics, ARR, CDP-12, CDP-24, CDI, 9HPT, T25FW, EDSS, SDMT, NEDA-3, PIRA, MRI parameters, SF-36v2, Neuro-QoL, RCL, ADA	• FPCD: Q1 2026 • Data anticipated: >2027
Phase Ib/II **PHOENIX** **NCT06897930**	Refractory systemic lupus erythematosus (SLE)	24	• Single-arm, open-label, multi-centre trial	• Primary endpoints (Phase I): safety and tolerability, determination of recommended dose for expansion phase • Secondary endpoints (Phase I): SRI-4, DORIS, LLDAS, BICLA, time from infusion to disease flare, PK parameters, LN-specific responses, disease related biomarker assessments, AZD0120 immunogenicity, RCL presence	• FPCD: Q3 2025 • Data anticipated: >2027
Phase I/II **NCT06530849**	Refractory systemic lupus erythematosus	21	• Single-arm, open label, multi-centre trial	• Primary endpoint (Phase I): safety at 28 days • Primary endpoint (Phase II): efficacy (SRI-4 response) at Week 48	• FPCD: Q3 2024 • Data anticipated: 2027

As of 29 April 2026.
Appendix: Glossary.

AZD1163 (anti-PAD2/4 bispecific antibody)

Rheumatoid arthritis

Trial	Population	Patients	Design	Endpoints	Status
Phase IIb **LaunchPAD-RA** **NCT07276581**	Moderate-to-severely active RA	320	• Double-blind, 4-arm study • Arm 1: s.c. injection of AZD1163 Dose 1 + SoC (csDMARDs or TNFi +/- csDMARD) • Arm 2: s.c. injection of AZD1163 Dose 2 + SoC (csDMARDs or TNFi +/- csDMARD) • Arm 3: s.c. injection of AZD1163 Dose 3 + SoC (csDMARDs or TNFi +/- csDMARD) • Arm 4: placebo + SoC (csDMARDs or TNFi +/- csDMARD)	• Primary endponit: Change from baseline in DAS28-CRP at Week 12 • Key secondary endpoint: Percentage of participants achieving ACR20, ACR50, CDAI and SDAI at Week 12.	• FPCD: Q1 2026 • Data anticipated: 2027
Phase I **NCT06103877**	Healthy volunteers	107	• Randomised, double-blind, placebo-controlled SAD/MAD trial • Part 1 (SAD): 9 cohorts with 8 i.v. administered dose levels and 1 s.c. administered dose level of AZD1163 • Part 2 (MAD): 2 cohorts with 2 s.c. dose levels of AZD1163 • Part 3 (Ethnic cohorts): 1 cohort with 1 s.c. administered dose level of AZD1163 and 2 cohorts with 1 s.c. dose levels of AZD1163	• Primary endpoint: incidence of AEs • Secondary endpoint: PK parameters	• FPCD: Q4 2023 • LPCD: Q2 2025 • Data anticipated: H1 2026

As of 29 April 2026.
Appendix: Glossary.

AZD4604 (inhaled JAK-1 inhibitor)

Asthma

Trial	Population	Patients	Design	Endpoints	Status
Phase IIa **AJAX** **NCT06020014**	Moderate-to-severe asthma uncontrolled on medium-to high-dose ICS-LABA	320	• Multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial • Arm 1: AZD4604 • Arm 2: placebo	• Primary endpoint: time to first CompEx asthma event • Secondary endpoints: Pre-BD FEV1, CAAT, ACQ-6, average morning and average evening PEF, daily asthma symptom score, time to first CompEx acute worsening event, CompEx event rate and CompEx acute worsening event rate	• FPCD: Q4 2023 • LPCD: Q4 2025 • Data anticipated: H1 2026
Phase IIa **ARTEMISIA** **NCT06435273**	Adult patients with moderate-to-severe asthma receiving treatment with medium-to-high dose ICS-LABA	48	• Multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial • Arm 1: AZD4604 • Arm 2: placebo	• Primary endpoint: gene expression in airway epithelial cells • Secondary endpoints: STAT phosphorylation and cellular pathology	• FPCD: Q3 2024 • LPCD: Q4 2025 • Data anticipated: H1 2026
Phase Ib **ATALANTA** **NCT06732882**	Adults with mild asthma	28	• Single bilnd, multi-centre, randomised, placebo-controlled, parallel-group trial via the Turbuhaler and Genuair devices • Arm 1: Genuair 1400 ug BID AZD4604 • Arm 2: Turbuhaler 1400 ug BID AZD4604 • Arm 3: Turbuhaler 150 ug BID AZD4604 • Arm 4: Genuair placebo • Arm 5: Turbuhaler Placebo	• Primary endpoints: PK parameters • Secondary endpoints: PD parameters, FeNO	• FPCD: Q1 2025 • LPCD: Q2 2025 • Data readout: Q4 2025
Phase I **NCT04769869**	Healthy volunteers and patients with mild asthma	137	• SAD/MAD/POM trial • Part 1 SAD • Part 2 MAD • Part 3 POM • UK only	• Primary endpoints: safety and tolerability • Secondary endpoints: PK parameters and FENO	• FPCD: Q4 2021 • LPCD: Q1 2023 • Data readout: Q1 2023
Phase I **NCT06519968**	Healthy volunteers	56	• Part 1a: SAD cohorts in healthy Japanese participants • Part 1b: multiple dose cohort in healthy Japanese participants • Part 2a: SAD cohort in healthy Chinese participants • Part 2b: multiple dose cohort in healthy Chinese participants	• Primary endpoints: safety and tolerability • Secondary endpoints: PK parameters	• FPCD: Q3 2024 • LPCD: Q4 2024 • Data readout: Q1 2025

As of 29 April 2026.
Appendix: Glossary.

AZD5492 (CD20 TITAN TCE)

SLE

Trial	Population	Patients	Design	Endpoints	Status
Phase I **TITAN** **NCT06916806**	Systemic lupus erythematosus (SLE) or Idiopathic inflammatory myopathies (IIM) or Rheumatoid Arthritis (RA)	70	• Open-label, multii-centre • Part 1: Single ascending dose with AZD5492 • Part 2: Step-up dosing with AZD5492	• Primary endpoints: safety and tolerability • Secondary endpoints: PK parameters	• Data anticipated: 2027

As of 29 April 2026.
Appendix: Glossary.

AZD6793 (IRAK4)

COPD

Trial	Population	Patients	Design	Endpoints	Status
Phase II **PRESTO** **NCT07082738**	Moderate to very severe COPD	1160	• Randomised, double-blind, placebo controlled 4 arm study • Dose 1 AZD6793 • Dose 2 AZD6793 • Dose 3 AZD6793 • Placebo	• Primary endpoint: annualised rate of moderate or severe COPD exacerbations • Secondary endpoints: time to first exacerbations, annualised rate of severe exacerbations, CompEx, pre-BD FEV1, post-BD FEV1, BCSS, CAT, SGRQ	• FPCD: Q3 2025 • Data anticipated: >2027
Phase I **NCT05662033**	Healthy volunteers	133	• Single-blind, randomised, placebo-controlled trial	• Primary endpoints: safety and tolerability • Secondary endpoint: PK parameters	• FPCD: Q4 2022 • LPCD: Q4 2024 • Data readout: Q3 2025
Phase I **NCT06368440**	Healthy volunteers	40	• Single-blind, randomised, placebo-controlled trial • Japanese and Chinese healthy participants	• Primary endpoint: safety • Secondary endpoints: PK parameters	• FPCD: Q2 2024 • LPCD: Q4 2024 • Data readout: Q2 2025
Phase I **NCT06494644**	Healthy participants	17	• A single-group trial with a duration of up to 8 weeks (maximum of 53 days) including Screening, Period 1, Period 2, Period 3 and Follow-up to assess the pharmacokinetics of AZD6793 when administered alone and in combination with itraconazole in healthy participants	• Primary endpoint: PK parameters (Cmax, AUC, CL/F, t1/2, tmax, Vz/F, RAUC) • Secondary endpoint: safety	• FPCD: Q3 2024 • LPCD: Q4 2024 • Data readout: Q2 2025
Phase I **NCT07433062**	Participants with Type 2 diabetes mellitus (T2DM)	28	• Double blind, 2-period cross over study to evaluate the effect of steady-state AZD6793 on the steady-state pharmacokinetics/pharmacodynamics of metformin in participants with Type 2 diabetes mellitus	• Mean glucose levels on Day 7 of each treatment period as assessed by CGM metrics (time in range, time in tight range, time below range, time above range, AUC(0-24))	• FPCD: Q1 2026 • Data anticipated: H2 2026

As of 29 April 2026.
Appendix: Glossary.

AZD6912 (siRNA)

Rheumatoid arthritis

Trial	Population	Patients	Design	Endpoints	Status
Phase I **NCT06115967**	Healthy volunteers	40	• Randomised, double-blind, placebo-controlled SAD trial • 5 cohorts with s.c. administered ascending dose level of AZD6912	• Primary endpoint: incidence of AEs • Secondary endpoint: PK parameters	• FPCD: Q4 2023 • LPCD: Q4 2024 • Discontinued due to strategic portfolio prioritisation

As of 29 April 2026.
Appendix: Glossary.

AZD7798 (humanised mAb)

Crohn's disease

Trial	Population	Patients	Design	Endpoints	Status
Phase IIa **AMALTHEA** **NCT06450197**	Moderate to severe Crohn's disease	120	• Randomised, double-blind, placebo-controlled trial • Arm 1: AZD7798 • Arm 2: placebo	• Primary endpoint: Crohn's Disease Activity Index (CDAI) remission • Secondary endpoints: endoscopic response, endoscopic remission, endoscopic score change from baseline, CDAI response, CDAI score change from baseline, symptomatic remission, PK parameters and ADA	• FPCD: Q4 2024 • Data anticipated: H2 2026
Phase II **CALLISTO** **NCT06681324**	Patients with active ileal Crohn's disease and an ileostomy	30	• Participant- and investigator-blind, randomised, placebo-controlled Phase II study • Arm 1: AZD7798 • Arm 2: Placebo	• Primary endpoint: safety • Secondary endpoints: Simple Endoscopic Score for Crohn's Disease (SES-CD) , endoscopic response and remission, PK parameters, ADA	• FPCD: Q1 2025 • Data anticipated: H2 2026
Phase I **NCT05452304**	Global, Japanese and Chinese healthy volunteers	112	• SAD, repeating dose trial • Arm 1: AZD7798 • Arm 2: placebo • s.c. and i.v. administration • UK only	• Primary endpoints: safety and tolerability • Secondary endpoints: PK parameters and immunogenicity	• FPCD: Q3 2022 • LPCD: Q3 2024 • Data readout: Q4 2023

As of 29 April 2026.
Appendix: Glossary.

AZD8630 (inhaled TSLP)

Asthma

Trial	Population	Patients	Design	Endpoints	Status
Phase II **LEVANTE** **NCT06529419** **Partnered (AMGEN)**	Adults with uncontrolled asthma at risk of exacerbations	516	• Randomised, placebo-controlled, double-blind, dose range-finding, multi-centre trial • Arm 1: AZD8630 Dose A • Arm 2: AZD8630 Dose B • Arm 3: AZD8630 Dose C • Arm 4: placebo	• Primary endpoint: time to first CompEx asthma event • Secondary endpoints: change from baseline in pre-bronchodilator forced expiratory volume in 1 second and safety and tolerability	• FPCD: Q3 2024 • LPCD: Q4 2025 • Data anticipated: H1 2026
Phase I **APkITA** **NCT07065331** **Partnered (AMGEN)**	Adolescent participants with asthma aged 11 to 17	22	• Phase 1, open label, single dose study in adolescent participants with asthma where the participants will receive AZD8630 administered via dry powder inhaler	• Area under the serum concentration-time curve from time zero to 24 hours (AUC0-24) • Maximum observed drug concentration (Cmax) • Time to reach peak or maximum observed concentration (Tmax)	• FPCD: Q2 2025 • LPCD: Q3 2025 • Data readout: Q1 2026
Phase I **NCT05110976** **Partnered (AMGEN)**	Healthy volunteers and patients with asthma	232	• SAD and MAD trial	• Primary endpoints: safety and tolerability • Secondary endpoints: PK parameters and FENO	• FPCD: Q1 2022 • LPCD: Q3 2023 • Data readout: Q4 2023 • Primary and Secondary endpoints met
Phase I **NCT06531811** **Partnered (AMGEN)**	Healthy volunteers	32	• Randomised, open-label, 2-treatment, 2-period trial	• Primary endpoints: safety and tolerability • Secondary endpoint: PK parameters	• FPCD: Q3 2024 • LPCD: Q3 2024 • Data readout: Q2 2025
Phase I **NCT06795906** **Partnered (AMGEN)**	Adults with asthma on medium-to-high dose inhaled corticosteroids and long-acting beta-agonists	24	• Randomised, placebo-controlled, double-blind, parallel design	• Primary endpoints: safety and tolerability, pharmacokinetic parameter • Secondary endpoint : change from baseline in FeNO at weeks 1 and 2	• FPCD: Q1 2025 • LPCD: Q2 2025 • Data readout: Q4 2025

As of 29 April 2026.
Appendix: Glossary.

AZD8965 (arginase enzyme inhibitor)

IPF

Trial	Population	Patients	Design	Endpoints	Status
Phase I **NCT06502379**	Healthy volunteers	163	• Randomised, single-blind, SAD/MAD, placebo-controlled, AZD8965/placebo administered orally • PART 1: SAD cohorts • PART 2: MAD cohorts • PART 3a: Japanese and Chinese participants SAD cohorts • PART 3b: Japanese and Chinese participants SMAD cohorts • PART 4: food effect cohort	• Primary endpoints (Part 1, 2, 3): safety and tolerability measures • Primary endpoint (Part 4): PK parameters • Secondary endpoint (Part 1, 2, 3): PK parameters • Secondary endpoints (Part 4): safety and tolerability measures under fasted and fed condition	• FPCD: Q3 2024 • LPCD: Q4 2025 • Data readout: Q1 2026

As of 29 April 2026.
Appendix: Glossary.

AZD0292 (Psl-PcrV N3Y-bispecific mAb)

Bronchiectasis

Trial	Population	Patients	Design	Endpoints	Status
Phase IIb **CLEAR** **NCT07088926**	Bronchiectasis patients ≥ 12 years of age, chronically colonized with PsA	435	• Randomised, double-blind, placebo-controlled, parallel, multidose • 2 dosage regimens (high dose, low dose) of AZD0292 i.v. vs placebo i.v.	• Primary: efficacy • Secondary: safety, PK	• FPCD: Q4 2025 • Data anticipated: >2027
Phase I **NCT06311760**	Healthy volunteers	32	• Randomised, single-blind, placebo-controlled trial • Arm 1: AZD0292 Dose 1 administered via i.v. infusion • Arm 2: AZD0292 Dose 2 administered via i.v. infusion • Arm 3: AZD0292 Dose 3 administered via i.v. infusion • Arm 4: AZD0292 Dose 4 administered via i.v. infusion • Arm 5: placebo administered via i.v. infusion	• Primary endpoints: AEs and participants with AESI • Secondary endpoints: Cmax, AUClast, AUCinfinity and ADA	• FPCD: Q2 2024 • LPCD: Q3 2024 • Data readout: Q2 2025

As of 29 April 2026.
Appendix: Glossary.

AZD5148 (anti-TcdB mAb)

Clostridium difficile

Trial	Population	Patients	Design	Endpoints	Status
Phase IIb **PRISM** **NCT07285213**	Adults with qualifying C. difficile infection episode	230	• Randomised, double-blind, placebo-controlled • AZD5148 or placebo	• Primary endpoint: efficacy • Secondary endpoint: safety, PK	• FPCD: Q4 2025 • Data anticipated: >2027
Phase I **NCT06469151**	Healthy volunteers	84	• Randomised, double-blind, placebo-controlled, dose escalation • Cohort 1: AZD5148 (dose 1, i.m.) or placebo • Cohort 2a: AZD5148 (dose 2, i.m.) or placebo • Cohort 2b: AZD5148 (dose 2, i.m., Chinese participants) or placebo • Cohort 3: AZD5148 (dose 2, i.v.) or placebo • Cohort 4a: AZD5148 (dose 3, i.v.) or placebo • Cohort 4b: AZD5148 (dose 3, i.v., Chinese participants) or placebo • Cohort 5: AZD5148 (dose 4, i.v.) or placebo	• Primary endpoint: safety • Secondary endpoint: PK parameters	• FPCD: Q2 2024 • LPCD: Q4 2024 • Data readout: Q1 2026

As of 29 April 2026.
Appendix: Glossary.

AZD7760 (mAb combination targeting S aureus virulence factors)

Prevention of Staph aureus infection

Trial	Population	Patients	Design	Endpoints	Status
Phase I/IIa **NCT06749457**	Phase I: healthy volunteers male and female participants aged 18 to 55 years Phase IIa: patients with ESKD receiving heamodialysis through a central venous catheter	231	• Phase I: randomised, double-blind, placebo-controlled, dose escalation trial to evaluate the safety and PK of AZD7760 to evaluate 3 doses • Phase IIa: randomised, double-blind, placebo-controlled trialto evaluate the safety and PK of AZD7760	• Primary endpoint (Phase I): safety • Primary endpoint (Phase IIa): safety • Secondary endpoints (Phase I): PK parameters and ADA • Secondary endpoints (Phase Iia): PA parameters, ADA and D451 safety	• FPCD: Q1 2025 • Data anticipated: 2027

As of 29 April 2026.
Appendix: Glossary.



Rare Disease

Approved medicines and late-stage pipeline

Koselugo (selumetinib, MEK inhibitor)

Neurofibromatosis type 1, solid tumours

Trial	Population	Patients	Design	Endpoints	Status
Phase III **KOMET** **NCT04924608** **Partnered (Merck Sharp & Dohme LLC)**	Adults with NF1 who have symptomatic, inoperable PN Available baseline chronic target PN pain score	145	• Multi-centre, international trial with a parallel, randomised, double-blind, placebo-controlled, 2 arm design • Arm 1: *Koselugo* 25mg/m2 BID • Arm 2: placebo BID until end of Cycle 12, then crossover to *Koselugo* 25mg/m2 BID	• Primary endpoint: ORR by end of Cycle 16 on Koselugo vs. placebo as determined by ICR per REiNS criteria • Key secondary endpoint: change from baseline of chronic PN-pain intensity on Koselugo vs. placebo	• FPCD: Q4 2021 • Data readout: Q3 2024 • Primary endpoint met

As of 29 April 2026.
Appendix: Glossary.

Ultomiris (anti-C5 mAb)

Haematology, nephrology, transplant

Trial	Population	Patients	Design	Endpoints	Status
Phase III **ARTEMIS** **NCT05746559**	CSA-AKI	736	• Randomised, double-blind, placebo-controlled, muticentre trial • *Ultomiris* i.v. to protect patients with CKD from CSA-AKI and subsequent MAKE	• Primary endpoint: to assess the efficacy of a single dose of Ultomiris i.v. vs. placebo in reducing the risk of the clinical consequences of AKI (MAKE) at 90 days in adult participants with CKD who undergo non-emergent cardiac surgery with CPB	• FPCD: Q1 2023 • Discontinued due to efficacy
Phase III **AWAKE** **NCT06830798**	Delayed graft function in high risk donor kidneys	450	• Arm1: Placebo • Arm2: *Ultomiris*	• Primary endpoint: time to freedom from dialysis • Secondary endpoints: DGF incidence, number of dialysis sessions, time to first occurrence of eGFR => 30 mL/min/1.73m^2.	• FPCD: Q2 2025 • Data anticipated: >2027
Phase III **I CAN** **NCT06291376**	Immunoglobulin A nephropathy	510	• Arm 1: *Ultomiris* via weight-based i.v. infusion • Arm 2: placebo via weight-based i.v. infusion	• Primary endpoints: change from baseline in proteinuria based on 24-hour UPCR at Week 34 and eGFR over 106 weeks • Secondary endpoints:, reduction in UPCR≥50%, change in proteinuria at week 10, time to sustained ≥30% eGFR decline, composite kidney endpoint	• FPCD: Q2 2024 • Data readout: Q1 2026 • Primary endpoint met
Phase III **TMA-313** **NCT04543591**	Thrombotic microangiopathy-associated haematopoietic stem cell transplant	146	• Arm 1: *Ultomiris* Q8W • Arm 2: placebo	• Primary endpoint: event free survival • Secondary endpoints: overall survival, non-relapse mortality, number of TMA response criteria met	• FPCD: Q4 2020 • LPCD: Q1 2025 • Data anticipated: H1 2026
Phase III **TMA-314** **NCT04557735**	Paedeatric thrombotic microangiopathy-associated haematopoietic stem cell transplant	41	• Arm 1: *Ultomiris* administered once every 4 to 8 weeks	• Primary endpoint: proportion of participants with TMA response • Secondary endpoints: time to TMA response, proportion of participants with TMA relapse	• FPCD: Q4 2020 • LPCD: Q2 2024 • Data readout: Q1 2025 • Positive high-level results

As of 29 April 2026.
Appendix: Glossary.

Ultomiris (anti-C5 mAb)

Nephropathy, neurology

Trial	Population	Patients	Design	Endpoints	Status
Phase II **SANCTUARY** **NCT04564339**	Proliferative lupus nephritis or immunoglobulin A nephropathy	120	• Arm 1: LN cohort, *Ultomiris* • Arm 2: LN cohort, placebo • Arm 3: IgAN cohort, *Ultomiris* • Arm 4: IgAN cohort, placebo	• Primary endpoint: percentage change in proteinuria from baseline to Week 26 • Secondary endpoints: percentage change in proteinuria from baseline to Week 50	• FPCD: Q1 2021 • LPCD: Q2 2025 • Data readout: Q2 2025 • Primary endpoint met (IgAN cohort) • Primary endpoint not met (LN cohort)
Phase II/III **ALXN1210-MG-319** **NCT05644561**	Paediatric patients (6 to < 18 years of age) with documented AChR-Ab (+) Myasthenia Gravis (MG)	12	• Single Arm • *Ultomiris* Q4W (<20 kg) or Q8W (≥20 Kg)	• PK, PD, Safety, Efficacy at Week 18	• FPCD: Q3 2023 • LPCD: Q4 2025 • Data anticipated: H2 2026
Phase II/III **ALXN1210-NMO-317** **NCT05346354**	Neuromyelitis optica spectrum disorder- Pediatric aged 2 to <18 years	12	• Arm 1: *Ultomiris* Q8W	• Primary endpoint: change from baseline in annualised relapse rate at Week 50	• FPCD: Q3 2022 • LPCD: Q2 2026 • Data anticipated: 2027

As of 29 April 2026.
Appendix: Glossary.

anselamimab (CAEL-101, fibril-reactive mAb)

AL amyloidosis

Trial	Population	Patients	Design	Endpoints	Status
Phase III **CARES-301** **NCT04504825**	AL amyloidosis (Mayo Stage IIIb)	124	• Arm 1: anselamimab combined with SoC for PCD • Arm 2: placebo combined with SoC for PCD	• Primary endpoint: a hierarchical combination of time to all-cause mortality and frequency of cardiovascular hospitalisation, safety (TEAEs) • Secondary endpoint: quality of life measures	• FPCD: Q1 2021 • LPCD: Q4 2023 • Data readout: Q3 2025 • Primary endpoint not met
Phase III **CARES-302** **NCT04512235**	AL amyloidosis (Mayo Stage IIIa)	267	• Arm 1: anselamimab combined with SoC for PCD • Arm 2: placebo combined with SoC for PCD	• Primary endpoint: Hierarchical combination of time to all-cause mortality and frequency of cardiovascular hospitalisation, safety (TEAEs) • Secondary endpoint: quality of life measures	• FPCD: Q4 2020 • LPCD: Q4 2023 • Data readout: Q3 2025 • Primary endpoint not met

As of 29 April 2026.
Appendix: Glossary.

cliramitug (ALXN2220, TTR depleter)

Amyloidosis

Trial	Population	Patients	Design	Endpoints	Status
Phase III **DepleTTR-CM** **NCT06183931**	ATTR-CM (wild-type and variant)	1180	• Arm 1: cliramitug via i.v. infusion Q4W for at least 30 months up to a maximum of 48 months • Arm 2: placebo via i.v. infusion Q4W for at least 30 months up to a maximum of 48 months	• Primary endpoint: composite all-cause mortality and total CV events. • Secondary endpoints: KCCQ, 6MWT, all-cause mortality, CV mortality, CV events	• FPCD: Q1 2024 • LPCD: Q2 2025 • Data anticipated: >2027

As of 29 April 2026.
Appendix: Glossary.

efzimfotase alfa (ALXN1850, next-generation asfotase alfa)

Hypophosphatasia

Trial	Population	Patients	Design	Endpoints	Status
Phase III **CHESTNUT** **NCT06079372**	Hypophosphatasia	40	• Arm 1: bodyweight-dependent doses of either 20mg, 35mg or 50mg of efzimfotase alfa Q2W via s.c. for 24 weeks • Arm 2: 6mg/kg/week of Strensiq via s.c. injection as either 2mg/kg 3 times per week or 1mg/kg 6 times per week for 24 weeks	• Primary endpoint: incidence of TEAEs	• FPCD: Q2 2024 • LPCD: Q1 2025 • Data readout: Q1 2026 • Primary endpoint met
Phase III **HICKORY** **NCT06079281**	Hypophosphatasia	114	• Arm 1: placebo on Day 1 followed by Q2W via s.c. injection for 24 weeks • Arm 2: bodyweight-dependent doses of either 20mg, 35mg or 50mg of efzimfotase alfa Q2W via s.c. injection for 24 weeks	• Primary endpoint: change from baseline in 6MWT at Day 169	• FPCD: Q2 2024 • LPCD: Q1 2025 • Data readout: Q1 2026 • Primary endpoint not met
Phase III **MULBERRY** **NCT06079359**	Hypophosphatasia	30	• Arm 1: bodyweight-dependent doses of either 25mg, 35mg, or 50mg of efzimfotase Q2W via s.c. injection for 24 weeks • Arm 2: placebo Q2W for 24 weeks	• Primary endpoint: Radiographic Global Impression of Change (RGI-C) Score at Day 169	• FPCD: Q3 2024 • LPCD: Q3 2025 • Data readout: Q1 2026 • Primary endpoint met
Phase I **ALXN1850-HPP-101** **NCT04980248**	Hypophosphatasia	15	• Arm 1: ALXN1850, 3 cohorts at low, medium and high dosages	• Primary endpoint: incidence of TEAEs and TESAEs	• FPCD: Q3 2021 • LPCD: Q2 2022 • Data readout: Q4 2022 • Primary endpoint met

As of 29 April 2026.
Appendix: Glossary.

eneboparatide (parathyroid hormone receptor 1 agonist)

Hypoparathyroidism

Trial	Population	Patients	Design	Endpoints	Status
Phase III **CALYPSO** **NCT05778071**	Chronic hypoparathyroidism	165	• Arm 1: 20mcg eneboparatide administered once daily via s.c. injection • Arm 2: placebo administered once daily via s.c. injection	• Primary endpoint: complete independence from active vitamin D, independence from therapeutic doses of oral calcium (i.e. taking oral elemental calcium supplements ≤600mg/day) and albumin-adjusted serum calcium within the normal range (8.3 to 10.6mg/dL) vs. placebo after 24 weeks of treatment	• FPCD: Q3 2023 • Data readout: Q1 2025 • Primary endpoint met

As of 29 April 2026.
Appendix: Glossary.

gefurulimab (ALXN1720, anti-C5 dual-binding nanobody)

Neurology

Trial	Population	Patients	Design	Endpoints	Status
Phase III **ALXN1720-MG-301** **NCT05556096**	Generalised myasthenia gravis	260	• Arm 1: weight-based maintenance treatment with gefurulimab on Day 1, followed by weight-based maintenance treatment of gefurulimab on Week 1 (Day 8) and Q1W thereafter for a total of 26 weeks • Arm 2: placebo	• Primary endpoint: change from baseline in MG-ADL total score at Week 26 • Key Secondary endpoints: Change from baseline in QMG total score, Change from baseline in the MGC total score	• FPCD: Q4 2022 • LPCD: Q4 2024 • Data readout: Q3 2025 • Primary endpoint met

As of 29 April 2026.
Appendix: Glossary.



Rare Disease

Early-stage development

tarperprumig (ALXN1820, anti-properdin)

Anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis

Trial	Population	Patients	Design	Endpoints	Status
Phase II **I-TRANSCEND** **NCT07160608**	Newly diagnosed or relapsing ANCA (Anti-Neutrophil Cytoplasmic Antibody)-associated vasculitis patients	75	• Randomised, double-blind, placebo-controlled, parallel group • taperprumig (dose regimen 1 or 2) placebo	• Primary endpoint: safety and tolerability • Secondary endpoints: Remission at Week 26; Sustained Remission at Week 52; Change from baseline in eGFR, uPCR, uACR and hematuria; Number of participants achieving BVAS of 0 through week 52; Time to first relapse	• FPCD: Q4 2025 • Data anticipated: >2027

As of 29 April 2026.
Appendix: Glossary.

ALXN1920 (kidney-targeted factor H fusion protein)

Nephrology

Trial	Population	Patients	Design	Endpoints	Status
Phase II **AUTUMN** **NCT07157787** -	Primary membranous nephropathy (PMN)	30	• Randomised, double-blind, placebo-controlled • ALXN1920 SC infusion • Placebo SC infusion	• Primary Endpoint: Change From Baseline in Proteinuria Based on 24-hour UPCR at Week 26 • Secondary endpoints: Change From Baseline in Proteinuria Based on 24-hour UPCR, Change From Baseline in Proteinuria Based on Spot UPCR at Week 26, Change From Baseline in Serum Albumin at Week 26, Change From Baseline in Anti-phospholipase A2 Receptor (anti-PLA2R) Antibody Level at Week 26, Change From Baseline in Peripheral Cluster of Differentiation 20 (CD20+) B Cell Count at Week 4, Week 8, and Week 26, Change From Baseline biomarker level at Week 26	• FPCD: Q1 2026 • Data anticipated: 2027
Phase I **ALXN1920-HV-101** **NCT05751642**	Healthy adults	48	• Randomised, double-blind, placebo-controlled SAD trial	• Primary endpoints: safety and tolerability • Secondary endpoints: PK/PD parameters	• FPCD: Q2 2023 • LPCD: Q4 2023 • Data readout: Q2 2024

As of 29 April 2026.
Appendix: Glossary.

ALXN2030 (siRNA targeting complement C3)

Transplant

Trial	Population	Patients	Design	Endpoints	Status
Phase II **CONCORD** **NCT06744647**	Kidney transplant recipients with late active or chronic active antibody-mediated rejection (AMR)	45	• Randomised, controlled, double-blind • ALXN2030 Dose A • ALXN2030 Dose B • Placebo	• Primary endpoint: Biopsy-proven histologic resolution at 52 weeks • Secondary endpoints: Biopsy-proven histologic resolution at 28 weeks, change from baseline in biopsy-proven histologic scores at 28 and 52 weeks, eGFR, TEAEs, PK measures	• FPCD: Q4 2025 • Data anticipated: 2027
Phase I **ALXN2030-HV-101** **NCT05501717**	Healthy volunteers	48	• Randomised, placebo-controlled SAD trial	• Primary endpoint: safety	• FPCD: Q4 2022 • LPCD: Q2 2025 • Data anticipated: H2 2026

As of 29 April 2026.
Appendix: Glossary.

ALXN2230

Neurology and haematology

Trial	Population	Patients	Design	Endpoints	Status
Phase I NCT07352423	Healthy participants	40	• Randomised, double-blind, placebo controlled trial • Single ascending dose of ALXN2230	• Primary endpoint: Safety and tolerability • Secondary endpoints: PK/PD	• FPCD: Q1 2026 • Data anticipated: 2027

As of 29 April 2026.
Appendix: Glossary.

ALXN2350 (AAV gene therapy)

BAG3-associated dilated cardiomyopathy (DCM)

Trial	Population	Patients	Design	Endpoints	Status
Phase I/II **DCMRestore** **NCT07218887**	BAG3 mutation associated dilated cardiomyopathy	18	• Open-label, dose finding and dose expansion study • ALXN2350 one of three doses as single IV infusion	• Primary endpoint: Part A TEAEs, SAEs up to week 78 • Secondary endpoints: Part B TEAEs, SAEs, cardiac events, time to first event of death, heart transplant, mechanical circulating supporting or aborted sudden cardiac death, up to week 78	• Data anticipated: >2027 • Initiating

As of 29 April 2026.
Appendix: Glossary.

ALXN2420 (GH receptor antagonist)

Acromegaly

Trial	Population	Patients	Design	Endpoints	Status
Phase IIb **ASTERIA** NCT07037420 -	Acromegaly	60	• Randomised, double-blinded, placebo-controlled, dose range-finding, multicentre study • ALXN2420 s.c.+ somatostatin analogs	• Primary endpoint: Percentage change from baseline in serum IGF-1 level at Week 15 • Secondary endpoints: Serum IGF-1 level ≤ 1.3 ULN at Week 15, Achievement of serum IGF-1 level ≤ 1.0 ULN at Week 15, Change from baseline in symptoms, as assessed by AcroSD/IGF-1 scores, at Week 15, Change from baseline in SF-36 summary scores and subscores at Week 15, Change from baseline in EQ-5D-5L at Week 15, Change from baseline in AcroQoL at Week 15, Change from baseline in global impression of severity at Week 15 as assessed by PGIS scale, Global impression of change at Week 15 as assessed by PGIC scale	• FPCD: Q4 2025 • Discontinued due to strategic portfolio prioritisation

As of 29 April 2026.
Appendix: Glossary.

AZD0120 (autologous anti-CD19 and anti-BCMA CAR-T)

AL amyloidosis

Trial	Population	Patients	Design	Endpoints	Status
Phase I/II **ALACRITY** **NCT07081646**	Relapsed or Refractory AL Amyloidosis	91	• Open-label, multicentre, non-randomised trial	• Primary endpoint: % of pts achieving complete hematologic response (CR) through 6 months • Secondary endpoints: % of patients achieving modified hematologic response (CR+VGPR+low dFLC response) through 6 months, MRD negativity through 6 months, OS, EFS	• FPCD: Q3 2025 • Data anticipated: >2027

As of 29 April 2026.
Appendix: Glossary.

AZD1390 (ATM inhibitor)

Solid tumours

Trial	Population	Patients	Design	Endpoints	Status
Phase I NCT03423628	Recurrent glioblastoma eligible for re-irradiation, brain metastases and leptomeningeal disease, newly-diagnosed glioblastoma patients	180	• Open-label trial • Arm 1: recurrent GBM, AZD1390 + RT in dose escalation cohorts (Japan safety/PK cohorts added); optional food effect cohort initiated • Arm 3: primary GBM, AZD1390 + RT in dose escalation cohorts	• Primary endpoints: safety, tolerability and MTD • Secondary endpoints: PK parameters and preliminary assessment of anti-tumour activity	• FPCD: Q2 2018 • Data anticipated: H2 2026

As of 29 April 2026.
Appendix: Glossary.

NEXT

Glossary – 1 of 5

14C	Carbon 14
1L, 2L, 3L	1st-, 2nd- or 3rd-line
5-FU	5-fluorouracil
6MWT	6-minute walk test
A2AR	Adenosine A2A receptor
AAV	Adeno-associated virus
ACE	Angiotensin-converting enzyme
AChR+	Acetylcholine receptor-positive
ACQ	Asthma Control Questionnaire
ACR	American College of Rheumatology Response Scoring System
ADA	Anti-drug antibody
ADC	Antibody-drug conjugate
ADP	Adenosine diphosphate
ADsCa	Albumin-adjusted serum calcium
AE	Adverse event
AER	Annual exacerbation rate
AEs	Adverse effects
AGA	Actional genomic alteration
aHUS	Atypical haemolytic uraemic syndrome
AI	Auto-injector
AI	Aromatase inhibitor
AKT	Protein kinase B
AL amyloidosis	Light-chain amyloidosis
ALK	Anaplastic large-cell lymphoma kinase
ALL	Acute lymphocytic leukaemia
alloSCT	Allogeneic stem cell tranplantation
ALSFRS-R	Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised
AML	Acute myeloid leukaemia
AMR	Antibody mediated rejection
anti-FRα	Anti-folate receptor alpha
anti-PCD	Anti-plasma cell dyscrasia
APFS	Accessorised pre-filled syringe
APOL1	Apolipoprotein L1
APOL1 G0/G1/G2	Sequences of the G0, G1, and G2 APOL1 variants from amino acids 339–398
AQLQ	Asthma Quality of Life Questionnaire
AQP4+	Aquaporin-4 antibody positive
ARB	Angiotensin receptor blockers
AS	Albuterol sulfate
ASCO	American Society of Clinical Oncology
ASI	Aldosterone synthase inhibitor
ASO	Antisense oligonucleotide
ATM	Ataxia telangiectasia mutated kinase
ATR	Ataxia telangiectasia and Rad3-related protein
ATTR	Transthyretin amyloidosis
ATTR-CM	Transthyretin amyloid cardiomyopathy
ATTR-PN	Transthyretin amyloid polyneuropathy
ATTRv-PN	Hereditary transthyretin-mediated amyloid polyneuropathy
AUC	Area under curve
AUCinf	Area under plasma concentration time curve from zero to infinity
AUClast	Area under plasma concentration curve from zero to the last quantifiable concentration
AUCt	Area under concentration-time curve
AUEC	Area under the effect-time curve
Avb8	Alpha v beta 8
B7H4	B7 homolog 4
BA	Bioavailability
BAFF	B-cell activating factor
B-ALL	B cell acute lymphoblastic leukaemia
BBB	Blood-brain barrier
BCG	Bacillus Calmette-Guérin
BCL2	B-cell leukemia/lymphoma 2 protein
BCMA	B-cell maturation antigen
BDA	Budesonide albuterol
BFF	Budesonide and formoterol fumarate
BGF	Budesonide, glycopyrronium and formoterol fumarate
BICLA	British Isles Lupus Assessment Group-based Composite Lupus Assessment
BICR	Blinded independent central review
BID	Twice per day
BIG	Big Ten Cancer Research Consortium
BM	Biomarker
BMD	Bone mineral density
BMFI	Bone metastasis-free interval
BMI	Body mass index
BOR	Best overall response rate
BR	Bendamustine and rituximab
BRCA	BReast CAncer gene
BRCAm	BReast CAncer gene-mutated
BRCAwt	BReast CAncer wild-type gene
BRD4	Bromodomain-containing protein 4
BTC	Biliary tract carcinoma
BTC	Biliary tract cancer
BTK	Bruton's tyrosine kinase
BTKi	Bruton's tyrosine kinase
BVAS	Birmingham Vasculitis Activity Score
C3	Complement component 3
C5	Complement component 5
CA-125	Cancer antigen-125
CAAT	Chronic Airways Assessment Test
CAD	Coronary artery disease
CAGR	Compound annual growth rate
cAMR	Chronic antibody-medicated rejection
CAR-T	Chimeric antigen receptor therapy
CBP	Cardiopulmonary bypass
CBR	Clinical benefit rate
CD	Cluster of differentiation
CD123	Interleukin 3 receptor a
CD19	Cluster of differentiation 19
CD3	Cluster of differentiation 3
CD39	Cluster of differentiation 39
CD73	Cluster of differentiation 73
CD8	Cluster of differentiation 8
CDAI	Clinical Disease Activity Index
CDK	Cyclin-dependent kinase
CDK2	Cyclin-dependent kinase 2
CDK4/6i	Cyclin-dependent kinase 4/6 inhibitor
CE	Clinically evaluable
CHD	Coronary heart disease
Chemo	Chemotherapy
CHF	Chronic heart failure
cHL	Classic Hodgkin lymphoma
CI	Confidence interval
CKD	Chronic kidney disease
CLD	Chronic lung disease
CLDN 18.2	Claudin-18.2
CLDN18.2	Claudin 18.2
CLL	Chronic lymphocytic leukaemia
cm	Centimetre
CM	Cardiomyopathy
CMAX	Maximum observed plasma concentration
cMET	C-mesenchymal epithelial transition factor
CMML	Chronic myelomonocytic leukaemia

Glossary – 2 of 5

CNS	Central nervous system
CNS-PFS	Central nervous system progression-free survial
CompEx	Composite endpoint for exacerbations
COPD	Chronic obstructive pulmonary disease
CPB	Cardiopulmonary bypass
CPI	Checkpoint inhibitor
CPI-experienced	Checkpoint inhibitor-experienced
CPI-naive	Checkpoint inhibitor-naïve
cPR	Central pathological review
CR	Complete response
CRC	Colorectal cancer
CrCl	Creatinine clearance
CRR	Complete response rate
CRR	Complete renal response
CRSwNP	Chronic rhinosinusitis with nasal polyps
CRT	Chemoradiotherapy
CRwNP	Chronic rhinosinusitis with nasal polyps
CSA-AKI	Cardiac surgery-associated acute kidney injury
CTC	Circulating tumour cell
CTCAE	Common Terminology Criteria for Adverse Events
ctDNA	Circulating tumor DNA
CTLA4	Cytotoxic T-lymphocyte associated protein 4
CTLA-4	Cytotoxic T-lymphocyte-associated antigen-4
CTx	Chemotherapy
CV	Cardiovascular
CVOT	Cardiovascular outcomes trial
CVRM	Cardiovascular, Renal and Metabolism
CXCR2	C-X-C Motif chemokine receptor 2
CyBorD	Cyclophosphamide, bortezomib and dexamethasone
Dato-DXd	Datopotamab deruxtecan
DCR	Disease control rate
DDFS	Distant disease-free survival
DDI	Drug-drug Interaction
DDR	DNA damage response
dECG	Differentiated electrocardiogram
DFS	Disease-free survival
DGF	Delayed graft function
DLBCL	Diffuse large B-cell lymphoma
DLT	Dose-limiting toxicity
DMARDs	Disease-modifying antirheumatic drugs
DNA	Deoxyribonucleic acid
dNCC	Directly measured non-ceruloplasmin-bound copper
dnTGFb	Dominant-negative transforming growth factor-beta
DoCR	Durability of complete response
DoR	Duration of response
DPB	Disease progression in bone
DPI	Dry powder inhaler
dPTEN	Phosphatase and tensin homolog deficient
DRFI	Disease recurrence-free interval
DSQ	Dysphagia Symptom Questionnaire
DXA	Dual energy X-ray absorptiometry
EBITDA	Earnings before interest, tax, depreciation and amortisation
EBRT	External beam radiation therapy
ECG	Electrocardiogram
ED	Emergency department
EFS	Event-free survival
EG	Eosinophilic gastritis
EGE	Eosinophilic gastroenteritis
eGFR	Estimated glomerular filtration rate
eGFR	Epidermal growth factor receptor-mutated
EGFRi	Epidermal growth factor receptor inhibitor
EGFRm	Epidermal growth factor receptor-mutated
EGPA	Eosinophilic granulomatosis with polyangiitis
EM	Emerging Markets
EoE	Eosinophilic oesophagitis
EOS	Eosinophil
EPI	Epigenetics
ER	Estrogen receptor
ER+	Estrogen receptor-positive
ERK	Extracellular signal-regulated kinase
ERoW	Established Rest of World
E-RS:COPD	Evaluating Respiratory Symptoms in Chronic Obstructive Pulmonary Disease
ERT	Enzyme replacement therapy
ESAI	Eczema Area and Severity Index
ESCC	Esophageal squamous cell carcinoma
ESKD	Early-stage kidney disease
ESR1	Estrogen receptor 1
ESRD	End-stage renal disease
ET	Endocrine therapy
ETA	Endothelin A
ETA	Endothelin A
ETA RA	Endothelin receptor A antagonist
EU	European Union
EVH	Extravascular haemolysis
FAF	Fundus autofluorescence
FCR	Fludarabine, cyclophosphamide and rituximab
FDC	Fixed-dose combination
FeNO	Fractional nitric oxide concentration in exhaled breath
FEV	Forced-expiratory volume
FEV1	Forced expiratory volume in 1 second
FGFR	Fibroblast growth factor receptor
FL	Follicular lymphoma
FLAP	5-lipoxygenase activating protein
FLOT	Fluorouracil, leucovorin, oxaliplatin and docetaxel
FOLFOX	Folinic acid, fluorouracil and oxaliplatin
FOXP3	Forkhead box P3
FP	5-fluorouracil/cisplatin
FPCD	First patient commenced dosing
FPG	Fasting plasma glucose
FRα	Folate receptor alpha
FX	Foreign exchange
G7	US, Japan, EU5
GA	Geographic atrophy
GBM	Glioblastoma
gBRCAm	Germline BRCA-mutated
GC	Gastric cancer
GCB	Germinal center B-cell
GEJ	Gastric/gastroesophogeal junction
GEJC	Gastroesophageal junction cancer
GFF	Glycopyrronium and formoterol fumarate
GI	Gastrointestinal
GLP-1	Glucagon-like peptide-1
GLP-1/glu	Glucagon-like peptide 1 receptor/glucagon dual peptide agonist
GLP-1RA	Glucagon-like peptide 1 receptor agonist
GMFR	Geometric mean fold rise
gMG	Generalised myasthenia gravis
GMT	Geometric mean titer
GN	Glomerulonephritis
GPC3	Glypican-3
GPC3-positive	Glypican 3-positive

Glossary – 3 of 5

GPRC5D	G protein-coupled receptor, class C, group 5, member D
GU	Genitourinary
GYN	Gynaecologic
H1	H1-antihistamine
hADME	Human mass balance
HbA1c	Glycated haemoglobin
HCC	Hepatocellular carcinoma
HD	High dose
HDL-C	High-density lipoprotein cholesterol
HER2	Human epidermal growth factor receptor 2
HER2-low	Human epidermal growth factor receptor 2-low
HER2-negative	Human epidermal growth factor receptor 2-negative
HER2-positive	Human epidermal growth factor receptor 2-positive
HES	Hyper eosinophilic syndrome
HF	Heart failure
HFA	Hydrofluoroalkane
HFO	Hydrofluoro-olefins
HFpEF	Heart failure with preserved ejection fraction
HFrEF	Heart failure with reduced ejection fraction
HGFR	Met/hepatocyte growth factor receptor
HGSC	High-grade serous carcinoma
hHF	Hospitalisation for heart failure
HIF-PH	Hypoxia inducible factor-prolyl hydroxylase
HK	Hyperkalaemia
HLA-A*02:01	Human leukocyte antigen serotype within the HLA-A serotype group
HLR	High-level results
hMPV	Human metapneumovirus
HNSCC	Head and neck squamous-cell carcinoma
HPD	Hyperprogressive disease
HPDD	Highest protocol-defined dose
HPF	High-power field
HPP	Hypophosphatasia
HR	Hazard ratio
HR+	Hormone receptor-positive
HRD	Homologous recombination deficiency
HRD+	Homologous recombination deficiency-positive
HR-low	Hormone receptor-low
HRR	homologous recombination repair
HRRm	Homologous recombination repair-mutated
HSCT-TMA	hematopoietic stem cell transplantation-associated thrombotic microangiopathy
HSD17B13	Hydroxysteroid 17-beta dehydrogenase 13
HVPG	Hepatic venous pressure gradient
i	Inhibitor
i.m.	Intramuscular
i.v.	Intravenous
IA	Investigator-assessed
IBD	Inflammatory bowel disease
ICR	Independent central review
ICS	Inhaled corticosteroid
ICS-LABA	Inhaled corticosteroid long-acting beta-agonists
ICU	Intensive care unit
IDFS	Invasive disease-free survival
IgAN	Immunoglobulin A nephropathy
IHF	Impaired hepatic function
IIT	Investigated initiated trial
iJAK1	Inhaled Janus kinase
IL	Interleukin
IL-12	Interleukin-12
IL-33	Interleukin-33
IL-5	Interleukin-5
IL-5R	Interleukin-5 receptor
IMAC-TIS	International Myositis Assessment And Clinical Studies-Total Improvement Score
IND	Investigational new drug
INV	Investigator review
IO	Immuno-oncology
IPF	Idiopathic pulmonary fibrosis
IPFS	Invasive progression-free survival
IRA	Inflation Reduction Act
IRAK4	Interleukin-1 receptor-associated kinase 4
IRC	Independent review committee
ISS	Investigator-sponsored studies
ISS7	Itch-severity score (weekly)
iTSLP	Inhaled thymic stromal lymphopoietin
ITT	Intent-to-treat
IVIg	Intravenous immunoglobulin
JAK-1	Janus kinase 1
K+	Potassium
KCCQ	Kansas City Cardiomyopathy Questionnaire
kg	Kilogram
Ki67	Antigen Kiel 67
LA amylin	Long-acting amylin
LAAB	Long-acting antibody
LABA	Long-acting beta agonist
LAMA	Long-acting muscarinic agonist
LCAT	Lecithin-cholesterol acyltransferase
LCM	Lifecycle management
LDH	Lactate dehydrogenase
LDL-C	Low-density lipoprotein cholesterol
LICA	Ligand-conjugated ASO
LIF	Low-density lipoprotein cholesterol
LN	Lupus nephritis
LoE	Loss of exclusivity
LOS	Length of stay
LPCD	Last patient commenced dosing
LSD	Last subject dosed
LS-SCLC	Limited stage small-cell lung cancer
LV	Left ventricle
m	Mutation
mAb	Monoclonal antibody
MABA	Muscarinic antagonist-beta2 agonist
MACE	Major adverse cardiac events
MAD	Multiple ascending dose
MAKE	Major adverse kidney events
MASH	Metabolic dysfunction-associated steatohepatitis
MASLD	Metabolic dysfunction-associated steatotic liver disease
mBC	Metastatic breast cancer
MCC	Mucociliary clearance
MCL	Mantle cell lymphona
mCRPC	Metastatic castrate-resistant prostate cancer
MDI	Metered-dose inhaler
mDOR	Median duration of response
MDS	Myelodysplastic syndrome
MEK	Mitogen-activated protein kinase
MET	Mesenchymal epithelial transition factor
mFOLFOX	Modified folinic acid, fluorouracil and oxaliplatin
mg	Milligram
mg/dL	Milligrams per decilitre
MG-ADL	Myasthenia Gravis-Activities of Daily Living
MGFA	Myasthenia Gravis Foundation of America
mHSPC	Metastatic hormone sensitive prostate cancer

Glossary – 4 of 5

MI	Myocardial infarction
mL	Millilitre
MM	Multiple myeloma
MMAE	Monomethyl auristatin E
MMT	Mixed meal test
MoA	Mechanism of action
mPFS	Median progression-free survival
MPO	Myeloperoxidase
mPR	Major pathological response
MR	Mineralocorticoid receptor
MRA	Mineralocorticoid receptor antagonist
MRD-negative	Minimal residual disease-negative
MRI	Magnetic resonance imaging
MRM	Mineralocorticoid receptor modulator
mRNA	Messenger ribonucleic acid
MSA	Multiple system atrophy
MTAP-deficient	Methylthioadenosine phosphorylase-deficient
MTD	Maximum tolerated dose
mTNBC	Metastatic triple-negative breast cancer
MZL	Marginal zone lymphoma
n/m	Not material
nAb	Neutralising antibody
NaC	Sodium channel
NAFLD	Non-alcoholic fatty liver disease
NASH	Non-alcoholic fatty liver disease
NBRx	New-to-brand prescription
NCFB	Non-cystic fibrosis bronchiectasis
NCI	National Cancer Institute
NCPV	Noncalcified plaque volume
Neo-adj	Neoadjuvant
NF1	Neurofibromatosis type 1
NF1-PN	Neurofibromatosis type 1 with plexiform neurofibromas
ng	Next-generation
NGF	Nerve growth factor
ngSERD	Next-generation oral selective estrogen receptor degrader
NHA	Novel hormonal agent
NHL	Non-Hodgkin's lymphoma
NIH	National Institute of Health
NKTCL	Extranodal natural killer T-cell lymphoma
NME	New molecular entity
NME	New molecular entity
NMOSD	Neuromyelitis optica spectrum disorder
NP	Nasal polyps
NRDL	National Reimbursement Drug List
NRG	National Clinical Trials Network in Oncology
NSCLC	Non-small cell lung cancer
NST	Neoadjuvant systemic treatment
NT-proBNP	N-terminal pro-B-type natriuretic peptide
NYHA	New York Heart Association
OBD	Optimal biological dose
OCS	Oral corticosteroid
OD	Once daily
oGLP1	Oral glucagon-like receptor peptide 1
OGTT	Oral glucose tolerance test
oPCSK9	Oral protein convertase subtilisin/kexin type 9
OR	Objective response
ORR	Overall response rate
oRXFP1	Oral relaxin family peptide receptor 1
OS	Overall survival
PA	Primary aldosteronism
PALB2m	Partner and localizer of BRCA2-mutated
PAR2	Protease-activated receptor 2
PARP	Poly ADP ribose polymerase
PARP1	poly(ADP-ribose) polymerase-1
PARP-1sel	Poly ADP ribose polymerase-1 selective
PARPi	poly-ADP ribose polymerase inhibitor
PASI	Psoriasis area severity index
PBD	Pyrrolobenzodiazepine
PCD	Plasma cell dyscrasia
pCR	Pathological complete response
PCSK9	Proprotein convertase subtilisin/kexin type 9
PD	Pharmacodynamics
PD1	Programmed cell death protein 1
PD-1	Programmed cell death protein-1
PDAC	Pancreatic ductal adenocarcinoma
PDE4	Phosphodiesterase type 4
PD-L1	Programmed death-ligand 1
PD-L1-high	Programmed death-ligand 1-high
Peak	Maximum
PET	Positron-emission tomography
PFS	Progression-free survival
PFS2	Time to second disease progression or death
PgR	Progesterone receptor
PI3K	Phosphoinositide 3 kinase
PIK3CA	Phosphatidylinositol-4,5-biphosphate 3-kinase catalytic subunit
PK	Pharmacokinetic
PK/PD	Pharmacokinetic/pharmacodynamic
PLEX	Plasma exchange
PLL	Prolymphocytic leukaemia
pMDI	Pressurised metered-dose inhaler
PN	Plexiform neurofibroma
PN	Polyneuropathy
PNH	Paroxysmal nocturnal haemoglobinuria
PNH-EVH	PNH with extravascular haemolysis
PNPLA3	Phospholipase domain-containing protein 3
POC	Proof-of-concept
POM	Proof-of-mechanism
post-BD	Post-bronchodilator
PP	Plasmapheresis
pPCI	Primary percutaneous coronary intervention
PR	Partial response
pre-BD	Pre-bronchodilator
PRMT5	Protein arginine methyltransferase 5
PRO	Patient reported outcome
PRR	Recurrent platinum resistant
PS	Propensity score
PSA	Prostate-specific antigen
PSA50	Prostate-specific antigen 50
PSC	Pulmonary sarcomatoid carcinoma
PSMA	Prostate-specific membrane antigen
PSR	Platinum-sensitive relapsed
PTCL	Peripheral T-cell lymphoma
PTEN	Phosphatase and tensin homolog gene
PTH	parathyroid hormone receptor
PVR	Pulmonary vascular resistance
Q1W	Every one week
Q2W	Every two weeks
Q4W	Every four weeks
Q8W	Every eight weeks
QCS	Quantitative continuous scoring

Glossary – 5 of 5

QD	Once daily
QID	Four times per day
QOD	Every other day
QoL	Quality of life
QoL-DN	Norfolk Quality of Life-Diabetic Neuropathy
QT	Duration of ventricular electrical systole
QTcF	Corrected QT interval by Fredericia
R&I	Respiratory and Immunology
R/R	Relapsed/refractory
r/r	Relapsed/refractory
RA	Rheumatoid arthritis
RAAS	Renin-angiotensin-aldosterone system
RAGE	Receptor for advanced glycation end products
RC	Radioconjugates
RECIST	Response Evaluation Criteria in Solid Tumours
REiNS	Response Evaluation in Neurofibromatosis and Schwannomatosis
RET	Rearranged during transfection
RFS	Relapse-free survival
rhLCAT	Recombinant human lecithin-cholesterol acyltransferase
rNDV	Recombinant Newcastle disease virus
RORγ	Related orphan receptor gamma
RP2D	Recommended Phase II dose
rPFS	Radiographic progression-free survival
RR	Response rate
RSV	Respiratory syncytial virus
RT	Radiation therapy
s. asthma	Severe asthma
s.c.	Subcutaneous
SABA	Short-acting beta2-agonist
SAD	Single ascending dose
SAE	Serious adverse event
SARS-CoV-2	Severe-acute-respiratory-syndrome-related coronavirus-19
SBP	Systolic blood pressure
SBRT	Stereotactic body radiation therapy
SCCHN	Squamous-cell carcinoma of the head and neck
SCD	Sickle cell disease
SCLC	Small cell lung cancer
SD	Stable disease
SERD	Selective estrogen receptor degrader
SG&A	Selling, General and Administrative
SGLT2	Sodium-glucose transport protein 2
SGLT2i	Sodium/glucose cotransporter 2 inhibitor
SGRM	Selective glucocorticoid receptor modulator
SGRQ	Saint George Respiratory Questionnaire
siRNA	Small interfering ribonucleic acid
SJC	Swollen joint count
sK	Serum potassium
SLE	Systemic lupus erythematosus
SLL	Small lymphocytic lymphoma
SMAD	Single and multiple ascending dose trial
SoC	Standard-of-care
sPGA	Static Physician's Global Assessment Score
SS	Steady state
ST2	Suppression of tumorigenicity 2
STAT3	Signal transducer and activator of transcription 3
Stg. I/II/III	Stage I/II/III
sUA	Serum uric acid
T2D	Type-2 diabetes
T2DM	Type-2 diabetes mellitus
T300	Imfinzi plus Imjudo
T790M	Threonine 790 substitution with methionine
TACE	Transarterial chemoembolization
tBRCAm	Tumour (somatic) BRCA-mutated
TCE	T-cell engager
TCR	T-cell receptor
TCR-T	T-cell receptor therapy
TDR	Tumour drivers and resistance
TEAE	Treatment-emergent adverse event
TESAE	Treatment-emergent serious adverse event
TFST	Time to first subsequent therapy or death
TGFbetaRIIDN	Transforming growth factor-beta RIIDN
THP	Paclitaxel, trastuzumab and pertuzumab
TID	Three times per day
TIGIT	T-cell immunoreceptor with Ig and ITIM domains
TIM3	T-cell immunoglobulin and mucin domain 3
TIM-3	T-cell immunoglobulin and mucin domain-containing protein
TJC	Tender joint count
TKI	Tyrosine kinase Inhibitor
TLR	Toll-like receptor 9
TMA	Thrombotic microangiopathy
Tmax	Time to reach maximum observed plasma concentration
TNBC	Triple negative breast cancer
TNF	Tumour necrosis factor
TNSALP	Tissue-nonspecific alkaline phosphatase
TOP1i	Topoisomerase 1 inhibitor
TP53	Tumour protein 53
TP53 R175H	Tumour protein p53 with arginine at position 175 is replaced with histidine
TPS	Tumour proportion score
Treg	Regulatory T-cell
TROP2	Trophoblast cell surface antigen 2
TSLP	Thymic stromal lymphopoietin
TTD	Time to treatment discontinuation
TTF	Time to treatment failure
TTNT	Time to next therapy
TTP	Time to tumour progression
TTR	Time to treatment response
TTR	Transthyretin
u/r HTN	Uncontrolled or treatment resistant hypertension
UACR	Urinary albumin/creatinine ratio
UK	United Kingdom
ULN	Upper limit of normal
u-LTE4	Urinary leukotriene E4
UMEC	Umeclidinium
UPCR	Urine protein creatinine ratio
URAT1	Uric acid transporter 1
US	United States
VEGF	Vascular endothelial growth factor
VHH	Single domain antibody
VLP	Virus-like particle
XELOX	Oxaliplatin and capecitabine